{"PMC7222050": [["IntroductionCopaiba, or copaiba oil, is the name of an oleoresin obtained from selected species of the genus Copaifera, Fabaceae (Leandro et al. 2012).", [["copaiba oil", "ANATOMY", 24, 35], ["IntroductionCopaiba", "CHEMICAL", 0, 19], ["oleoresin", "CHEMICAL", 55, 64], ["oleoresin", "CHEMICAL", 55, 64], ["copaiba oil", "SIMPLE_CHEMICAL", 24, 35], ["oleoresin", "SIMPLE_CHEMICAL", 55, 64], ["Copaifera", "ORGANISM", 109, 118], ["Fabaceae", "ORGANISM", 120, 128]]], ["Copaiba is widely used in the traditional medicine in Brazil and other Latin American countries for treatment of various diseases, such as skin and urinary tract infections, respiratory diseases, ulcers, rheumatism, herpes, tumours and tetanus disease (Ohsaki et al. 1994).", [["skin", "ANATOMY", 139, 143], ["urinary tract", "ANATOMY", 148, 161], ["respiratory", "ANATOMY", 174, 185], ["ulcers", "ANATOMY", 196, 202], ["tumours", "ANATOMY", 224, 231], ["Copaiba", "CHEMICAL", 0, 7], ["skin and urinary tract infections", "DISEASE", 139, 172], ["respiratory diseases", "DISEASE", 174, 194], ["ulcers", "DISEASE", 196, 202], ["rheumatism", "DISEASE", 204, 214], ["herpes, tumours", "DISEASE", 216, 231], ["tetanus disease", "DISEASE", 236, 251], ["Copaiba", "SIMPLE_CHEMICAL", 0, 7], ["skin", "ORGAN", 139, 143], ["urinary tract", "ORGANISM_SUBDIVISION", 148, 161], ["ulcers", "PATHOLOGICAL_FORMATION", 196, 202], ["herpes", "ORGANISM", 216, 222], ["tumours", "CANCER", 224, 231], ["Copaiba", "TREATMENT", 0, 7], ["various diseases", "PROBLEM", 113, 129], ["skin and urinary tract infections", "PROBLEM", 139, 172], ["respiratory diseases", "PROBLEM", 174, 194], ["ulcers", "PROBLEM", 196, 202], ["rheumatism", "PROBLEM", 204, 214], ["herpes", "PROBLEM", 216, 222], ["tumours", "PROBLEM", 224, 231], ["tetanus disease", "PROBLEM", 236, 251], ["diseases", "OBSERVATION", 121, 129], ["skin", "ANATOMY", 139, 143], ["urinary tract", "ANATOMY", 148, 161], ["infections", "OBSERVATION", 162, 172], ["respiratory diseases", "OBSERVATION", 174, 194], ["ulcers", "OBSERVATION", 196, 202], ["rheumatism", "OBSERVATION", 204, 214], ["tetanus disease", "OBSERVATION", 236, 251]]], ["Due to its antibacterial, antihelminthic, trypanocidal and leishmanicidal applications, the oleoresin represents an important natural remedy for people without access to modern medicine and commercial drugs (Ohsaki et al. 1994; Leandro et al. 2012).IntroductionCopaiba consists of sesquiterpenes and diterpenes, the latter usually being present as diterpene acids (Leandro et al. 2012).", [["oleoresin", "CHEMICAL", 92, 101], ["diterpene acids", "CHEMICAL", 348, 363], ["oleoresin", "CHEMICAL", 92, 101], ["sesquiterpenes", "CHEMICAL", 281, 295], ["diterpenes", "CHEMICAL", 300, 310], ["diterpene acids", "CHEMICAL", 348, 363], ["oleoresin", "SIMPLE_CHEMICAL", 92, 101], ["people", "ORGANISM", 145, 151], ["sesquiterpenes", "SIMPLE_CHEMICAL", 281, 295], ["diterpenes", "SIMPLE_CHEMICAL", 300, 310], ["diterpene acids", "SIMPLE_CHEMICAL", 348, 363], ["people", "SPECIES", 145, 151], ["its antibacterial", "TREATMENT", 7, 24], ["antihelminthic", "TREATMENT", 26, 40], ["trypanocidal", "TREATMENT", 42, 54], ["leishmanicidal applications", "TREATMENT", 59, 86], ["the oleoresin", "TREATMENT", 88, 101], ["modern medicine", "TREATMENT", 170, 185], ["commercial drugs", "TREATMENT", 190, 206], ["sesquiterpenes", "TREATMENT", 281, 295], ["diterpenes", "TREATMENT", 300, 310], ["antibacterial", "OBSERVATION_MODIFIER", 11, 24]]], ["Sesquiterpenes represent the main compounds that can count up to 98% of the oleoresin by weight, and show a rather stable metabolite pattern, with \u03b2-caryophyllene being the major constituent in most Copaifera species (Leandro et al. 2012).", [["Sesquiterpenes", "CHEMICAL", 0, 14], ["\u03b2-caryophyllene", "CHEMICAL", 147, 162], ["Sesquiterpenes", "CHEMICAL", 0, 14], ["oleoresin", "CHEMICAL", 76, 85], ["\u03b2-caryophyllene", "CHEMICAL", 147, 162], ["Sesquiterpenes", "SIMPLE_CHEMICAL", 0, 14], ["oleoresin", "SIMPLE_CHEMICAL", 76, 85], ["\u03b2-caryophyllene", "SIMPLE_CHEMICAL", 147, 162], ["Sesquiterpenes", "TREATMENT", 0, 14], ["a rather stable metabolite pattern", "PROBLEM", 106, 140], ["\u03b2-caryophyllene", "PROBLEM", 147, 162], ["main", "OBSERVATION_MODIFIER", 29, 33], ["stable", "OBSERVATION_MODIFIER", 115, 121], ["metabolite pattern", "OBSERVATION", 122, 140], ["most Copaifera", "OBSERVATION_MODIFIER", 194, 208]]], ["However, \u03b2-bisabolene has been identified as the major sesquiterpene of Copaifera reticulata Ducke collected in the Par\u00e1 region (northern Brazil) (Pfeifer Barbosa et al. 2019).", [["\u03b2-bisabolene", "CHEMICAL", 9, 21], ["\u03b2-bisabolene", "CHEMICAL", 9, 21], ["sesquiterpene", "CHEMICAL", 55, 68], ["\u03b2-bisabolene", "SIMPLE_CHEMICAL", 9, 21], ["sesquiterpene", "SIMPLE_CHEMICAL", 55, 68], ["Copaifera reticulata", "ORGANISM", 72, 92], ["Ducke", "ORGANISM", 93, 98], ["Copaifera reticulata", "SPECIES", 72, 92], ["Copaifera reticulata", "SPECIES", 72, 92], ["\u03b2-bisabolene", "TREATMENT", 9, 21], ["Copaifera reticulata Ducke", "TREATMENT", 72, 98]]], ["In contrast to the sesquiterpenes, copaiba diterpenoids show much higher interspecific variation and therefore attracted particular interest in recent years due to varying biological activities observed for the different Copaifera species (Leandro et al. 2012).", [["copaiba diterpenoids", "CHEMICAL", 35, 55], ["sesquiterpenes", "CHEMICAL", 19, 33], ["copaiba diterpenoids", "CHEMICAL", 35, 55], ["sesquiterpenes", "SIMPLE_CHEMICAL", 19, 33], ["copaiba diterpenoids", "SIMPLE_CHEMICAL", 35, 55], ["copaiba diterpenoids", "TEST", 35, 55], ["varying biological activities", "PROBLEM", 164, 193], ["the different Copaifera species", "PROBLEM", 207, 238], ["much higher", "OBSERVATION_MODIFIER", 61, 72], ["interspecific variation", "OBSERVATION", 73, 96]]], ["These activities comprise cytotoxic, antibacterial, antifungal and antiprotozoal properties as part of numerous in vitro and in vivo studies attempting to attribute the detected effect to certain compounds or compound classes.IntroductionThe cytotoxic potential of the copaiba oleoresin seems to mainly derive from its sesquiterpene constituents, as respective investigations on diterpenoids resulted in weak to moderate (but then non-selective) cytotoxic effects (Cavalcanti et al. 2009; Pfeifer Barbosa et al. 2019).", [["oleoresin", "CHEMICAL", 277, 286], ["copaiba oleoresin", "CHEMICAL", 269, 286], ["sesquiterpene", "CHEMICAL", 319, 332], ["diterpenoids", "CHEMICAL", 379, 391], ["copaiba oleoresin", "SIMPLE_CHEMICAL", 269, 286], ["sesquiterpene", "SIMPLE_CHEMICAL", 319, 332], ["diterpenoids", "SIMPLE_CHEMICAL", 379, 391], ["antibacterial", "TREATMENT", 37, 50], ["antifungal", "TREATMENT", 52, 62], ["antiprotozoal properties", "TREATMENT", 67, 91], ["vivo studies", "TEST", 128, 140], ["certain compounds", "PROBLEM", 188, 205], ["the copaiba oleoresin", "TREATMENT", 265, 286], ["diterpenoids", "TREATMENT", 379, 391], ["weak to moderate (but then non-selective) cytotoxic effects", "PROBLEM", 404, 463], ["weak to moderate", "OBSERVATION_MODIFIER", 404, 420]]], ["The only exception is kolavenol, which showed antitumour effects against IMC carcinoma in mice, determined by an increase of life span of the animals (Ohsaki et al. 1994).", [["IMC carcinoma", "ANATOMY", 73, 86], ["kolavenol", "CHEMICAL", 22, 31], ["IMC carcinoma", "DISEASE", 73, 86], ["kolavenol", "CHEMICAL", 22, 31], ["IMC", "CHEMICAL", 73, 76], ["kolavenol", "SIMPLE_CHEMICAL", 22, 31], ["antitumour", "CANCER", 46, 56], ["IMC carcinoma", "CANCER", 73, 86], ["mice", "ORGANISM", 90, 94], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["kolavenol", "TREATMENT", 22, 31], ["antitumour effects", "PROBLEM", 46, 64], ["IMC carcinoma", "PROBLEM", 73, 86], ["carcinoma", "OBSERVATION", 77, 86], ["increase", "OBSERVATION_MODIFIER", 113, 121]]], ["In contrast, the main sesquiterpenes showed selective moderate (\u03b2-bisabolol) to pronounced (\u03b2-caryophyllene and \u03b2-caryophyllene oxide) cytotoxic activities (Kubo et al. 1996; Yeo et al. 2016).", [["\u03b2-bisabolol", "CHEMICAL", 64, 75], ["\u03b2-caryophyllene", "CHEMICAL", 92, 107], ["\u03b2-caryophyllene oxide", "CHEMICAL", 112, 133], ["sesquiterpenes", "CHEMICAL", 22, 36], ["(\u03b2-bisabolol", "CHEMICAL", 63, 75], ["(\u03b2-caryophyllene", "CHEMICAL", 91, 107], ["\u03b2-caryophyllene oxide", "CHEMICAL", 112, 133], ["sesquiterpenes", "SIMPLE_CHEMICAL", 22, 36], ["\u03b2-bisabolol", "SIMPLE_CHEMICAL", 64, 75], ["(\u03b2-caryophyllene", "SIMPLE_CHEMICAL", 91, 107], ["\u03b2-caryophyllene oxide", "SIMPLE_CHEMICAL", 112, 133], ["the main sesquiterpenes", "TEST", 13, 36], ["selective moderate (\u03b2-bisabolol)", "PROBLEM", 44, 76], ["\u03b2-caryophyllene and \u03b2-caryophyllene oxide", "TREATMENT", 92, 133], ["cytotoxic activities", "PROBLEM", 135, 155], ["selective", "OBSERVATION_MODIFIER", 44, 53], ["moderate", "OBSERVATION_MODIFIER", 54, 62]]], ["With respect to their higher concentration in the oleoresin, it is more likely that sesquiterpenes are responsible for the antitumour properties of copaiba (Pfeifer Barbosa et al. 2019).IntroductionOn the other hand, copaiba diterpenoids showed good in vitro activities against causative agents of infectious parasitic diseases.", [["antitumour", "ANATOMY", 123, 133], ["oleoresin", "CHEMICAL", 50, 59], ["copaiba diterpenoids", "CHEMICAL", 217, 237], ["infectious parasitic diseases", "DISEASE", 298, 327], ["oleoresin", "CHEMICAL", 50, 59], ["sesquiterpenes", "CHEMICAL", 84, 98], ["diterpenoids", "CHEMICAL", 225, 237], ["oleoresin", "SIMPLE_CHEMICAL", 50, 59], ["sesquiterpenes", "SIMPLE_CHEMICAL", 84, 98], ["antitumour", "CANCER", 123, 133], ["copaiba", "SIMPLE_CHEMICAL", 148, 155], ["copaiba diterpenoids", "SIMPLE_CHEMICAL", 217, 237], ["copaiba diterpenoids", "TEST", 217, 237], ["infectious parasitic diseases", "PROBLEM", 298, 327], ["oleoresin", "ANATOMY", 50, 59], ["more likely", "UNCERTAINTY", 67, 78], ["infectious", "OBSERVATION_MODIFIER", 298, 308]]], ["Copalic acid, 3\u03b2-hydroxycopalic acid and methyl copalate, for example, inhibited the growth of the amastigote forms of Trypanosoma cruzi, whereas kaurenoic acid (2) and some of its semi-synthetic derivatives were found active against its erythrocytic trypomastigote forms (Vieira et al. 2002; Izumi et al. 2012). (\u2212)-Polyalthic acid (1), another major copaiba diterpenoid showed activity against T. brucei and amastigote forms of Leishmania donovani (Mizuno et al. 2015).", [["Copalic acid", "CHEMICAL", 0, 12], ["3\u03b2-hydroxycopalic acid", "CHEMICAL", 14, 36], ["methyl copalate", "CHEMICAL", 41, 56], ["Trypanosoma cruzi", "DISEASE", 119, 136], ["kaurenoic acid", "CHEMICAL", 146, 160], ["Polyalthic acid", "CHEMICAL", 317, 332], ["copaiba diterpenoid", "CHEMICAL", 352, 371], ["Copalic acid", "CHEMICAL", 0, 12], ["3\u03b2-hydroxycopalic acid", "CHEMICAL", 14, 36], ["methyl copalate", "CHEMICAL", 41, 56], ["kaurenoic acid", "CHEMICAL", 146, 160], ["(\u2212)-Polyalthic acid", "CHEMICAL", 313, 332], ["diterpenoid", "CHEMICAL", 360, 371], ["Copalic acid", "SIMPLE_CHEMICAL", 0, 12], ["3\u03b2-hydroxycopalic acid", "SIMPLE_CHEMICAL", 14, 36], ["methyl copalate", "SIMPLE_CHEMICAL", 41, 56], ["Trypanosoma cruzi", "ORGANISM", 119, 136], ["kaurenoic acid", "SIMPLE_CHEMICAL", 146, 160], ["semi-synthetic derivatives", "SIMPLE_CHEMICAL", 181, 207], ["(\u2212)-Polyalthic acid", "SIMPLE_CHEMICAL", 313, 332], ["copaiba diterpenoid", "SIMPLE_CHEMICAL", 352, 371], ["T. brucei", "ORGANISM", 396, 405], ["Leishmania donovani", "ORGANISM", 430, 449], ["Trypanosoma cruzi", "SPECIES", 119, 136], ["T. brucei", "SPECIES", 396, 405], ["Leishmania donovani", "SPECIES", 430, 449], ["Trypanosoma cruzi", "SPECIES", 119, 136], ["T. brucei", "SPECIES", 396, 405], ["Leishmania donovani", "SPECIES", 430, 449], ["Copalic acid", "TREATMENT", 0, 12], ["hydroxycopalic acid", "TREATMENT", 17, 36], ["methyl copalate", "TREATMENT", 41, 56], ["Trypanosoma cruzi", "PROBLEM", 119, 136], ["its semi-synthetic derivatives", "PROBLEM", 177, 207], ["its erythrocytic trypomastigote forms", "PROBLEM", 234, 271], ["Polyalthic acid", "TEST", 317, 332], ["another major copaiba diterpenoid", "TEST", 338, 371], ["T. brucei", "PROBLEM", 396, 405], ["Trypanosoma cruzi", "OBSERVATION", 119, 136], ["semi-synthetic derivatives", "OBSERVATION", 181, 207]]], ["Also here, semi-synthetic derivatives were prepared, of which some showed comparable to slightly higher activities than the natural product.", [["semi-synthetic derivatives", "SIMPLE_CHEMICAL", 11, 37], ["semi-synthetic derivatives", "TREATMENT", 11, 37], ["slightly higher activities", "PROBLEM", 88, 114], ["slightly", "OBSERVATION_MODIFIER", 88, 96], ["higher activities", "OBSERVATION_MODIFIER", 97, 114]]], ["However, neither (\u2212)-polyalthic acid (1) nor any of its derivatives was leishmanicidal against promastigote forms of L. donovani.IntroductionMoreover, copaiba diterpenoids revealed antibacterial activity against both gram-positive and gram-negative bacteria, with pronounced effects against Bacillus subtilis and five different Streptococcus species (Tincusi et al. 2002; Souza et al. 2011).", [["polyalthic acid", "CHEMICAL", 21, 36], ["leishmanicidal", "CHEMICAL", 72, 86], ["copaiba diterpenoids", "CHEMICAL", 151, 171], ["(\u2212)-polyalthic acid", "CHEMICAL", 17, 36], ["diterpenoids", "CHEMICAL", 159, 171], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 17, 36], ["leishmanicidal", "SIMPLE_CHEMICAL", 72, 86], ["L. donovani", "ORGANISM", 117, 128], ["copaiba diterpenoids", "SIMPLE_CHEMICAL", 151, 171], ["Bacillus subtilis", "ORGANISM", 291, 308], ["Streptococcus species", "ORGANISM", 328, 349], ["L. donovani", "SPECIES", 117, 128], ["Bacillus subtilis", "SPECIES", 291, 308], ["L. donovani", "SPECIES", 117, 128], ["Bacillus subtilis", "SPECIES", 291, 308], ["polyalthic acid", "TEST", 21, 36], ["L. donovani", "PROBLEM", 117, 128], ["copaiba diterpenoids", "TEST", 151, 171], ["antibacterial activity", "PROBLEM", 181, 203], ["both gram", "TEST", 212, 221], ["gram-negative bacteria", "PROBLEM", 235, 257], ["Bacillus subtilis", "PROBLEM", 291, 308], ["five different Streptococcus species", "PROBLEM", 313, 349], ["L. donovani", "OBSERVATION", 117, 128], ["antibacterial activity", "OBSERVATION", 181, 203], ["negative bacteria", "OBSERVATION", 240, 257], ["Streptococcus species", "OBSERVATION", 328, 349]]], ["In our previous study, we reported strong inhibitory effects against the two clinically relevant bacterial strains methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecium for three diterpene acids, of which one was kaurenoic acid (2) (Pfeifer Barbosa et al. 2019).", [["methicillin", "CHEMICAL", 115, 126], ["Staphylococcus aureus", "DISEASE", 137, 158], ["diterpene acids", "CHEMICAL", 201, 216], ["kaurenoic acid", "CHEMICAL", 235, 249], ["methicillin", "CHEMICAL", 115, 126], ["diterpene acids", "CHEMICAL", 201, 216], ["kaurenoic acid", "CHEMICAL", 235, 249], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 115, 158], ["MRSA", "ORGANISM", 160, 164], ["Enterococcus faecium", "ORGANISM", 170, 190], ["diterpene acids", "SIMPLE_CHEMICAL", 201, 216], ["kaurenoic acid", "SIMPLE_CHEMICAL", 235, 249], ["Staphylococcus aureus", "SPECIES", 137, 158], ["MRSA", "SPECIES", 160, 164], ["Enterococcus faecium", "SPECIES", 170, 190], ["Staphylococcus aureus", "SPECIES", 137, 158], ["MRSA", "SPECIES", 160, 164], ["Enterococcus faecium", "SPECIES", 170, 190], ["our previous study", "TEST", 3, 21], ["the two clinically relevant bacterial strains methicillin-resistant Staphylococcus aureus", "PROBLEM", 69, 158], ["MRSA", "PROBLEM", 160, 164], ["Enterococcus faecium", "PROBLEM", 170, 190], ["three diterpene acids", "TEST", 195, 216], ["kaurenoic acid", "TEST", 235, 249], ["Staphylococcus aureus", "OBSERVATION", 137, 158]]], ["In the same study, antidermatophytic activity against two Trichopyhton species was detected for (\u2212)-polyalthic acid (1), the major diterpenoid in the Copaifera reticulata oleoresin, along with weak [(\u2212)-polyalthic acid, 1] to moderate (kaurenoic acid, 2) cytotoxic effects against six cancer cell lines.", [["cancer cell lines", "ANATOMY", 285, 302], ["oleoresin", "CHEMICAL", 171, 180], ["kaurenoic acid", "CHEMICAL", 236, 250], ["cancer", "DISEASE", 285, 291], ["(\u2212)-polyalthic acid", "CHEMICAL", 96, 115], ["diterpenoid", "CHEMICAL", 131, 142], ["[(\u2212)-polyalthic acid", "CHEMICAL", 198, 218], ["kaurenoic acid", "CHEMICAL", 236, 250], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 96, 115], ["diterpenoid", "SIMPLE_CHEMICAL", 131, 142], ["Copaifera reticulata", "ORGANISM", 150, 170], ["oleoresin", "SIMPLE_CHEMICAL", 171, 180], ["[(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 198, 218], ["kaurenoic acid", "SIMPLE_CHEMICAL", 236, 250], ["cancer cell lines", "CELL", 285, 302], ["cancer cell lines", "CELL_LINE", 285, 302], ["Copaifera reticulata", "SPECIES", 150, 170], ["Copaifera reticulata", "SPECIES", 150, 170], ["the same study", "TEST", 3, 17], ["two Trichopyhton species", "TEST", 54, 78], ["polyalthic acid", "TEST", 100, 115], ["polyalthic acid", "TEST", 203, 218], ["moderate (kaurenoic acid", "PROBLEM", 226, 250], ["cytotoxic effects", "PROBLEM", 255, 272], ["six cancer cell lines", "PROBLEM", 281, 302], ["cancer cell lines", "OBSERVATION", 285, 302]]], ["These findings prompted us to prepare semi-synthetic derivatives of both compounds in an attempt to enhance their antimicrobial and cytotoxic properties and to get more insights into their structure-activity-relationships (SAR).", [["semi-synthetic derivatives of both compounds", "TREATMENT", 38, 82], ["their antimicrobial", "TREATMENT", 108, 127], ["cytotoxic properties", "TREATMENT", 132, 152]]], ["Furthermore, additional screenings were performed to discover new lead compounds against both human and plant pathogens.Plant Material and Chemicals ::: Materials and Methods(\u2212)-Polyalthic acid (1) and kaurenoic acid (2) were isolated from the oleoresin of Copaifera reticulata Ducke, Fabaceae, as described in our previous studies (\u00c7i\u00e7ek et al. 2018; Pfeifer Barbosa et al. 2019).", [["kaurenoic acid", "CHEMICAL", 202, 216], ["(\u2212)-Polyalthic acid", "CHEMICAL", 174, 193], ["kaurenoic acid", "CHEMICAL", 202, 216], ["human", "ORGANISM", 94, 99], ["(\u2212)-Polyalthic acid (1)", "SIMPLE_CHEMICAL", 174, 197], ["kaurenoic acid (2)", "SIMPLE_CHEMICAL", 202, 220], ["oleoresin", "SIMPLE_CHEMICAL", 244, 253], ["Copaifera reticulata Ducke", "ORGANISM", 257, 283], ["Fabaceae", "ORGANISM", 285, 293], ["human", "SPECIES", 94, 99], ["Copaifera reticulata", "SPECIES", 257, 277], ["human", "SPECIES", 94, 99], ["Copaifera reticulata", "SPECIES", 257, 277], ["additional screenings", "TEST", 13, 34], ["new lead compounds", "PROBLEM", 62, 80], ["both human and plant pathogens", "PROBLEM", 89, 119], ["Methods", "TEST", 167, 174], ["Polyalthic acid", "TEST", 178, 193], ["kaurenoic acid", "TREATMENT", 202, 216], ["plant pathogens", "OBSERVATION", 104, 119], ["Fabaceae", "OBSERVATION", 285, 293]]], ["N-Chlorosuccinimide (98%) and triphenylphosphine (ReagentPlus, 99%), sulphuric acid (puriss., analytical grade) and LC-MS grade formic acid were purchased from Sigma-Aldrich Co., St. Louis, MO, USA.", [["N-Chlorosuccinimide", "CHEMICAL", 0, 19], ["triphenylphosphine", "CHEMICAL", 30, 48], ["ReagentPlus", "CHEMICAL", 50, 61], ["sulphuric acid", "CHEMICAL", 69, 83], ["formic acid", "CHEMICAL", 128, 139], ["N-Chlorosuccinimide", "CHEMICAL", 0, 19], ["triphenylphosphine", "CHEMICAL", 30, 48], ["ReagentPlus", "CHEMICAL", 50, 61], ["sulphuric acid", "CHEMICAL", 69, 83], ["formic acid", "CHEMICAL", 128, 139], ["N-Chlorosuccinimide", "SIMPLE_CHEMICAL", 0, 19], ["triphenylphosphine", "SIMPLE_CHEMICAL", 30, 48], ["ReagentPlus", "SIMPLE_CHEMICAL", 50, 61], ["sulphuric acid", "SIMPLE_CHEMICAL", 69, 83], ["puriss.", "SIMPLE_CHEMICAL", 85, 92], ["formic acid", "SIMPLE_CHEMICAL", 128, 139], ["St. Louis", "ORGANISM", 179, 188], ["Chlorosuccinimide", "TREATMENT", 2, 19], ["triphenylphosphine (ReagentPlus", "TREATMENT", 30, 61], ["sulphuric acid", "TEST", 69, 83], ["analytical grade", "TEST", 94, 110], ["LC", "TEST", 116, 118], ["MS grade formic acid", "PROBLEM", 119, 139], ["LC", "ANATOMY", 116, 118]]], ["Hydrochloric acid (25%, analytical grade) was obtained from Honeywell, Seelze, Germany, while sodium hydroxide solution (2N) was purchased from Carl Roth GmbH, Karlsruhe, Germany.", [["Hydrochloric acid", "CHEMICAL", 0, 17], ["sodium hydroxide", "CHEMICAL", 94, 110], ["Hydrochloric acid", "CHEMICAL", 0, 17], ["sodium hydroxide", "CHEMICAL", 94, 110], ["Hydrochloric acid", "SIMPLE_CHEMICAL", 0, 17], ["sodium hydroxide", "SIMPLE_CHEMICAL", 94, 110], ["Hydrochloric acid", "TREATMENT", 0, 17], ["sodium hydroxide solution", "TREATMENT", 94, 119]]], ["Diethylamine (for synthesis), acetone (analytical grade), methanol (gradient grade or LC-MS grade) and water (LC-MS grade) as well as other analytical grade solvents used for purification were obtained from VWR International GmbH, Darmstadt, Germany.", [["Diethylamine", "CHEMICAL", 0, 12], ["acetone", "CHEMICAL", 30, 37], ["methanol", "CHEMICAL", 58, 66], ["Diethylamine", "CHEMICAL", 0, 12], ["acetone", "CHEMICAL", 30, 37], ["methanol", "CHEMICAL", 58, 66], ["Diethylamine", "SIMPLE_CHEMICAL", 0, 12], ["acetone", "SIMPLE_CHEMICAL", 30, 37], ["methanol", "SIMPLE_CHEMICAL", 58, 66], ["Diethylamine", "TREATMENT", 0, 12], ["synthesis)", "TREATMENT", 18, 28], ["acetone", "TREATMENT", 30, 37], ["methanol (gradient grade", "TEST", 58, 82], ["LC", "TEST", 86, 88], ["MS grade)", "PROBLEM", 89, 98], ["other analytical grade solvents", "PROBLEM", 134, 165]]], ["Solid phase extraction (SPE) columns (Chromabond SB 3 ml/500 mg) were obtained from Macherey-Nagel GmbH & Co. KG, D\u00fcren, Germany.", [["Co", "CHEMICAL", 106, 108], ["Solid phase extraction (SPE) columns (Chromabond SB", "TREATMENT", 0, 51], ["Macherey", "TEST", 84, 92]]], ["Deuterated methanol (Lot P3021, 99.80%), deuterated DMSO (Lot S1051, 99.80%) and deuterated chloroform (Lot Q1981, 99.80%) for NMR spectroscopy were obtained from Eurisotop GmbH, Saarbr\u00fccken, Germany.", [["Deuterated methanol", "CHEMICAL", 0, 19], ["DMSO", "CHEMICAL", 52, 56], ["S1051", "CHEMICAL", 62, 67], ["deuterated chloroform", "CHEMICAL", 81, 102], ["methanol", "CHEMICAL", 11, 19], ["DMSO", "CHEMICAL", 52, 56], ["chloroform", "CHEMICAL", 92, 102], ["methanol", "SIMPLE_CHEMICAL", 11, 19], ["Lot P3021", "SIMPLE_CHEMICAL", 21, 30], ["DMSO", "SIMPLE_CHEMICAL", 52, 56], ["Lot S1051", "SIMPLE_CHEMICAL", 58, 67], ["deuterated chloroform", "SIMPLE_CHEMICAL", 81, 102], ["deuterated DMSO", "PROBLEM", 41, 56], ["NMR spectroscopy", "TEST", 127, 143]]], ["Conventional 5-mm sample tubes were purchased from Rototec-Spintec GmbH, Griesheim, Germany.General Experimental Procedures ::: Materials and MethodsSemi-synthetic derivatives of compounds 1 and 2 were prepared in 5-ml V-Vials (Wheaton, Millville, NJ, USA) using a RET basic magnetic stirrer with integrated heater (IKA-Werke GmbH & Co. KG, Staufen, Germany).", [["sample tubes", "ANATOMY", 18, 30], ["Co", "CHEMICAL", 333, 335], ["V-Vials", "SIMPLE_CHEMICAL", 219, 226], ["Conventional 5-mm sample tubes", "TREATMENT", 0, 30], ["MethodsSemi-synthetic derivatives of compounds", "TREATMENT", 142, 188], ["5-mm", "OBSERVATION_MODIFIER", 13, 17]]], ["LC-DAD-ELSD analysis was accomplished as stated in \u00c7i\u00e7ek et al. (2018); LC-MS and GC-MS analyses were conducted as described in Pfeifer Barbosa et al. (2019).", [["ELSD analysis", "TEST", 7, 20], ["LC", "TEST", 72, 74], ["MS", "TEST", 75, 77], ["GC", "TEST", 82, 84], ["MS analyses", "TEST", 85, 96]]], ["High-resolution MS spectrum was recorded on micrOTOF II-High-performance TOF-MS system (Bruker\u00ae, Billerica, MA, USA) equipped with an electrospray ionisation source.", [["micrOTOF II", "TEST", 44, 55], ["an electrospray ionisation source", "TREATMENT", 131, 164]]], ["Specific rotation of the compounds measured in methanol on a Jasco P-2000 polarimeter (Jasco, Pfungstadt, Germany).", [["methanol", "CHEMICAL", 47, 55], ["methanol", "SIMPLE_CHEMICAL", 47, 55], ["rotation", "OBSERVATION_MODIFIER", 9, 17], ["compounds", "OBSERVATION_MODIFIER", 25, 34]]], ["NMR spectra were recorded using a Bruker Avance III 400 NMR spectrometer operating at 400 MHz for the proton channel and 100 MHz for the 13C channel with a 5 mm PABBO broad band probe with a z gradient unit at 293 K (Bruker BioSpin GmbH, Rheinstetten, Germany).", [["13C", "CHEMICAL", 137, 140], ["NMR spectra", "TEST", 0, 11], ["a Bruker Avance III", "TREATMENT", 32, 51], ["the proton channel", "TREATMENT", 98, 116], ["a 5 mm PABBO broad band probe", "TREATMENT", 154, 183], ["a z gradient unit", "TREATMENT", 189, 206]]], ["Reference values were 3.31 (1H) and 49.15 ppm (13C) for methanol as well as 2.50 (1H) and 39.51 ppm (13C) for DMSO, respectively.Carboxyl Amides ::: Preparation of Derivatives ::: Materials and MethodsThe compound (100 \u03bcmol) and triphenylphosphine were dissolved in 2 ml of dichloromethane, and the mixture was cooled in an ice bath.", [["methanol", "CHEMICAL", 56, 64], ["DMSO", "CHEMICAL", 110, 114], ["Carboxyl Amides", "CHEMICAL", 129, 144], ["triphenylphosphine", "CHEMICAL", 229, 247], ["dichloromethane", "CHEMICAL", 274, 289], ["13C", "CHEMICAL", 47, 50], ["methanol", "CHEMICAL", 56, 64], ["1H", "CHEMICAL", 82, 84], ["13C", "CHEMICAL", 101, 104], ["DMSO", "CHEMICAL", 110, 114], ["Carboxyl Amides", "CHEMICAL", 129, 144], ["triphenylphosphine", "CHEMICAL", 229, 247], ["dichloromethane", "CHEMICAL", 274, 289], ["methanol", "SIMPLE_CHEMICAL", 56, 64], ["DMSO", "SIMPLE_CHEMICAL", 110, 114], ["Carboxyl Amides", "SIMPLE_CHEMICAL", 129, 144], ["triphenylphosphine", "SIMPLE_CHEMICAL", 229, 247], ["dichloromethane", "SIMPLE_CHEMICAL", 274, 289], ["Reference values", "TEST", 0, 16], ["methanol", "TREATMENT", 56, 64], ["DMSO", "PROBLEM", 110, 114], ["Materials", "TREATMENT", 180, 189], ["Methods", "TREATMENT", 194, 201], ["The compound (100 \u03bcmol)", "TREATMENT", 201, 224], ["triphenylphosphine", "TREATMENT", 229, 247], ["dichloromethane", "TREATMENT", 274, 289], ["an ice bath", "TREATMENT", 321, 332]]], ["After adding 110 \u03bcmol of N-chlorosuccinimide in small portions, the mixture was vigorously stirred for 30 min at room temperature.", [["N-chlorosuccinimide", "CHEMICAL", 25, 44], ["N-chlorosuccinimide", "CHEMICAL", 25, 44], ["N-chlorosuccinimide", "SIMPLE_CHEMICAL", 25, 44], ["N-chlorosuccinimide in small portions", "TREATMENT", 25, 62]]], ["Diethylamine (110 \u03bcmol) in 100 \u03bcmol of pyridine was added, and the mixture was stirred for another 10 min at room temperature.", [["Diethylamine", "CHEMICAL", 0, 12], ["pyridine", "CHEMICAL", 39, 47], ["Diethylamine", "CHEMICAL", 0, 12], ["pyridine", "CHEMICAL", 39, 47], ["Diethylamine", "SIMPLE_CHEMICAL", 0, 12], ["pyridine", "SIMPLE_CHEMICAL", 39, 47], ["Diethylamine", "TREATMENT", 0, 12], ["pyridine", "TREATMENT", 39, 47]]], ["The mixture was subsequently concentrated under reduced pressure, and the by-products were removed by filtration and solid phase extraction using hexane as solvent to afford 6.2 mg of (\u2212)-polyalthic acid-N,N-diethylamide (1a) and 7.5 mg kaurenoic acid-N,N-diethylamide (2a).Carboxyl Esters ::: Preparation of Derivatives ::: Materials and MethodsThe formation of ester was accomplished in the same manner except that diethylamine was substituted with methanol in the last reaction step.", [["hexane", "CHEMICAL", 146, 152], ["polyalthic acid-N,N-diethylamide", "CHEMICAL", 188, 220], ["kaurenoic acid-N,N-diethylamide", "CHEMICAL", 237, 268], ["Carboxyl", "CHEMICAL", 274, 282], ["ester", "CHEMICAL", 363, 368], ["diethylamine", "CHEMICAL", 417, 429], ["methanol", "CHEMICAL", 451, 459], ["hexane", "CHEMICAL", 146, 152], ["(\u2212)-polyalthic acid-N,N-diethylamide", "CHEMICAL", 184, 220], ["kaurenoic acid-N,N-diethylamide", "CHEMICAL", 237, 268], ["Carboxyl", "CHEMICAL", 274, 282], ["ester", "CHEMICAL", 363, 368], ["diethylamine", "CHEMICAL", 417, 429], ["methanol", "CHEMICAL", 451, 459], ["hexane", "SIMPLE_CHEMICAL", 146, 152], ["(\u2212)-polyalthic acid-N", "SIMPLE_CHEMICAL", 184, 205], ["N-diethylamide", "SIMPLE_CHEMICAL", 206, 220], ["kaurenoic acid-N,N-diethylamide", "SIMPLE_CHEMICAL", 237, 268], ["Carboxyl Esters", "SIMPLE_CHEMICAL", 274, 289], ["ester", "SIMPLE_CHEMICAL", 363, 368], ["diethylamine", "SIMPLE_CHEMICAL", 417, 429], ["methanol", "SIMPLE_CHEMICAL", 451, 459], ["solid phase extraction", "TREATMENT", 117, 139], ["hexane", "TREATMENT", 146, 152], ["polyalthic acid", "TREATMENT", 188, 203], ["diethylamide", "TREATMENT", 208, 220], ["7.5 mg kaurenoic acid", "TREATMENT", 230, 251], ["N-diethylamide", "TREATMENT", 254, 268], ["Methods", "TREATMENT", 339, 346], ["diethylamine", "TREATMENT", 417, 429], ["methanol", "TREATMENT", 451, 459], ["reduced", "OBSERVATION_MODIFIER", 48, 55], ["pressure", "OBSERVATION_MODIFIER", 56, 64], ["ester", "OBSERVATION_MODIFIER", 363, 368]]], ["This reaction yielded 4.2 mg (\u2212)-polyalthic acid methyl ester (1b) and 7.3 mg kaurenoic acid methyl ester (2b).Dihydroxy Derivatives ::: Preparation of Derivatives ::: Materials and MethodsThe compound (100 \u03bcmol) was dissolved under heating in a mixture of 800 \u03bcl of water and 200 \u03bcl of 2 M sodium hydroxide.", [["polyalthic acid methyl ester", "CHEMICAL", 33, 61], ["kaurenoic acid methyl ester", "CHEMICAL", 78, 105], ["sodium hydroxide", "CHEMICAL", 291, 307], ["(\u2212)-polyalthic acid methyl ester", "CHEMICAL", 29, 61], ["kaurenoic acid methyl ester", "CHEMICAL", 78, 105], ["Dihydroxy", "CHEMICAL", 111, 120], ["sodium hydroxide", "CHEMICAL", 291, 307], ["(\u2212)-polyalthic acid methyl ester", "SIMPLE_CHEMICAL", 29, 61], ["kaurenoic acid methyl ester", "SIMPLE_CHEMICAL", 78, 105], ["Dihydroxy Derivatives", "SIMPLE_CHEMICAL", 111, 132], ["sodium hydroxide", "SIMPLE_CHEMICAL", 291, 307], ["This reaction", "PROBLEM", 0, 13], ["polyalthic acid methyl ester", "TREATMENT", 33, 61], ["7.3 mg kaurenoic acid methyl ester", "TREATMENT", 71, 105], ["Materials", "TREATMENT", 168, 177], ["Methods", "TREATMENT", 182, 189], ["2 M sodium hydroxide", "TREATMENT", 287, 307]]], ["The solution was subsequently cooled to 5 \u00b0C, and 250 mg of ice was added before adding a cold solution of 20.5 mg potassium permanganate in 500 \u03bcl of water over a period of 30 min.", [["potassium permanganate", "CHEMICAL", 115, 137], ["potassium permanganate", "CHEMICAL", 115, 137], ["potassium permanganate", "SIMPLE_CHEMICAL", 115, 137], ["The solution", "TREATMENT", 0, 12], ["ice", "TREATMENT", 60, 63], ["a cold solution of 20.5 mg potassium permanganate", "TREATMENT", 88, 137]]], ["The mixture was kept at 0 to 5 \u00b0C for another 60 min before the precipitate was filtered off and washed with hot water.", [["The mixture", "TREATMENT", 0, 11]]], ["The filtrate was acidified with acetic acid, and the resulting precipitate was filtered of and washed with cold water and dried to afford 8.8 mg of (4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid [(1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid] (1c) and 13.0 mg of 16\u03b1,17-dihydroxy-ent-kauran-19-oic acid (2c), respectively, after recrystallisation from a mixture of hexane and tert-butyl methyl ether.Monohydroxy Derivative ::: Preparation of Derivatives ::: Materials and MethodsCompound 2 (50 mg) was dissolved in a mixture of 1500 \u03bcl acetone, 350 \u03bcl water and 150 \u03bcl hydrochloric acid (25%) and kept at 56 \u00b0C for 2 h under stirring.", [["acetic acid", "CHEMICAL", 32, 43], ["4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "CHEMICAL", 149, 218], ["1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid", "CHEMICAL", 221, 358], ["16\u03b1,17-dihydroxy-ent-kauran-19-oic acid", "CHEMICAL", 380, 419], ["hexane", "CHEMICAL", 482, 488], ["tert-butyl methyl ether", "CHEMICAL", 493, 516], ["hydrochloric acid", "CHEMICAL", 686, 703], ["acetic acid", "CHEMICAL", 32, 43], ["(4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "CHEMICAL", 148, 218], ["(1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid", "CHEMICAL", 220, 358], ["16\u03b1,17-dihydroxy-ent-kauran-19-oic acid", "CHEMICAL", 380, 419], ["hexane", "CHEMICAL", 482, 488], ["tert-butyl methyl ether", "CHEMICAL", 493, 516], ["Monohydroxy", "CHEMICAL", 517, 528], ["acetone", "CHEMICAL", 653, 660], ["hydrochloric acid", "CHEMICAL", 686, 703], ["acetic acid", "SIMPLE_CHEMICAL", 32, 43], ["(4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "SIMPLE_CHEMICAL", 148, 218], ["(1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid] (1c)", "SIMPLE_CHEMICAL", 220, 364], ["16\u03b1,17-dihydroxy-ent-kauran-19-oic acid (2c)", "SIMPLE_CHEMICAL", 380, 424], ["hexane", "SIMPLE_CHEMICAL", 482, 488], ["tert-butyl methyl ether", "SIMPLE_CHEMICAL", 493, 516], ["acetone", "SIMPLE_CHEMICAL", 653, 660], ["hydrochloric acid", "SIMPLE_CHEMICAL", 686, 703], ["The filtrate", "TREATMENT", 0, 12], ["acetic acid", "TREATMENT", 32, 43], ["cold water", "TREATMENT", 107, 117], ["epoxy", "TEST", 162, 167], ["labdadien", "TEST", 197, 206], ["oic acid", "TEST", 210, 218], ["carboxylic acid", "TREATMENT", 343, 358], ["dihydroxy", "TREATMENT", 387, 396], ["kauran", "TREATMENT", 401, 407], ["hexane", "TREATMENT", 482, 488], ["tert-butyl methyl ether", "TREATMENT", 493, 516], ["MethodsCompound", "TREATMENT", 589, 604], ["\u03bcl hydrochloric acid", "TREATMENT", 683, 703], ["filtrate", "OBSERVATION", 4, 12]]], ["The solution was then transferred to a beaker containing 10 ml of water ,and the resulting precipitate was filtered and recrystallised from acetone to obtain 12.2 mg of 16\u03b1-hydroxy-ent-kauran-19-oic acid (2d).Methoxy Derivative ::: Preparation of Derivatives ::: Materials and MethodsCompound 2 (50 mg) was dissolved in a mixture of 2500 \u03bcl methanol and 150 \u03bcl sulphuric acid and kept at 65 \u00b0C for 3 h under stirring.", [["acetone", "CHEMICAL", 140, 147], ["16\u03b1-hydroxy-ent-kauran-19-oic acid", "CHEMICAL", 169, 203], ["sulphuric acid", "CHEMICAL", 361, 375], ["acetone", "CHEMICAL", 140, 147], ["16\u03b1-hydroxy-ent-kauran-19-oic acid", "CHEMICAL", 169, 203], ["Methoxy", "CHEMICAL", 209, 216], ["methanol", "CHEMICAL", 341, 349], ["sulphuric acid", "CHEMICAL", 361, 375], ["water", "SIMPLE_CHEMICAL", 66, 71], ["acetone", "SIMPLE_CHEMICAL", 140, 147], ["16\u03b1-hydroxy-ent-kauran-19-oic acid", "SIMPLE_CHEMICAL", 169, 203], ["methanol", "SIMPLE_CHEMICAL", 341, 349], ["sulphuric acid", "SIMPLE_CHEMICAL", 361, 375], ["The solution", "TREATMENT", 0, 12], ["acetone", "TREATMENT", 140, 147], ["hydroxy", "TREATMENT", 173, 180], ["kauran", "TREATMENT", 185, 191], ["MethodsCompound", "TREATMENT", 277, 292], ["2500 \u03bcl methanol", "TREATMENT", 333, 349], ["\u03bcl sulphuric acid", "TREATMENT", 358, 375]]], ["The solution was subsequently cooled to \u2212 18 \u00b0C and the resulting precipitate was filtered and recrystallised from methanol to obtain 7.9 mg of 16\u03b1-methoxy-ent-kauran-19-oic acid (2e).Antibacterial and Antiyeast Activity ::: Biological Activity Testing ::: Materials and MethodsThe samples were tested against the ESKAPE panel of multidrug resistant bacterial human pathogens, including the gram-positive bacteria Enterococcus faecium (DSM 20477) and methillicin-resistant Staphylococcus aureus (MRSA, DSM 18827), and the gram-negative bacteria Klebsiella pneumoniae (DSM 30104), Acinetobacter baumannii (DSM 30007), Pseudomonas aeruginosa (DSM 1128) and Escherichia coli (DSM 1576).", [["samples", "ANATOMY", 282, 289], ["16\u03b1-methoxy-ent-kauran-19-oic acid", "CHEMICAL", 144, 178], ["bacterial human pathogens", "DISEASE", 350, 375], ["Enterococcus faecium", "CHEMICAL", 414, 434], ["DSM 20477", "CHEMICAL", 436, 445], ["methillicin", "CHEMICAL", 451, 462], ["Staphylococcus aureus", "DISEASE", 473, 494], ["MRSA", "CHEMICAL", 496, 500], ["DSM 18827", "CHEMICAL", 502, 511], ["Klebsiella pneumoniae", "DISEASE", 545, 566], ["DSM 30104", "CHEMICAL", 568, 577], ["Acinetobacter baumannii", "DISEASE", 580, 603], ["DSM 30007", "CHEMICAL", 605, 614], ["Pseudomonas aeruginosa (DSM 1128", "CHEMICAL", 617, 649], ["methanol", "CHEMICAL", 115, 123], ["16\u03b1-methoxy-ent-kauran-19-oic acid", "CHEMICAL", 144, 178], ["methanol", "SIMPLE_CHEMICAL", 115, 123], ["16\u03b1-methoxy-ent-kauran-19-oic acid", "SIMPLE_CHEMICAL", 144, 178], ["human", "ORGANISM", 360, 365], ["Enterococcus faecium", "ORGANISM", 414, 434], ["DSM 20477", "ORGANISM", 436, 445], ["methillicin-resistant Staphylococcus aureus", "ORGANISM", 451, 494], ["Klebsiella pneumoniae", "ORGANISM", 545, 566], ["DSM 30104", "ORGANISM", 568, 577], ["Acinetobacter baumannii", "ORGANISM", 580, 603], ["DSM 30007", "ORGANISM", 605, 614], ["Pseudomonas aeruginosa", "ORGANISM", 617, 639], ["DSM 1128", "ORGANISM", 641, 649], ["Escherichia coli", "ORGANISM", 655, 671], ["human", "SPECIES", 360, 365], ["Enterococcus faecium", "SPECIES", 414, 434], ["Staphylococcus aureus", "SPECIES", 473, 494], ["MRSA", "SPECIES", 496, 500], ["Klebsiella pneumoniae", "SPECIES", 545, 566], ["Acinetobacter baumannii", "SPECIES", 580, 603], ["Pseudomonas aeruginosa", "SPECIES", 617, 639], ["Escherichia coli", "SPECIES", 655, 671], ["human", "SPECIES", 360, 365], ["Enterococcus faecium (DSM 20477)", "SPECIES", 414, 446], ["Staphylococcus aureus", "SPECIES", 473, 494], ["Klebsiella pneumoniae", "SPECIES", 545, 566], ["Acinetobacter baumannii", "SPECIES", 580, 603], ["Pseudomonas aeruginosa (DSM 1128)", "SPECIES", 617, 650], ["Escherichia coli", "SPECIES", 655, 671], ["The solution", "TREATMENT", 0, 12], ["methanol", "TREATMENT", 115, 123], ["methoxy", "TREATMENT", 148, 155], ["kauran", "TREATMENT", 160, 166], ["Antibacterial", "TREATMENT", 184, 197], ["Methods", "TREATMENT", 271, 278], ["The samples", "TEST", 278, 289], ["the ESKAPE panel", "TEST", 310, 326], ["multidrug resistant bacterial human pathogens", "PROBLEM", 330, 375], ["the gram", "TEST", 387, 395], ["positive bacteria Enterococcus faecium", "PROBLEM", 396, 434], ["DSM", "TEST", 436, 439], ["methillicin-resistant Staphylococcus aureus", "PROBLEM", 451, 494], ["MRSA", "PROBLEM", 496, 500], ["DSM", "TEST", 502, 505], ["the gram", "TEST", 518, 526], ["negative bacteria Klebsiella pneumoniae", "PROBLEM", 527, 566], ["DSM", "TEST", 568, 571], ["Acinetobacter baumannii", "PROBLEM", 580, 603], ["DSM", "TEST", 605, 608], ["Pseudomonas aeruginosa", "PROBLEM", 617, 639], ["DSM", "TEST", 641, 644], ["Escherichia coli", "PROBLEM", 655, 671], ["DSM", "TEST", 673, 676], ["multidrug resistant", "OBSERVATION_MODIFIER", 330, 349], ["bacterial human pathogens", "OBSERVATION", 350, 375], ["positive bacteria", "OBSERVATION_MODIFIER", 396, 413], ["Enterococcus faecium", "OBSERVATION", 414, 434], ["Staphylococcus aureus", "OBSERVATION", 473, 494], ["negative bacteria", "OBSERVATION_MODIFIER", 527, 544], ["Klebsiella pneumoniae", "OBSERVATION", 545, 566], ["Escherichia coli", "OBSERVATION", 655, 671]]], ["Furthermore the activity of the samples against four phytopathogenic bacteria, Pseudomonas syringae (DSM 50252), Xanthomonas campestris (DSM 2405), Erwinia amylovora (DSM 50901) and Ralstonia solanacearum (DSM 9544), and against two human pathogen yeasts, Candida albicans (DSM 1386) and Cryptococcus neoformans (DSM 6973), was carried out.", [["samples", "ANATOMY", 32, 39], ["DSM 50252", "CHEMICAL", 101, 110], ["Xanthomonas campestris", "CHEMICAL", 113, 135], ["DSM 2405", "CHEMICAL", 137, 145], ["Erwinia amylovora", "DISEASE", 148, 165], ["DSM 50901", "CHEMICAL", 167, 176], ["DSM 9544", "CHEMICAL", 206, 214], ["Candida albicans", "DISEASE", 256, 272], ["DSM 1386", "CHEMICAL", 274, 282], ["Cryptococcus neoformans", "DISEASE", 288, 311], ["Pseudomonas syringae", "ORGANISM", 79, 99], ["DSM 50252", "ORGANISM", 101, 110], ["Xanthomonas campestris", "ORGANISM", 113, 135], ["DSM 2405", "ORGANISM", 137, 145], ["Erwinia amylovora", "ORGANISM", 148, 165], ["DSM 50901", "ORGANISM", 167, 176], ["Ralstonia solanacearum", "ORGANISM", 182, 204], ["DSM 9544", "ORGANISM", 206, 214], ["human", "ORGANISM", 233, 238], ["pathogen yeasts", "ORGANISM", 239, 254], ["Candida albicans", "ORGANISM", 256, 272], ["DSM 1386", "ORGANISM", 274, 282], ["Cryptococcus neoformans", "ORGANISM", 288, 311], ["Pseudomonas syringae", "SPECIES", 79, 99], ["Xanthomonas campestris", "SPECIES", 113, 135], ["Erwinia amylovora", "SPECIES", 148, 165], ["Ralstonia solanacearum", "SPECIES", 182, 204], ["human", "SPECIES", 233, 238], ["Candida albicans", "SPECIES", 256, 272], ["Cryptococcus neoformans", "SPECIES", 288, 311], ["Pseudomonas syringae", "SPECIES", 79, 99], ["Xanthomonas campestris (DSM 2405)", "SPECIES", 113, 146], ["Erwinia amylovora (DSM 50901)", "SPECIES", 148, 177], ["Ralstonia solanacearum (DSM 9544)", "SPECIES", 182, 215], ["human", "SPECIES", 233, 238], ["Candida albicans", "SPECIES", 256, 272], ["DSM 1386)", "SPECIES", 274, 283], ["Cryptococcus neoformans (DSM 6973)", "SPECIES", 288, 322], ["the samples", "TEST", 28, 39], ["four phytopathogenic bacteria", "PROBLEM", 48, 77], ["Pseudomonas syringae", "PROBLEM", 79, 99], ["DSM", "TEST", 101, 104], ["Xanthomonas campestris (DSM", "TEST", 113, 140], ["Erwinia amylovora (DSM", "TEST", 148, 170], ["Ralstonia solanacearum", "PROBLEM", 182, 204], ["two human pathogen yeasts", "PROBLEM", 229, 254], ["Candida albicans", "TEST", 256, 272], ["Cryptococcus neoformans", "PROBLEM", 288, 311], ["Cryptococcus neoformans", "OBSERVATION", 288, 311]]], ["All test strains were purchased from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany.Antibacterial and Antiyeast Activity ::: Biological Activity Testing ::: Materials and MethodsThe bacteria were cultivated in TSB medium (1.2% tryptic soy broth, 0.5% NaCl), except E. faecium which was cultivated in M92 medium (3% trypticase soy broth, 0.3% yeast extract, pH 7.0\u20137.2) and R. solanacearum which was grown in M186 (1% glucose, 0.5% peptone from soymeal, 0.3% malt extract, 0.3 yeast extract).", [["Cell Cultures", "ANATOMY", 100, 113], ["extract", "ANATOMY", 401, 408], ["extract", "ANATOMY", 535, 542], ["NaCl", "CHEMICAL", 304, 308], ["M186", "CHEMICAL", 461, 465], ["glucose", "CHEMICAL", 470, 477], ["peptone", "CHEMICAL", 484, 491], ["soymeal", "CHEMICAL", 497, 504], ["malt extract", "CHEMICAL", 511, 523], ["NaCl", "CHEMICAL", 304, 308], ["glucose", "CHEMICAL", 470, 477], ["Cell Cultures", "CELL", 100, 113], ["E. faecium", "ORGANISM", 318, 328], ["R. solanacearum", "ORGANISM", 426, 441], ["M186", "SIMPLE_CHEMICAL", 461, 465], ["glucose", "SIMPLE_CHEMICAL", 470, 477], ["peptone", "SIMPLE_CHEMICAL", 484, 491], ["soymeal", "SIMPLE_CHEMICAL", 497, 504], ["E. faecium", "SPECIES", 318, 328], ["yeast", "SPECIES", 395, 400], ["R. solanacearum", "SPECIES", 426, 441], ["yeast", "SPECIES", 529, 534], ["E. faecium", "SPECIES", 318, 328], ["yeast", "SPECIES", 395, 400], ["R. solanacearum", "SPECIES", 426, 441], ["yeast", "SPECIES", 529, 534], ["All test strains", "TEST", 0, 16], ["Microorganisms", "PROBLEM", 81, 95], ["Cell Cultures", "TEST", 100, 113], ["Antibacterial", "TREATMENT", 137, 150], ["The bacteria", "PROBLEM", 231, 243], ["TSB medium", "TEST", 263, 273], ["tryptic soy broth", "TEST", 280, 297], ["E. faecium", "PROBLEM", 318, 328], ["trypticase soy broth", "TEST", 368, 388], ["yeast extract", "TEST", 395, 408], ["pH", "TEST", 410, 412], ["R. solanacearum", "TEST", 426, 441], ["glucose", "TEST", 470, 477], ["peptone", "TEST", 484, 491], ["soymeal", "TEST", 497, 504], ["bacteria", "OBSERVATION_MODIFIER", 235, 243]]], ["The cultivation of C. albicans took place in M186/3 (0.3% glucose, 0.17% peptone from soymeal, 0.1% malt extract, 0.1% yeast extract) and for C. neoformans M186 was used as well.", [["extract", "ANATOMY", 125, 132], ["M186/3", "CHEMICAL", 45, 51], ["glucose", "CHEMICAL", 58, 65], ["peptone", "CHEMICAL", 73, 80], ["soymeal", "CHEMICAL", 86, 93], ["malt extract", "CHEMICAL", 100, 112], ["yeast extract", "CHEMICAL", 119, 132], ["glucose", "CHEMICAL", 58, 65], ["C. albicans", "ORGANISM", 19, 30], ["M186/3", "SIMPLE_CHEMICAL", 45, 51], ["glucose", "SIMPLE_CHEMICAL", 58, 65], ["peptone", "SIMPLE_CHEMICAL", 73, 80], ["soymeal", "SIMPLE_CHEMICAL", 86, 93], ["C. neoformans M186", "ORGANISM", 142, 160], ["C. albicans", "SPECIES", 19, 30], ["yeast", "SPECIES", 119, 124], ["C. neoformans", "SPECIES", 142, 155], ["C. albicans", "SPECIES", 19, 30], ["yeast", "SPECIES", 119, 124], ["C. neoformans M186", "SPECIES", 142, 160], ["C. albicans", "PROBLEM", 19, 30], ["glucose", "TEST", 58, 65], ["soymeal", "TEST", 86, 93], ["C. neoformans M186", "TREATMENT", 142, 160]]], ["Overnight cultures of the test organisms were prepared and diluted to an optical density (600 nm) of 0.01\u20130.03.", [["Overnight cultures", "TEST", 0, 18], ["the test organisms", "TEST", 22, 40], ["an optical density", "TEST", 70, 88]]], ["To prepare the assay, the test samples (20 mg/ml DMSO stock solution) were dissolved in medium and transferred into a 96-well microtiter plate and 200 \u03bcl of the cell suspension cultures was added to each well.", [["samples", "ANATOMY", 31, 38], ["cell", "ANATOMY", 161, 165], ["DMSO", "CHEMICAL", 49, 53], ["cell", "CELL", 161, 165], ["cell suspension cultures", "CELL_LINE", 161, 185], ["the test samples", "TEST", 22, 38], ["DMSO stock solution", "TREATMENT", 49, 68], ["a 96-well microtiter plate", "TREATMENT", 116, 142], ["the cell suspension cultures", "TREATMENT", 157, 185]]], ["The final assay concentration of the substances was 100 \u03bcg/ml.", [["the substances", "TREATMENT", 33, 47]]], ["The inoculated microplates were incubated for 5 h at 37 \u00b0C and 200 rpm (E. faecium without shaking), or 28 \u00b0C and 200 rpm for 7 h for the phytopathogen bacteria and C. neoformans, respectively.", [["C. neoformans", "ORGANISM", 165, 178], ["E. faecium", "SPECIES", 72, 82], ["C. neoformans", "SPECIES", 165, 178], ["E. faecium", "SPECIES", 72, 82], ["C. neoformans", "SPECIES", 165, 178], ["The inoculated microplates", "TREATMENT", 0, 26], ["shaking", "PROBLEM", 91, 98], ["the phytopathogen bacteria", "PROBLEM", 134, 160], ["C. neoformans", "PROBLEM", 165, 178], ["neoformans", "OBSERVATION", 168, 178]]], ["To detect the inhibitory effect of the substances 10 \u03bcl of a resazurin solution (0.3 mg/ml phosphate-buffered saline) was added to the microplates and incubated again for 5\u201330 min before the fluorescence signal (560 nm/590 nm) was measured using the microplate reader (Tecan Infinite M200).", [["resazurin", "CHEMICAL", 61, 70], ["phosphate", "CHEMICAL", 91, 100], ["resazurin", "CHEMICAL", 61, 70], ["phosphate", "CHEMICAL", 91, 100], ["resazurin", "SIMPLE_CHEMICAL", 61, 70], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 91, 116], ["the substances", "TREATMENT", 35, 49], ["a resazurin solution", "TREATMENT", 59, 79], ["phosphate-buffered saline)", "TREATMENT", 91, 117], ["the microplates", "TREATMENT", 131, 146], ["the fluorescence signal", "TEST", 187, 210], ["the microplate reader", "TREATMENT", 246, 267]]], ["For E. faecium the pH indicator bromocresol purple was used to determine the acidification caused by growing, and for R. solanacearum and C. neoformans the optical density at 600 nm after incubation time was recorded using the microplate reader as well.", [["bromocresol", "CHEMICAL", 32, 43], ["E. faecium", "ORGANISM", 4, 14], ["R. solanacearum", "ORGANISM", 118, 133], ["C. neoformans", "ORGANISM", 138, 151], ["E. faecium", "SPECIES", 4, 14], ["R. solanacearum", "SPECIES", 118, 133], ["C. neoformans", "SPECIES", 138, 151], ["E. faecium", "SPECIES", 4, 14], ["R. solanacearum", "SPECIES", 118, 133], ["C. neoformans", "SPECIES", 138, 151], ["E. faecium", "PROBLEM", 4, 14], ["the pH", "TEST", 15, 21], ["bromocresol purple", "PROBLEM", 32, 50], ["the acidification", "PROBLEM", 73, 90], ["R. solanacearum", "PROBLEM", 118, 133], ["the microplate reader", "TREATMENT", 223, 244], ["faecium", "OBSERVATION", 7, 14]]], ["The resulting values were compared with a positive control (chloramphenicol for the bacteria, except R. solanacearum where tetracycline was used, nystatin for C. albicans and amphotericin B for C. neoformans) and a negative control (no compound) on the same plate.", [["chloramphenicol", "CHEMICAL", 60, 75], ["tetracycline", "CHEMICAL", 123, 135], ["nystatin", "CHEMICAL", 146, 154], ["amphotericin B", "CHEMICAL", 175, 189], ["chloramphenicol", "CHEMICAL", 60, 75], ["tetracycline", "CHEMICAL", 123, 135], ["nystatin", "CHEMICAL", 146, 154], ["amphotericin B", "CHEMICAL", 175, 189], ["chloramphenicol", "SIMPLE_CHEMICAL", 60, 75], ["R. solanacearum", "ORGANISM", 101, 116], ["tetracycline", "SIMPLE_CHEMICAL", 123, 135], ["nystatin", "SIMPLE_CHEMICAL", 146, 154], ["C. albicans", "ORGANISM", 159, 170], ["amphotericin B", "SIMPLE_CHEMICAL", 175, 189], ["C. neoformans", "ORGANISM", 194, 207], ["R. solanacearum", "SPECIES", 101, 116], ["C. albicans", "SPECIES", 159, 170], ["C. neoformans", "SPECIES", 194, 207], ["R. solanacearum", "SPECIES", 101, 116], ["C. albicans", "SPECIES", 159, 170], ["C. neoformans", "SPECIES", 194, 207], ["a positive control (chloramphenicol", "TREATMENT", 40, 75], ["the bacteria", "PROBLEM", 80, 92], ["R. solanacearum", "TREATMENT", 101, 116], ["tetracycline", "TREATMENT", 123, 135], ["nystatin", "TREATMENT", 146, 154], ["C. albicans", "TREATMENT", 159, 170], ["amphotericin B", "TREATMENT", 175, 189], ["C. neoformans", "PROBLEM", 194, 207]]], ["For IC50 determination, a dilution series was prepared and the IC50 value was calculated by Excel or GraphPad Prism as the concentration that shows 50% inhibition of viability on the basis of a negative control (no compound).Cytotoxic Activity and Activity Against Dermatophytic Fungi ::: Biological Activity Testing ::: Materials and MethodsMeasurements of cytotoxic activity and activity against dermatophytic fungi were performed as described in our previous study (Pfeifer Barbosa et al. 2019).Amides and Methyl Esters ::: Preparation of Semi-synthetic Derivatives 1a\u20131c and 2a\u20132e ::: Results and DiscussionAmidation and esterification of diterpenoids was accomplished using N-chlorosuccinimide and triphenylphosphine for conversion of the carboxylic acids and adding either N,N-diethylamine or methanol in pyridine to the reaction mixture as described in the protocols of Fr\u00f8yen (1994, 1995).", [["Methyl Esters", "CHEMICAL", 509, 522], ["esterification of diterpenoids", "CHEMICAL", 625, 655], ["N-chlorosuccinimide", "CHEMICAL", 679, 698], ["triphenylphosphine", "CHEMICAL", 703, 721], ["carboxylic acids", "CHEMICAL", 744, 760], ["N,N-diethylamine", "CHEMICAL", 779, 795], ["methanol", "CHEMICAL", 799, 807], ["pyridine", "CHEMICAL", 811, 819], ["Amides", "CHEMICAL", 498, 504], ["Methyl Esters", "CHEMICAL", 509, 522], ["diterpenoids", "CHEMICAL", 643, 655], ["N-chlorosuccinimide", "CHEMICAL", 679, 698], ["triphenylphosphine", "CHEMICAL", 703, 721], ["carboxylic acids", "CHEMICAL", 744, 760], ["N,N-diethylamine", "CHEMICAL", 779, 795], ["methanol", "CHEMICAL", 799, 807], ["pyridine", "CHEMICAL", 811, 819], ["Amides", "SIMPLE_CHEMICAL", 498, 504], ["Methyl Esters", "SIMPLE_CHEMICAL", 509, 522], ["Semi-synthetic Derivatives 1a\u20131c", "SIMPLE_CHEMICAL", 542, 574], ["2a\u20132e", "SIMPLE_CHEMICAL", 579, 584], ["N-chlorosuccinimide", "SIMPLE_CHEMICAL", 679, 698], ["triphenylphosphine", "SIMPLE_CHEMICAL", 703, 721], ["carboxylic acids", "SIMPLE_CHEMICAL", 744, 760], ["N,N-diethylamine", "SIMPLE_CHEMICAL", 779, 795], ["methanol", "SIMPLE_CHEMICAL", 799, 807], ["pyridine", "SIMPLE_CHEMICAL", 811, 819], ["IC50 determination", "TEST", 4, 22], ["a dilution series", "TEST", 24, 41], ["the IC50 value", "TEST", 59, 73], ["cytotoxic activity", "PROBLEM", 358, 376], ["dermatophytic fungi", "PROBLEM", 398, 417], ["our previous study", "TEST", 449, 467], ["diterpenoids", "TREATMENT", 643, 655], ["N-chlorosuccinimide", "TREATMENT", 679, 698], ["triphenylphosphine", "TREATMENT", 703, 721], ["the carboxylic acids", "TREATMENT", 740, 760], ["diethylamine", "TREATMENT", 783, 795], ["methanol", "TREATMENT", 799, 807], ["pyridine", "TREATMENT", 811, 819], ["the reaction mixture", "TREATMENT", 823, 843], ["negative", "OBSERVATION", 194, 202], ["cytotoxic activity", "OBSERVATION", 358, 376]]], ["The experiments were therefore downsized to 100 \u03bcmol of reactants (instead of 5 mmol) except for dichloromethane, of which 2 ml (instead of 6 ml) was used.", [["dichloromethane", "CHEMICAL", 97, 112], ["dichloromethane", "CHEMICAL", 97, 112], ["dichloromethane", "SIMPLE_CHEMICAL", 97, 112], ["reactants", "TREATMENT", 56, 65], ["dichloromethane", "TREATMENT", 97, 112]]], ["Purification was conducted as described in the protocols (concentration, filtration and washing with diethyl ether, silica gel column with ether as eluent).", [["diethyl ether", "CHEMICAL", 101, 114], ["silica gel", "CHEMICAL", 116, 126], ["diethyl ether", "CHEMICAL", 101, 114], ["silica gel", "CHEMICAL", 116, 126], ["ether", "CHEMICAL", 139, 144], ["diethyl ether", "SIMPLE_CHEMICAL", 101, 114], ["silica", "SIMPLE_CHEMICAL", 116, 122], ["ether", "SIMPLE_CHEMICAL", 139, 144], ["filtration", "TREATMENT", 73, 83], ["washing with diethyl ether, silica gel column", "TREATMENT", 88, 133]]], ["However, for the last purification step another silica gel column with n-hexane as eluent was preferred over crystallisation or distillation, respectively.", [["n-hexane", "CHEMICAL", 71, 79], ["silica gel", "CHEMICAL", 48, 58], ["n-hexane", "CHEMICAL", 71, 79], ["silica", "SIMPLE_CHEMICAL", 48, 54], ["n-hexane", "SIMPLE_CHEMICAL", 71, 79], ["the last purification step another silica gel column", "TREATMENT", 13, 65], ["n-hexane", "TREATMENT", 71, 79]]], ["All four derivatives were subsequently analysed by GC-MS2 showing the expected m/z ratios of 371 (1a), 357 (2a), 330 (1b), and 316 (2b) and by NMR spectroscopy comparing their spectra to literature data (Narayanan and Venkatasubramanian 1965; Vieira et al. 2002; Mizuno et al. 2015; Santos et al. 2016).", [["the expected m/z ratios", "TEST", 66, 89], ["NMR spectroscopy", "TEST", 143, 159]]], ["The methyl esters (1b and 2b) were additionally identified by comparing their mass spectra to the spectra available in the NIST database.Dihydroxy Derivatives ::: Preparation of Semi-synthetic Derivatives 1a\u20131c and 2a\u20132e ::: Results and DiscussionDihydroxy derivatives of compounds 1 and 2 were prepared with potassium permanganate in alkaline medium following a protocol for the hydroxylation of lambertianic acid (Chernov et al. 2006).", [["methyl esters", "CHEMICAL", 4, 17], ["Dihydroxy", "CHEMICAL", 137, 146], ["potassium permanganate", "CHEMICAL", 309, 331], ["lambertianic acid", "CHEMICAL", 397, 414], ["methyl esters", "CHEMICAL", 4, 17], ["Dihydroxy", "CHEMICAL", 137, 146], ["Dihydroxy", "CHEMICAL", 247, 256], ["potassium permanganate", "CHEMICAL", 309, 331], ["lambertianic acid", "CHEMICAL", 397, 414], ["methyl esters", "SIMPLE_CHEMICAL", 4, 17], ["Dihydroxy Derivatives", "SIMPLE_CHEMICAL", 137, 158], ["Semi-synthetic Derivatives 1a\u20131c", "SIMPLE_CHEMICAL", 178, 210], ["2a\u20132e", "SIMPLE_CHEMICAL", 215, 220], ["Dihydroxy derivatives", "SIMPLE_CHEMICAL", 247, 268], ["potassium permanganate", "SIMPLE_CHEMICAL", 309, 331], ["lambertianic acid", "SIMPLE_CHEMICAL", 397, 414], ["The methyl esters", "TEST", 0, 17], ["DiscussionDihydroxy derivatives of compounds", "TREATMENT", 237, 281], ["potassium permanganate in alkaline medium", "TREATMENT", 309, 350], ["a protocol", "TREATMENT", 361, 371], ["the hydroxylation of lambertianic acid", "TREATMENT", 376, 414], ["methyl", "ANATOMY_MODIFIER", 4, 10]]], ["Lambertianic acid is an epimer of (+)-polyalthic acid at position C-4 and thus a stereoisomer of (\u2212)-polyalthic acid (1), showing different configurations at positions C-5, C-9, and C-10.", [["Lambertianic acid", "CHEMICAL", 0, 17], ["Lambertianic acid", "CHEMICAL", 0, 17], ["(+)-polyalthic acid", "CHEMICAL", 34, 53], ["(\u2212)-polyalthic acid", "CHEMICAL", 97, 116], ["Lambertianic acid", "SIMPLE_CHEMICAL", 0, 17], ["(+)-polyalthic acid", "SIMPLE_CHEMICAL", 34, 53], ["C-4", "SIMPLE_CHEMICAL", 66, 69], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 97, 116], ["C-5", "SIMPLE_CHEMICAL", 168, 171], ["C-9", "SIMPLE_CHEMICAL", 173, 176], ["C-10", "SIMPLE_CHEMICAL", 182, 186], ["Lambertianic acid", "TEST", 0, 17], ["an epimer", "TEST", 21, 30], ["polyalthic acid", "TEST", 38, 53], ["polyalthic acid", "TEST", 101, 116], ["C", "TEST", 168, 169], ["C", "TEST", 173, 174], ["C", "TEST", 182, 183]]], ["Using scales of 100 \u03bcmol of diterpenoid instead of 20 mmol, the reaction yielded (4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid (1c), a previously undescribed compound, and the known compound 16\u03b1,17-dihydroxy-ent-kauran-19-oic acid (2c).", [["4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "CHEMICAL", 82, 151], ["16\u03b1,17-dihydroxy-ent-kauran-19-oic acid", "CHEMICAL", 216, 255], ["diterpenoid", "CHEMICAL", 28, 39], ["(4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "CHEMICAL", 81, 151], ["16\u03b1,17-dihydroxy-ent-kauran-19-oic acid", "CHEMICAL", 216, 255], ["diterpenoid", "SIMPLE_CHEMICAL", 28, 39], ["(4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid (1c)", "SIMPLE_CHEMICAL", 81, 156], ["compound 16\u03b1,17-dihydroxy-ent-kauran-19-oic acid (2c", "SIMPLE_CHEMICAL", 207, 259], ["diterpenoid", "TREATMENT", 28, 39], ["the reaction", "TEST", 60, 72], ["epoxy", "TEST", 95, 100], ["dihydroxy", "TEST", 106, 115], ["labdadien", "TEST", 130, 139], ["dihydroxy", "TEST", 223, 232], ["kauran", "TEST", 237, 243]]], ["Whereas the latter compound was identified by comparison of MS and NMR spectra to literature data (Song et al. 2018), structure elucidation of compound 1c is described in \u201cStructure Elucidation and Configuration of Compound 1c\u201d.Monohydroxy and Methoxy Derivatives ::: Preparation of Semi-synthetic Derivatives 1a\u20131c and 2a\u20132e ::: Results and DiscussionPreparation of 16\u03b1-hydroxy-ent-kauran-19-oic acid (2d), 16\u03b1-methoxy-ent-kauran-19-oic acid (2e) was performed using acid-catalysed hydroxylation and methoxylation, respectively (Cavalcanti et al. 2009).", [["Monohydroxy", "CHEMICAL", 228, 239], ["16\u03b1-hydroxy-ent-kauran-19-oic acid", "CHEMICAL", 367, 401], ["16\u03b1-methoxy-ent-kauran-19-oic acid", "CHEMICAL", 408, 442], ["Monohydroxy", "CHEMICAL", 228, 239], ["Methoxy", "CHEMICAL", 244, 251], ["16\u03b1-hydroxy-ent-kauran-19-oic acid", "CHEMICAL", 367, 401], ["16\u03b1-methoxy-ent-kauran-19-oic acid", "CHEMICAL", 408, 442], ["Monohydroxy", "SIMPLE_CHEMICAL", 228, 239], ["Methoxy Derivatives ::", "SIMPLE_CHEMICAL", 244, 266], ["Semi-synthetic Derivatives 1a\u20131c", "SIMPLE_CHEMICAL", 283, 315], ["2a\u20132e ::", "SIMPLE_CHEMICAL", 320, 328], ["16\u03b1-hydroxy-ent-kauran-19-oic acid", "SIMPLE_CHEMICAL", 367, 401], ["2d", "SIMPLE_CHEMICAL", 403, 405], ["16\u03b1-methoxy-ent-kauran-19-oic acid", "SIMPLE_CHEMICAL", 408, 442], ["2e", "SIMPLE_CHEMICAL", 444, 446], ["MS", "TEST", 60, 62], ["literature data", "TEST", 82, 97], ["compound 1c", "PROBLEM", 143, 154], ["Monohydroxy and Methoxy Derivatives", "TREATMENT", 228, 263], ["Semi-synthetic Derivatives", "TREATMENT", 283, 309], ["DiscussionPreparation", "TEST", 342, 363], ["hydroxy", "TEST", 371, 378], ["kauran", "TEST", 383, 389], ["oic acid", "TEST", 393, 401], ["methoxy", "TREATMENT", 412, 419], ["kauran", "TEST", 424, 430], ["acid-catalysed hydroxylation", "TREATMENT", 468, 496], ["methoxylation", "TREATMENT", 501, 514], ["compound 1c", "OBSERVATION", 143, 154], ["Compound 1c", "OBSERVATION", 215, 226]]], ["For these reactions, amounts of 50 mg were applied instead of 1 g and the resulting products were identified by comparison of their MS and NMR data to literature (Chen et al. 2000; Yaouba et al. 2018).Structure Elucidation and Configuration of Compound 1c ::: Results and DiscussionAs mentioned above, compound 1c was synthesised using a protocol (Chernov et al. 2006) reported for the transformation of lambertianic acid, a stereoisomer of (\u2212)-polyalthic acid (1).", [["lambertianic acid", "CHEMICAL", 404, 421], ["stereoisomer of (\u2212)-polyalthic acid", "CHEMICAL", 425, 460], ["lambertianic acid", "CHEMICAL", 404, 421], ["(\u2212)-polyalthic acid", "CHEMICAL", 441, 460], ["lambertianic acid", "SIMPLE_CHEMICAL", 404, 421], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 441, 460], ["these reactions", "PROBLEM", 4, 19], ["NMR data", "TEST", 139, 147], ["a protocol", "TREATMENT", 336, 346], ["lambertianic acid", "TREATMENT", 404, 421], ["polyalthic acid", "TREATMENT", 445, 460]]], ["The side chain at C-10 of lambertianic acid is \u03b2-oriented leading to \u03b1-oriented hydroxylation at position C-8, due to steric hindrance by the furanoethyl group.", [["C-10 of lambertianic acid", "CHEMICAL", 18, 43], ["C-8", "CHEMICAL", 106, 109], ["furanoethyl", "CHEMICAL", 142, 153], ["lambertianic acid", "CHEMICAL", 26, 43], ["furanoethyl", "CHEMICAL", 142, 153], ["C-10", "SIMPLE_CHEMICAL", 18, 22], ["lambertianic acid", "SIMPLE_CHEMICAL", 26, 43], ["C-8", "SIMPLE_CHEMICAL", 106, 109], ["furanoethyl", "SIMPLE_CHEMICAL", 142, 153], ["\u03b1-oriented hydroxylation at position C", "PROBLEM", 69, 107], ["side", "OBSERVATION_MODIFIER", 4, 8], ["chain", "OBSERVATION_MODIFIER", 9, 14]]], ["In contrast, (\u2212)-polyalthic acid (1) shows an \u03b1-oriented side chain at C-10; hence, the resulting hydroxy group at position C-8 had to have \u03b2-orientation and the hydroxymethylene group \u03b1-orientation instead.", [["polyalthic acid", "CHEMICAL", 17, 32], ["hydroxy", "CHEMICAL", 98, 105], ["hydroxymethylene", "CHEMICAL", 162, 178], ["(\u2212)-polyalthic acid", "CHEMICAL", 13, 32], ["hydroxy", "CHEMICAL", 98, 105], ["hydroxymethylene", "CHEMICAL", 162, 178], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 13, 32], ["C-10", "SIMPLE_CHEMICAL", 71, 75], ["hydroxy", "SIMPLE_CHEMICAL", 98, 105], ["hydroxymethylene", "SIMPLE_CHEMICAL", 162, 178], ["polyalthic acid", "TEST", 17, 32], ["an \u03b1-oriented side chain", "PROBLEM", 43, 67], ["\u03b2-orientation", "TREATMENT", 140, 153], ["the hydroxymethylene group \u03b1-orientation", "TREATMENT", 158, 198]]], ["The \u03b1-orientation of the hydroxymethylene group was confirmed using NOESY, where NOE correlations were observed for the protons at C-17 on both the methylene group at C-11 and the C-20 methyl group.", [["hydroxymethylene", "CHEMICAL", 25, 41], ["C-17", "CHEMICAL", 131, 135], ["methylene", "CHEMICAL", 148, 157], ["C-11", "CHEMICAL", 167, 171], ["C-20 methyl", "CHEMICAL", 180, 191], ["hydroxymethylene", "CHEMICAL", 25, 41], ["methylene", "CHEMICAL", 148, 157], ["C-20 methyl", "CHEMICAL", 180, 191], ["hydroxymethylene", "SIMPLE_CHEMICAL", 25, 41], ["NOE", "SIMPLE_CHEMICAL", 81, 84], ["protons", "SIMPLE_CHEMICAL", 120, 127], ["C-17", "SIMPLE_CHEMICAL", 131, 135], ["methylene", "SIMPLE_CHEMICAL", 148, 157], ["C-11", "SIMPLE_CHEMICAL", 167, 171], ["C-20 methyl", "SIMPLE_CHEMICAL", 180, 191], ["the C-20 methyl group", "TREATMENT", 176, 197]]], ["Thus, the structure was identified as (4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid or (rel-1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid, respectively (see \u201cStereochemistry of Polyalthic Acid, Daniellic Acid and Lambertianic Acid\u201d).", [["4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "CHEMICAL", 39, 108], ["rel-1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid", "CHEMICAL", 113, 254], ["(4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "CHEMICAL", 38, 108], ["(rel-1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid", "CHEMICAL", 112, 254], ["Polyalthic Acid", "CHEMICAL", 294, 309], ["Daniellic Acid", "CHEMICAL", 311, 325], ["Lambertianic Acid", "CHEMICAL", 330, 347], ["(4S,8S)-15,16-epoxy-8,17-dihydroxy-13(16),14-ent-labdadien-18-oic acid", "SIMPLE_CHEMICAL", 38, 108], ["(rel-1S,4aR,5S,6S,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-hydroxy-6-hydroxymethyl-3,4,5,7,8,8a-hexahydro-2H-naphthalene-1-carboxylic acid", "SIMPLE_CHEMICAL", 112, 254], ["Polyalthic Acid", "SIMPLE_CHEMICAL", 294, 309], ["Daniellic Acid", "SIMPLE_CHEMICAL", 311, 325], ["Lambertianic Acid", "SIMPLE_CHEMICAL", 330, 347], ["epoxy", "TEST", 52, 57], ["labdadien", "TREATMENT", 87, 96], ["oic acid", "TEST", 100, 108], ["furan", "TEST", 141, 146], ["ethyl", "TEST", 152, 157], ["-hydroxy", "TEST", 174, 182], ["hexahydro", "TEST", 212, 221], ["naphthalene", "TREATMENT", 225, 236], ["carboxylic acid", "TREATMENT", 239, 254], ["Polyalthic Acid", "TREATMENT", 294, 309], ["Daniellic Acid", "TREATMENT", 311, 325], ["Lambertianic Acid\u201d", "TREATMENT", 330, 348]]], ["Same as (\u2212)-polyalthic acid (1), the new compound (1c) showed a negative specific rotation value [\u03b1D20\u201314.9, c = 0.1, methanol).", [["(\u2212)-polyalthic acid", "CHEMICAL", 8, 27], ["methanol", "CHEMICAL", 118, 126], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 8, 27], ["methanol", "SIMPLE_CHEMICAL", 118, 126], ["polyalthic acid", "TEST", 12, 27], ["\u03b1D20", "TEST", 98, 102]]], ["HR-ESI-MS revealed m/z ratios of 373.1994 [M + Na]+ and 723.4090 [2 M + Na]+, corresponding to the molecular formula C20H30O5 with the experimental mass of M 350.2096 (calculated mass was M 350.2093).", [["Na", "CHEMICAL", 47, 49], ["Na", "CHEMICAL", 72, 74], ["Na", "CHEMICAL", 47, 49], ["Na", "CHEMICAL", 72, 74], ["C20H30O5", "CHEMICAL", 117, 125], ["+ Na]+", "SIMPLE_CHEMICAL", 70, 76], ["C20H30O5", "SIMPLE_CHEMICAL", 117, 125], ["HR", "TEST", 0, 2], ["ESI", "TEST", 3, 6], ["m/z ratios", "TEST", 19, 29], ["Na", "TEST", 47, 49], ["Na", "TEST", 72, 74], ["the molecular formula", "TEST", 95, 116], ["mass", "OBSERVATION", 148, 152]]], ["NMR data for compound 1c is given in Table 1.Stereochemistry of Polyalthic Acid, Daniellic Acid and Lambertianic Acid ::: Results and DiscussionAs described above, hydroxylation of (\u2212)-polyalthic acid (1) followed a protocol of Chernov et al. (2006), who used lambertianic acid as starting material.", [["Polyalthic Acid", "CHEMICAL", 64, 79], ["Daniellic Acid", "CHEMICAL", 81, 95], ["polyalthic acid", "CHEMICAL", 185, 200], ["lambertianic acid", "CHEMICAL", 260, 277], ["Polyalthic Acid", "CHEMICAL", 64, 79], ["Daniellic Acid", "CHEMICAL", 81, 95], ["Lambertianic Acid", "CHEMICAL", 100, 117], ["(\u2212)-polyalthic acid", "CHEMICAL", 181, 200], ["lambertianic acid", "CHEMICAL", 260, 277], ["Polyalthic Acid", "SIMPLE_CHEMICAL", 64, 79], ["Daniellic Acid", "SIMPLE_CHEMICAL", 81, 95], ["Lambertianic Acid", "SIMPLE_CHEMICAL", 100, 117], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 181, 200], ["lambertianic acid", "SIMPLE_CHEMICAL", 260, 277], ["NMR data", "TEST", 0, 8], ["Polyalthic Acid", "TREATMENT", 64, 79], ["Daniellic Acid", "TREATMENT", 81, 95], ["polyalthic acid", "TREATMENT", 185, 200], ["lambertianic acid", "TREATMENT", 260, 277]]], ["However, during the course of the structure determination of compound 1c and assignment of the absolute configuration, some inconsistencies have been observed with regard to the stereochemistry of polyalthic acid and its structural isomers, which we attempted to resolve hereafter.Stereochemistry of Polyalthic Acid, Daniellic Acid and Lambertianic Acid ::: Results and DiscussionThe first two of these four compounds to be reported were (\u2212)-polyalthic acid (1) and daniellic acid in 1961.", [["polyalthic acid", "CHEMICAL", 197, 212], ["Polyalthic Acid", "CHEMICAL", 300, 315], ["Daniellic Acid", "CHEMICAL", 317, 331], ["daniellic acid", "CHEMICAL", 466, 480], ["polyalthic acid", "CHEMICAL", 197, 212], ["Polyalthic Acid", "CHEMICAL", 300, 315], ["Daniellic Acid", "CHEMICAL", 317, 331], ["Lambertianic Acid", "CHEMICAL", 336, 353], ["(\u2212)-polyalthic acid", "CHEMICAL", 438, 457], ["daniellic acid", "CHEMICAL", 466, 480], ["polyalthic acid", "SIMPLE_CHEMICAL", 197, 212], ["Polyalthic Acid", "SIMPLE_CHEMICAL", 300, 315], ["Daniellic Acid", "SIMPLE_CHEMICAL", 317, 331], ["Lambertianic Acid", "SIMPLE_CHEMICAL", 336, 353], ["(\u2212)-polyalthic acid (1)", "SIMPLE_CHEMICAL", 438, 461], ["daniellic acid", "SIMPLE_CHEMICAL", 466, 480], ["the absolute configuration", "PROBLEM", 91, 117], ["polyalthic acid", "PROBLEM", 197, 212], ["Polyalthic Acid", "TREATMENT", 300, 315], ["Daniellic Acid", "TREATMENT", 317, 331], ["absolute configuration", "OBSERVATION", 95, 117]]], ["As the absolute configuration has not been determined yet, (\u2212)-polyalthic acid is correctly described as (rel-1S,4aS,5R,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid.", [["rel-1S,4aS,5R,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid", "CHEMICAL", 106, 213], ["(\u2212)-polyalthic acid", "CHEMICAL", 59, 78], ["(rel-1S,4aS,5R,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid", "CHEMICAL", 105, 213], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 59, 78], ["(rel-1S,4aS,5R,8aS)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid", "SIMPLE_CHEMICAL", 105, 213], ["polyalthic acid", "TEST", 63, 78], ["4aS", "TEST", 113, 116], ["8aS", "TEST", 120, 123], ["furan", "TEST", 131, 136], ["ethyl", "TEST", 142, 147], ["dimethyl", "TREATMENT", 154, 162], ["-methylene", "TREATMENT", 164, 174], ["decahydronaphthalene", "TREATMENT", 175, 195], ["carboxylic acid", "TREATMENT", 198, 213]]], ["Daniellic acid was isolated from Daniellia oliveri (Fabaceae, Caesalpinioideae) (Haeuser and Ourisson 1961), whereas (\u2212)-polyalthic acid (1) was obtained from Polyalthia fragrans (Annonaceae) and named polyalthic acid (Gopinath et al. 1961).", [["Daniellic acid", "CHEMICAL", 0, 14], ["(\u2212)-polyalthic acid", "CHEMICAL", 117, 136], ["polyalthic acid", "CHEMICAL", 202, 217], ["Daniellic acid", "CHEMICAL", 0, 14], ["(\u2212)-polyalthic acid", "CHEMICAL", 117, 136], ["polyalthic acid", "CHEMICAL", 202, 217], ["Daniellic acid", "SIMPLE_CHEMICAL", 0, 14], ["Daniellia oliveri", "ORGANISM", 33, 50], ["Fabaceae", "ORGANISM", 52, 60], ["Caesalpinioideae", "ORGANISM", 62, 78], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 117, 136], ["Polyalthia fragrans", "ORGANISM", 159, 178], ["Annonaceae", "ORGANISM", 180, 190], ["polyalthic acid", "SIMPLE_CHEMICAL", 202, 217], ["Daniellia oliveri", "SPECIES", 33, 50], ["Polyalthia fragrans", "SPECIES", 159, 178], ["Daniellia oliveri", "SPECIES", 33, 50], ["Polyalthia fragrans", "SPECIES", 159, 178], ["Daniellic acid", "TREATMENT", 0, 14], ["polyalthic acid", "TREATMENT", 121, 136]]], ["Both compounds were attributed to possess the \u201cwrong\u201d configuration corresponding to an ent-labdane scaffold and showing negative optical rotation values.", [["ent-labdane", "CHEMICAL", 88, 99]]], ["Both compounds are epimers, only differing in the orientation of the carboxyl group at position C-4, which is axial for daniellic acid and equatorial for (\u2212)-polyalthic acid (1).", [["daniellic acid", "CHEMICAL", 120, 134], ["carboxyl", "CHEMICAL", 69, 77], ["daniellic acid", "CHEMICAL", 120, 134], ["(\u2212)-polyalthic acid", "CHEMICAL", 154, 173], ["C-4", "SIMPLE_CHEMICAL", 96, 99], ["daniellic acid", "SIMPLE_CHEMICAL", 120, 134], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 154, 173], ["daniellic acid", "TEST", 120, 134], ["epimers", "OBSERVATION_MODIFIER", 19, 26]]], ["Five years later, the first report for lambertianic acid, isolated from Pinus lambertiana (Pinaceae), was made (Dauben and Dauben and German 1965).", [["lambertianic acid", "CHEMICAL", 39, 56], ["lambertianic acid", "CHEMICAL", 39, 56], ["lambertianic acid", "SIMPLE_CHEMICAL", 39, 56], ["Pinus lambertiana", "ORGANISM", 72, 89], ["Pinus lambertiana", "SPECIES", 72, 89], ["Pinus lambertiana", "SPECIES", 72, 89], ["lambertianic acid", "PROBLEM", 39, 56], ["Pinus lambertiana", "OBSERVATION", 72, 89]]], ["Lambertianic acid was found to be the optical antipode of daniellic acid and thus to be the first furan diterpene with the so-called normal labdane configuration.", [["Lambertianic acid", "CHEMICAL", 0, 17], ["daniellic acid", "CHEMICAL", 58, 72], ["furan diterpene", "CHEMICAL", 98, 113], ["Lambertianic acid", "CHEMICAL", 0, 17], ["daniellic acid", "CHEMICAL", 58, 72], ["furan diterpene", "CHEMICAL", 98, 113], ["labdane", "CHEMICAL", 140, 147], ["Lambertianic acid", "SIMPLE_CHEMICAL", 0, 17], ["daniellic acid", "SIMPLE_CHEMICAL", 58, 72], ["furan diterpene", "SIMPLE_CHEMICAL", 98, 113], ["labdane", "SIMPLE_CHEMICAL", 140, 147], ["Lambertianic acid", "TEST", 0, 17], ["daniellic acid", "PROBLEM", 58, 72], ["normal", "OBSERVATION", 133, 139], ["labdane configuration", "OBSERVATION", 140, 161]]], ["The last of the four isomers was the optical antipode of (\u2212)-polyalthic acid (1), isolated from Sequoia semperivirens, Taxodiaceae (Ohta and Nawamaki 1978).", [["(\u2212)-polyalthic acid", "CHEMICAL", 57, 76], ["(\u2212)-polyalthic acid", "CHEMICAL", 57, 76], ["(\u2212)-polyalthic acid (1)", "SIMPLE_CHEMICAL", 57, 80], ["Sequoia semperivirens", "ORGANISM", 96, 117], ["Taxodiaceae", "ORGANISM", 119, 130], ["Sequoia semperivirens", "SPECIES", 96, 117], ["Sequoia semperivirens", "SPECIES", 96, 117], ["polyalthic acid", "PROBLEM", 61, 76]]], ["However, instead of choosing an original trivial name (e.g. semperiviric acid), the authors named the compound (+)-polyalthic acid, being (rel-1R,4aR,5S,8aR)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid.", [["semperiviric acid", "CHEMICAL", 60, 77], ["rel-1R,4aR,5S,8aR)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid", "CHEMICAL", 139, 246], ["semperiviric acid", "CHEMICAL", 60, 77], ["(+)-polyalthic acid", "CHEMICAL", 111, 130], ["(rel-1R,4aR,5S,8aR)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid", "CHEMICAL", 138, 246], ["semperiviric acid", "SIMPLE_CHEMICAL", 60, 77], ["(+)-polyalthic acid", "SIMPLE_CHEMICAL", 111, 130], ["(rel-1R,4aR,5S,8aR)-5-[2-(furan-3-yl)ethyl]-1,4a-dimethyl-6-methylene-decahydronaphthalene-1-carboxylic acid", "SIMPLE_CHEMICAL", 138, 246], ["polyalthic acid", "TEST", 115, 130], ["4aR", "TEST", 146, 149], ["8aR", "TEST", 153, 156], ["furan", "TEST", 164, 169], ["ethyl", "TEST", 175, 180], ["dimethyl", "TREATMENT", 187, 195], ["-methylene", "TREATMENT", 197, 207], ["decahydronaphthalene", "TREATMENT", 208, 228], ["carboxylic acid", "TREATMENT", 231, 246]]], ["Thus, from then onwards, two forms of polyalthic acid existed in the literature.", [["polyalthic acid", "CHEMICAL", 38, 53], ["polyalthic acid", "CHEMICAL", 38, 53], ["polyalthic acid", "SIMPLE_CHEMICAL", 38, 53], ["polyalthic acid", "PROBLEM", 38, 53]]], ["Except for the last 3 years, where (+)- and (\u2212)- or ent- prefixes were used to differentiate between the two enantiomers (Bardaj\u00ed et al. 2016; Borges et al. 2016; Carneiro et al. 2018; \u00c7i\u00e7ek et al. 2018; Pfeifer Barbosa et al. 2019; Senedese et al. 2019), only one publication in almost four decades adopted such prefixes (Miyazawa et al. 1995).", [["(\u2212)", "SIMPLE_CHEMICAL", 44, 47], ["ent- prefixes", "SIMPLE_CHEMICAL", 52, 65]]], ["The missing stereochemistry did not represent a problem as long as the studies were dealing with Copaifera, because the ent-configuration is abundant in this genus (Leandro et al. 2012).", [["the studies", "TEST", 67, 78], ["did not represent", "UNCERTAINTY", 28, 45]]], ["However, some studies investigated plant species from other plant families; wherefore, the identity of the right enantiomer remained unknown.", [["some studies", "TEST", 9, 21], ["right", "ANATOMY_MODIFIER", 107, 112]]], ["Thus, reporting the right configuration for polyalthic acid is absolutely necessary.Stereochemistry of Polyalthic Acid, Daniellic Acid and Lambertianic Acid ::: Results and DiscussionAnother problem is that the introduction of (+)-polyalthic acid and the recent use of the ent-prefix for differentiation of the enantiomers seems to have caused confusions in some large databases, such as SciFinder\u2122 or Reaxys\u2122.", [["polyalthic acid", "CHEMICAL", 44, 59], ["Polyalthic Acid", "CHEMICAL", 103, 118], ["Daniellic Acid", "CHEMICAL", 120, 134], ["Lambertianic Acid", "CHEMICAL", 139, 156], ["polyalthic acid", "CHEMICAL", 231, 246], ["polyalthic acid", "CHEMICAL", 44, 59], ["Polyalthic Acid", "CHEMICAL", 103, 118], ["Daniellic Acid", "CHEMICAL", 120, 134], ["Lambertianic Acid", "CHEMICAL", 139, 156], ["(+)-polyalthic acid", "CHEMICAL", 227, 246], ["polyalthic acid", "SIMPLE_CHEMICAL", 44, 59], ["Polyalthic Acid", "SIMPLE_CHEMICAL", 103, 118], ["Daniellic Acid", "SIMPLE_CHEMICAL", 120, 134], ["Lambertianic Acid", "SIMPLE_CHEMICAL", 139, 156], ["(+)-polyalthic acid", "SIMPLE_CHEMICAL", 227, 246], ["SciFinder\u2122", "SIMPLE_CHEMICAL", 388, 398], ["polyalthic acid", "PROBLEM", 44, 59], ["Polyalthic Acid", "TREATMENT", 103, 118], ["Daniellic Acid", "TREATMENT", 120, 134], ["polyalthic acid", "PROBLEM", 231, 246], ["the ent-prefix", "TREATMENT", 269, 283], ["the enantiomers", "PROBLEM", 307, 322], ["confusions", "PROBLEM", 344, 354], ["right", "ANATOMY_MODIFIER", 20, 25]]], ["For example, when searching for structure templates of polyalthic acid in the Reaxys database, three suggestions are delivered, of which two display (\u2212)-polyalthic acid and the other one shows (+)-polyalthic acid.", [["polyalthic acid", "CHEMICAL", 55, 70], ["polyalthic acid", "CHEMICAL", 55, 70], ["(\u2212)-polyalthic acid", "CHEMICAL", 149, 168], ["(+)-polyalthic acid", "CHEMICAL", 193, 212], ["polyalthic acid", "SIMPLE_CHEMICAL", 55, 70], ["polyalthic acid", "SIMPLE_CHEMICAL", 153, 168], ["(+)-polyalthic acid", "SIMPLE_CHEMICAL", 193, 212], ["polyalthic acid", "PROBLEM", 55, 70], ["polyalthic acid", "TEST", 153, 168], ["polyalthic acid", "PROBLEM", 197, 212]]], ["However, by using the name ent-polyalthic acid, also two structures are displayed, one for (\u2212)-polyalthic acid and the second one for daniellic acid.", [["daniellic acid", "CHEMICAL", 134, 148], ["polyalthic acid", "CHEMICAL", 31, 46], ["(\u2212)-polyalthic acid", "CHEMICAL", 91, 110], ["daniellic acid", "CHEMICAL", 134, 148], ["ent-polyalthic acid", "SIMPLE_CHEMICAL", 27, 46], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 91, 110], ["daniellic acid", "SIMPLE_CHEMICAL", 134, 148], ["polyalthic acid", "TREATMENT", 95, 110], ["daniellic acid", "TREATMENT", 134, 148]]], ["By looking for chemical structures in the SciFinder database, the name polyalthic acid leads to the structure of (\u2212)-polyalthic acid, which is historically correct, whereas the search for ent-polyalthic acid gives the structure of daniellic acid and thus the wrong compound.", [["polyalthic acid", "CHEMICAL", 71, 86], ["ent-polyalthic acid", "CHEMICAL", 188, 207], ["daniellic acid", "CHEMICAL", 231, 245], ["polyalthic acid", "CHEMICAL", 71, 86], ["(\u2212)-polyalthic acid", "CHEMICAL", 113, 132], ["ent-polyalthic acid", "CHEMICAL", 188, 207], ["daniellic acid", "CHEMICAL", 231, 245], ["polyalthic acid", "SIMPLE_CHEMICAL", 71, 86], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 113, 132], ["ent-polyalthic acid", "SIMPLE_CHEMICAL", 188, 207], ["daniellic acid", "SIMPLE_CHEMICAL", 231, 245], ["polyalthic acid", "PROBLEM", 117, 132], ["ent-polyalthic acid", "TREATMENT", 188, 207], ["daniellic acid", "PROBLEM", 231, 245]]], ["Alas, these inconsistencies or confusions, respectively, led to several publications showing the structure of daniellic acid instead of (\u2212)-polyalthic acid (Leandro et al. 2012, \u00c7i\u00e7ek et al. 2018, Da Silva et al. 2017; Pfeifer Barbosa et al. 2019).", [["daniellic acid", "CHEMICAL", 110, 124], ["daniellic acid", "CHEMICAL", 110, 124], ["(\u2212)-polyalthic acid", "CHEMICAL", 136, 155], ["daniellic acid", "SIMPLE_CHEMICAL", 110, 124], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 136, 155], ["confusions", "PROBLEM", 31, 41], ["daniellic acid", "TREATMENT", 110, 124]]], ["The mentioned problems can be partly dealt with by using the prefixes of the respective optical rotations, leading to the exact structures for both (+)- and (\u2212)-polyalthic acid in the Reaxys database and also to the correct structure for (+)-polyalthic acid with the SciFinder database.", [["(+)- and (\u2212)-polyalthic acid", "CHEMICAL", 148, 176], ["(+)-polyalthic acid", "CHEMICAL", 238, 257], ["(+)", "SIMPLE_CHEMICAL", 148, 151], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 157, 176], ["(+)-polyalthic acid", "SIMPLE_CHEMICAL", 238, 257]]], ["Only the name (\u2212)-polyalthic acid does not yield any results with SciFinder, but as the name polyalthic acid leads to the structure of (\u2212)-polyalthic acid and the optical rotation can be retrieved from the experimental details, at least no misinformation is spread.", [["polyalthic acid", "CHEMICAL", 93, 108], ["(\u2212)-polyalthic acid", "CHEMICAL", 14, 33], ["polyalthic acid", "CHEMICAL", 93, 108], ["(\u2212)-polyalthic acid", "CHEMICAL", 135, 154], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 14, 33], ["SciFinder", "SIMPLE_CHEMICAL", 66, 75], ["polyalthic acid", "SIMPLE_CHEMICAL", 93, 108], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 135, 154], ["polyalthic acid", "PROBLEM", 18, 33], ["polyalthic acid", "PROBLEM", 139, 154]]], ["We therefore suggest to use the prefix for the optical rotation only.Cytotoxic Effects ::: Results and DiscussionIn our previous study, we investigated the effect of copaiba diterpenoids against A-375, HepG2, HT-29, HCT-116, A-549 and MDA-MB-231 cancer cell lines as well as non-cancerous HaCaT cell lines resulting in weak to moderate non-selective cytotoxic effects with IC50 values of 66.2 to 96.4 \u03bcg/ml for (\u2212)-polyalthic acid (1) and 50.2 to 79.6 \u03bcg/ml for kaurenoic acid (2) (Pfeifer Barbosa et al. 2019).", [["A-375", "ANATOMY", 195, 200], ["HepG2", "ANATOMY", 202, 207], ["HT-29", "ANATOMY", 209, 214], ["HCT-116", "ANATOMY", 216, 223], ["A-549", "ANATOMY", 225, 230], ["MDA-MB-231 cancer cell lines", "ANATOMY", 235, 263], ["non-cancerous HaCaT cell lines", "ANATOMY", 275, 305], ["copaiba diterpenoids", "CHEMICAL", 166, 186], ["A-375", "CHEMICAL", 195, 200], ["kaurenoic acid", "CHEMICAL", 462, 476], ["diterpenoids", "CHEMICAL", 174, 186], ["(\u2212)-polyalthic acid", "CHEMICAL", 411, 430], ["kaurenoic acid", "CHEMICAL", 462, 476], ["copaiba diterpenoids", "SIMPLE_CHEMICAL", 166, 186], ["A-375", "CELL", 195, 200], ["HepG2", "CELL", 202, 207], ["HT-29, HCT-116, A-549", "CELL", 209, 230], ["MDA-MB-231 cancer cell lines", "CELL", 235, 263], ["non-cancerous HaCaT cell lines", "CELL", 275, 305], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 411, 430], ["kaurenoic acid", "SIMPLE_CHEMICAL", 462, 476], ["A-375, HepG2, HT-29, HCT-116", "CELL_LINE", 195, 223], ["A-549", "CELL_LINE", 225, 230], ["MDA-MB-231 cancer cell lines", "CELL_LINE", 235, 263], ["non-cancerous HaCaT cell lines", "CELL_LINE", 275, 305], ["A-375", "SPECIES", 195, 200], ["previous study", "TEST", 120, 134], ["copaiba diterpenoids", "TEST", 166, 186], ["HepG2", "TEST", 202, 207], ["HT", "TEST", 209, 211], ["HCT", "TEST", 216, 219], ["A", "TEST", 225, 226], ["MDA", "TEST", 235, 238], ["MB", "TEST", 239, 241], ["cancer cell lines", "TREATMENT", 246, 263], ["non-cancerous HaCaT cell lines", "TREATMENT", 275, 305], ["weak to moderate non-selective cytotoxic effects", "PROBLEM", 319, 367], ["IC50 values", "TEST", 373, 384], ["polyalthic acid", "TEST", 415, 430], ["kaurenoic acid", "TEST", 462, 476], ["cancer cell lines", "OBSERVATION", 246, 263], ["HaCaT cell lines", "OBSERVATION", 289, 305], ["weak", "OBSERVATION_MODIFIER", 319, 323], ["moderate", "OBSERVATION_MODIFIER", 327, 335]]], ["Thus, the effect of derivatising either the carboxyl group or the exocyclic methylene group was the main aim of the present study.", [["exocyclic methylene", "CHEMICAL", 66, 85], ["carboxyl", "CHEMICAL", 44, 52], ["methylene", "CHEMICAL", 76, 85], ["methylene", "SIMPLE_CHEMICAL", 76, 85], ["the carboxyl group", "TREATMENT", 40, 58], ["the exocyclic methylene group", "TREATMENT", 62, 91], ["the present study", "TEST", 112, 129]]], ["In a first screening at a concentration of 100 \u03bcg/ml no effects for derivatives without the exocyclic methylene group (1c and 2c\u20132e) were observed (Table S1).", [["exocyclic methylene", "CHEMICAL", 92, 111], ["exocyclic methylene", "CHEMICAL", 92, 111], ["exocyclic methylene group", "SIMPLE_CHEMICAL", 92, 117], ["2c\u20132e", "SIMPLE_CHEMICAL", 126, 131], ["derivatives", "TREATMENT", 68, 79], ["the exocyclic methylene group", "TREATMENT", 88, 117]]], ["Compounds 2d and 2e were earlier tested on four different cancer cell lines (K562, HL-60, MDA-MB435 and SF295) as well as on healthy peripheral blood mononuclear cells and compared with kaurenoic acid (Cavalcanti et al. 2009).", [["cancer cell lines", "ANATOMY", 58, 75], ["K562", "ANATOMY", 77, 81], ["HL-60", "ANATOMY", 83, 88], ["MDA-MB435", "ANATOMY", 90, 99], ["SF295", "ANATOMY", 104, 109], ["peripheral blood mononuclear cells", "ANATOMY", 133, 167], ["cancer", "DISEASE", 58, 64], ["kaurenoic acid", "CHEMICAL", 186, 200], ["kaurenoic acid", "CHEMICAL", 186, 200], ["2e", "SIMPLE_CHEMICAL", 17, 19], ["cancer cell lines", "CELL", 58, 75], ["K562", "CELL", 77, 81], ["HL-60", "CELL", 83, 88], ["MDA-MB435", "CELL", 90, 99], ["SF295", "CELL", 104, 109], ["peripheral blood mononuclear cells", "CELL", 133, 167], ["kaurenoic acid", "SIMPLE_CHEMICAL", 186, 200], ["cancer cell lines", "CELL_LINE", 58, 75], ["K562", "CELL_LINE", 77, 81], ["HL-60", "CELL_LINE", 83, 88], ["MDA-MB435", "CELL_LINE", 90, 99], ["SF295", "CELL_LINE", 104, 109], ["healthy peripheral blood mononuclear cells", "CELL_TYPE", 125, 167], ["K562", "TEST", 77, 81], ["HL", "TEST", 83, 85], ["MDA", "TEST", 90, 93], ["healthy peripheral blood mononuclear cells", "TREATMENT", 125, 167], ["kaurenoic acid", "TREATMENT", 186, 200], ["cancer cell lines", "OBSERVATION", 58, 75], ["peripheral", "ANATOMY_MODIFIER", 133, 143], ["blood", "ANATOMY", 144, 149], ["mononuclear cells", "OBSERVATION", 150, 167]]], ["Also here, the cytotoxic effect disappeared after derivatisation; wherefore, the authors hypothesised that the exocyclic methylene group is crucial for the cytotoxic effect.Cytotoxic Effects ::: Results and DiscussionHowever, also derivatisation of the carboxyl group (compounds 1a, 1b, 2a and 2b) did not result in total growth inhibition at 100 \u03bcg/ml, but rather affected healthy HaCaT cells at this concentration.", [["HaCaT cells", "ANATOMY", 382, 393], ["exocyclic methylene", "CHEMICAL", 111, 130], ["compounds 1a, 1b, 2a and 2b", "CHEMICAL", 269, 296], ["methylene", "CHEMICAL", 121, 130], ["carboxyl", "CHEMICAL", 253, 261], ["methylene", "SIMPLE_CHEMICAL", 121, 130], ["HaCaT cells", "CELL", 382, 393], ["HaCaT cells", "CELL_LINE", 382, 393], ["the cytotoxic effect", "PROBLEM", 11, 31], ["the exocyclic methylene group", "TREATMENT", 107, 136], ["the cytotoxic effect", "PROBLEM", 152, 172], ["total growth inhibition", "PROBLEM", 316, 339], ["rather affected healthy HaCaT cells", "PROBLEM", 358, 393], ["cytotoxic effect", "OBSERVATION", 15, 31], ["cytotoxic effect", "OBSERVATION", 156, 172], ["HaCaT cells", "OBSERVATION", 382, 393]]], ["Because of the only low cytotoxic activity of compounds 1 and 2 found in our previous study and the not too promising results of the preliminary screening, we decided to focus on the antimicrobial effects of our compounds.Antibacterial Effects ::: Results and DiscussionDue to the strong effects of (\u2212)-polyalthic acid (1) and especially kaurenoic acid (2) against E. faecium and methicillin-resistant Staphylococcus aureus (MRSA) (Pfeifer Barbosa et al. 2019), additional assays on Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli as well as phytopathogens Pseudomonas syringae, Xanthomonas campestris, Erwinia amylovora and Ralstonia solanacearum were included in our investigations (Table S2).", [["polyalthic acid", "CHEMICAL", 303, 318], ["kaurenoic acid", "CHEMICAL", 338, 352], ["methicillin", "CHEMICAL", 380, 391], ["Staphylococcus aureus", "DISEASE", 402, 423], ["Klebsiella pneumoniae", "DISEASE", 483, 504], ["(\u2212)-polyalthic acid", "CHEMICAL", 299, 318], ["kaurenoic acid", "CHEMICAL", 338, 352], ["methicillin", "CHEMICAL", 380, 391], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 299, 318], ["kaurenoic acid (2)", "SIMPLE_CHEMICAL", 338, 356], ["E. faecium", "ORGANISM", 365, 375], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 380, 423], ["MRSA", "ORGANISM", 425, 429], ["Klebsiella pneumoniae", "ORGANISM", 483, 504], ["Acinetobacter baumannii", "ORGANISM", 506, 529], ["Pseudomonas aeruginosa", "ORGANISM", 531, 553], ["Escherichia coli", "ORGANISM", 558, 574], ["phytopathogens", "ORGANISM", 586, 600], ["Pseudomonas syringae", "ORGANISM", 601, 621], ["Xanthomonas campestris", "ORGANISM", 623, 645], ["Erwinia amylovora", "ORGANISM", 647, 664], ["Ralstonia solanacearum", "ORGANISM", 669, 691], ["E. faecium", "SPECIES", 365, 375], ["Staphylococcus aureus", "SPECIES", 402, 423], ["MRSA", "SPECIES", 425, 429], ["Klebsiella pneumoniae", "SPECIES", 483, 504], ["Acinetobacter baumannii", "SPECIES", 506, 529], ["Pseudomonas aeruginosa", "SPECIES", 531, 553], ["Escherichia coli", "SPECIES", 558, 574], ["Pseudomonas syringae", "SPECIES", 601, 621], ["Xanthomonas campestris", "SPECIES", 623, 645], ["Erwinia amylovora", "SPECIES", 647, 664], ["Ralstonia solanacearum", "SPECIES", 669, 691], ["E. faecium", "SPECIES", 365, 375], ["Staphylococcus aureus", "SPECIES", 402, 423], ["MRSA", "SPECIES", 425, 429], ["Klebsiella pneumoniae", "SPECIES", 483, 504], ["Acinetobacter baumannii", "SPECIES", 506, 529], ["Pseudomonas aeruginosa", "SPECIES", 531, 553], ["Escherichia coli", "SPECIES", 558, 574], ["Pseudomonas syringae", "SPECIES", 601, 621], ["Xanthomonas campestris", "SPECIES", 623, 645], ["Erwinia amylovora", "SPECIES", 647, 664], ["Ralstonia solanacearum", "SPECIES", 669, 691], ["our previous study", "TEST", 73, 91], ["the preliminary screening", "TEST", 129, 154], ["the antimicrobial effects", "TREATMENT", 179, 204], ["polyalthic acid", "TEST", 303, 318], ["kaurenoic acid", "TEST", 338, 352], ["E. faecium", "TEST", 365, 375], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 380, 423], ["MRSA", "PROBLEM", 425, 429], ["additional assays", "TEST", 462, 479], ["Klebsiella pneumoniae", "PROBLEM", 483, 504], ["Acinetobacter baumannii", "PROBLEM", 506, 529], ["Pseudomonas aeruginosa", "PROBLEM", 531, 553], ["Escherichia coli", "PROBLEM", 558, 574], ["phytopathogens Pseudomonas syringae", "PROBLEM", 586, 621], ["Xanthomonas campestris", "PROBLEM", 623, 645], ["Erwinia amylovora and Ralstonia solanacearum", "PROBLEM", 647, 691], ["low", "OBSERVATION_MODIFIER", 20, 23], ["cytotoxic", "OBSERVATION_MODIFIER", 24, 33], ["activity", "OBSERVATION_MODIFIER", 34, 42], ["Staphylococcus aureus", "OBSERVATION", 402, 423], ["Escherichia coli", "OBSERVATION", 558, 574], ["Ralstonia solanacearum", "OBSERVATION", 669, 691]]], ["However, at a concentration of 100 \u03bcg/ml, activity of compounds 1 and 2 as well as their derivatives against the additionally investigated organisms was rather low or non-existent in contrast to the already known effects against E. faecium and MRSA.", [["E. faecium", "ORGANISM", 229, 239], ["MRSA", "CANCER", 244, 248], ["E. faecium", "SPECIES", 229, 239], ["MRSA", "SPECIES", 244, 248], ["E. faecium", "SPECIES", 229, 239], ["MRSA", "SPECIES", 244, 248], ["activity of compounds", "TREATMENT", 42, 63], ["their derivatives", "TREATMENT", 83, 100], ["the additionally investigated organisms", "PROBLEM", 109, 148], ["E. faecium", "PROBLEM", 229, 239], ["MRSA", "PROBLEM", 244, 248], ["MRSA", "OBSERVATION", 244, 248]]], ["But also against the latter two strains derivatisations did not lead to an improved activity (Table 2).", [["the latter two strains derivatisations", "PROBLEM", 17, 55]]], ["Here, only compound 2c showed (at least moderate) effects, with IC50 values of 59.7 \u03bcg/ml against E. faecium and 34.7 \u03bcg/ml against MRSA.", [["E. faecium", "ORGANISM", 98, 108], ["E. faecium", "SPECIES", 98, 108], ["MRSA", "SPECIES", 132, 136], ["E. faecium", "SPECIES", 98, 108], ["MRSA", "SPECIES", 132, 136], ["IC50 values", "TEST", 64, 75], ["E. faecium", "TEST", 98, 108], ["MRSA", "PROBLEM", 132, 136]]], ["In contrast, (\u2212)-polyalthic acid (1) and kaurenoic acid (2) showed IC50 values of 8.5 and 2.3 \u03bcg/ml against E. faecium as well as 8.9 and 3.4 \u03bcg/ml against MRSA, respectively.", [["polyalthic acid", "CHEMICAL", 17, 32], ["kaurenoic acid", "CHEMICAL", 41, 55], ["(\u2212)-polyalthic acid", "CHEMICAL", 13, 32], ["kaurenoic acid", "CHEMICAL", 41, 55], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 13, 32], ["1)", "SIMPLE_CHEMICAL", 34, 36], ["kaurenoic acid (2)", "SIMPLE_CHEMICAL", 41, 59], ["E. faecium", "ORGANISM", 108, 118], ["E. faecium", "SPECIES", 108, 118], ["MRSA", "SPECIES", 156, 160], ["E. faecium", "SPECIES", 108, 118], ["MRSA", "SPECIES", 156, 160], ["polyalthic acid", "TEST", 17, 32], ["kaurenoic acid", "TEST", 41, 55], ["IC50 values", "TEST", 67, 78], ["E. faecium", "TEST", 108, 118], ["MRSA", "PROBLEM", 156, 160]]], ["Thus, both the carboxyl group and the exocyclic methylene group seem to be pivotal for the activity against these two clinically relevant strains.Antifungal Effects ::: Results and Discussion(\u2212)-Polyalthic acid (1) was the most potent compound against Trichopyhton species dermatophytes in our previous study, with IC50 values of 6.8 \u03bcg/ml against T. rubrum and 4.3 \u03bcg/ml against T. mentagrophytes, respectively (Pfeifer Barbosa et al. 2019), while kaurenoic acid (2) only showed weak (70.8 \u03bcg/ml) to moderate effects (15.5 \u03bcg/ml) against these two strains (Table 3).", [["exocyclic methylene", "CHEMICAL", 38, 57], ["Polyalthic acid", "CHEMICAL", 195, 210], ["kaurenoic acid", "CHEMICAL", 449, 463], ["carboxyl", "CHEMICAL", 15, 23], ["methylene", "CHEMICAL", 48, 57], ["(\u2212)-Polyalthic acid", "CHEMICAL", 191, 210], ["kaurenoic acid", "CHEMICAL", 449, 463], ["methylene", "SIMPLE_CHEMICAL", 48, 57], ["(\u2212)-Polyalthic acid", "SIMPLE_CHEMICAL", 191, 210], ["Trichopyhton", "ORGANISM", 252, 264], ["T. rubrum", "ORGANISM", 348, 357], ["T. mentagrophytes", "ORGANISM", 380, 397], ["kaurenoic acid", "SIMPLE_CHEMICAL", 449, 463], ["T. rubrum", "SPECIES", 348, 357], ["T. mentagrophytes", "SPECIES", 380, 397], ["T. rubrum", "SPECIES", 348, 357], ["T. mentagrophytes", "SPECIES", 380, 397], ["the carboxyl group", "TREATMENT", 11, 29], ["the exocyclic methylene group", "TREATMENT", 34, 63], ["Trichopyhton species dermatophytes", "PROBLEM", 252, 286], ["our previous study", "TEST", 290, 308], ["IC50 values", "TEST", 315, 326], ["T. rubrum", "TEST", 348, 357], ["T. mentagrophytes", "TEST", 380, 397], ["kaurenoic acid", "TEST", 449, 463], ["weak", "TEST", 480, 484], ["moderate effects", "PROBLEM", 501, 517], ["these two strains", "PROBLEM", 539, 556]]], ["Derivatisation of the two natural products this time revealed a different picture, leading to one equally potent (1b) and another still moderately active compound (1a) against T. rubrum, with IC50 values of 7.7 \u03bcg/ml for (\u2212)-polyalthic acid methyl ester (1b) and 13.8 \u03bcg/ml for (\u2212)-polyalthic acid N,N-diethylamide (1a), respectively.", [["polyalthic acid methyl ester", "CHEMICAL", 225, 253], ["N-diethylamide", "CHEMICAL", 300, 314], ["(\u2212)-polyalthic acid methyl ester", "CHEMICAL", 221, 253], ["(\u2212)-polyalthic acid N,N-diethylamide", "CHEMICAL", 278, 314], ["T. rubrum", "ORGANISM", 176, 185], ["(\u2212)-polyalthic acid methyl ester", "SIMPLE_CHEMICAL", 221, 253], ["(\u2212)-polyalthic acid N", "SIMPLE_CHEMICAL", 278, 299], ["N-diethylamide", "SIMPLE_CHEMICAL", 300, 314], ["T. rubrum", "SPECIES", 176, 185], ["T. rubrum", "SPECIES", 176, 185], ["Derivatisation", "TREATMENT", 0, 14], ["a different picture", "PROBLEM", 62, 81], ["T. rubrum", "TEST", 176, 185], ["IC50 values", "TEST", 192, 203], ["polyalthic acid methyl ester", "TREATMENT", 225, 253], ["polyalthic acid N", "TREATMENT", 282, 299], ["moderately", "OBSERVATION_MODIFIER", 136, 146], ["active", "OBSERVATION", 147, 153]]], ["Notably, this effect was not observed against T. mentagrophytes, where the IC50 value was increased by the factor five.", [["T. mentagrophytes", "ORGANISM", 46, 63], ["T. mentagrophytes", "SPECIES", 46, 63], ["T. mentagrophytes", "SPECIES", 46, 63], ["T. mentagrophytes", "PROBLEM", 46, 63], ["the IC50 value", "TEST", 71, 85]]], ["For kaurenoic acid (2), a similar picture was observed.", [["kaurenoic acid", "CHEMICAL", 4, 18], ["kaurenoic acid", "CHEMICAL", 4, 18], ["kaurenoic acid", "SIMPLE_CHEMICAL", 4, 18], ["kaurenoic acid", "TEST", 4, 18]]], ["Here, amidation (2a) and esterification (2b) yielded even more active compounds against T. rubrum, though on an overall higher level.", [["T. rubrum", "ORGANISM", 88, 97], ["T. rubrum", "SPECIES", 88, 97], ["T. rubrum", "SPECIES", 88, 97], ["amidation", "TREATMENT", 6, 15], ["esterification (2b)", "TREATMENT", 25, 44], ["T. rubrum", "PROBLEM", 88, 97]]], ["Still, also against T. mentagrophytes the activity was drastically reduced by derivatisation of the carboxyl group.", [["carboxyl", "CHEMICAL", 100, 108], ["T. mentagrophytes", "ORGANISM", 20, 37], ["T. mentagrophytes", "SPECIES", 20, 37], ["T. mentagrophytes", "SPECIES", 20, 37], ["T. mentagrophytes", "PROBLEM", 20, 37], ["derivatisation of the carboxyl group", "TREATMENT", 78, 114]]], ["Of the remaining derivatives, only compound 1c showed activity, with an IC50 of 61.8 \u03bcg/ml against T. rubrum and 31.9 \u03bcg/ml against T. mentagrophytes.Antifungal Effects ::: Results and DiscussionThe compounds were furthermore investigated for their inhibitory potential against two yeasts, Candida albicans and Cryptococcus neoformans.", [["Candida albicans", "DISEASE", 290, 306], ["Cryptococcus neoformans", "DISEASE", 311, 334], ["compound 1c", "SIMPLE_CHEMICAL", 35, 46], ["T. rubrum", "ORGANISM", 99, 108], ["T. mentagrophytes", "ORGANISM", 132, 149], ["Candida albicans", "ORGANISM", 290, 306], ["Cryptococcus neoformans", "ORGANISM", 311, 334], ["T. rubrum", "SPECIES", 99, 108], ["T. mentagrophytes", "SPECIES", 132, 149], ["Candida albicans", "SPECIES", 290, 306], ["Cryptococcus neoformans", "SPECIES", 311, 334], ["T. rubrum", "SPECIES", 99, 108], ["T. mentagrophytes", "SPECIES", 132, 149], ["Candida albicans", "SPECIES", 290, 306], ["Cryptococcus neoformans", "SPECIES", 311, 334], ["an IC50", "TEST", 69, 76], ["T. rubrum", "TEST", 99, 108], ["T. mentagrophytes", "PROBLEM", 132, 149], ["Candida albicans", "PROBLEM", 290, 306], ["Cryptococcus neoformans", "PROBLEM", 311, 334], ["activity", "OBSERVATION_MODIFIER", 54, 62], ["Cryptococcus neoformans", "OBSERVATION", 311, 334]]], ["While the activity against C. albicans was negligible (Table S3), the results against C. neoformans revealed interesting findings for compounds 1, 1a and 1b.", [["C. albicans", "ORGANISM", 27, 38], ["C. neoformans", "ORGANISM", 86, 99], ["C. albicans", "SPECIES", 27, 38], ["C. neoformans", "SPECIES", 86, 99], ["C. albicans", "SPECIES", 27, 38], ["C. neoformans", "SPECIES", 86, 99], ["C. albicans", "PROBLEM", 27, 38], ["C. neoformans", "TEST", 86, 99]]], ["All three compounds showed similar IC50 values, which were in the range of 9.5 to 11.2 \u03bcg/ml (Table 3).", [["similar IC50 values", "TEST", 27, 46], ["IC50 values", "OBSERVATION", 35, 46]]], ["However, below this concentrations the activity of (\u2212)-polyalthic acid (1) decreased rapidly in contrast to its two non-acidic derivatives (1a and 1b) (Fig. 1).Conclusion(\u2212)-Polyalthic acid (1) and kaurenoic acid (2) as well as their semi-synthetic derivatives (1a\u20131c and 2a\u20132e) were investigated for their cytotoxic, antibacterial and antifungal properties, with different outcomes.", [["(\u2212)-polyalthic acid", "CHEMICAL", 51, 70], ["Polyalthic acid", "CHEMICAL", 174, 189], ["kaurenoic acid", "CHEMICAL", 198, 212], ["1a\u20131c and 2a\u20132e", "CHEMICAL", 262, 277], ["(\u2212)-polyalthic acid", "CHEMICAL", 51, 70], ["(\u2212)-Polyalthic acid", "CHEMICAL", 170, 189], ["kaurenoic acid", "CHEMICAL", 198, 212], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 51, 70], ["(\u2212)-Polyalthic acid", "SIMPLE_CHEMICAL", 170, 189], ["1)", "SIMPLE_CHEMICAL", 191, 193], ["kaurenoic acid", "SIMPLE_CHEMICAL", 198, 212], ["semi-synthetic derivatives", "SIMPLE_CHEMICAL", 234, 260], ["1a\u20131c", "SIMPLE_CHEMICAL", 262, 267], ["2a\u20132e", "SIMPLE_CHEMICAL", 272, 277], ["polyalthic acid", "TEST", 55, 70], ["Polyalthic acid", "TREATMENT", 174, 189], ["kaurenoic acid", "TREATMENT", 198, 212], ["their semi-synthetic derivatives", "TREATMENT", 228, 260], ["antibacterial", "TREATMENT", 318, 331], ["antifungal properties", "TREATMENT", 336, 357]]], ["While the previously discussed importance of an exocyclic methylene group for the cytotoxic effect was also apparent in our study, we furthermore found that both the exocyclic methylene and the carboxylic acid group were necessary for the effect against E. faecium and MRSA.ConclusionHowever, different results were obtained with regard to the antifungal activity of the two natural products and their derivatives.", [["exocyclic methylene", "CHEMICAL", 48, 67], ["exocyclic methylene", "CHEMICAL", 166, 185], ["carboxylic acid", "CHEMICAL", 194, 209], ["methylene", "CHEMICAL", 58, 67], ["exocyclic methylene", "CHEMICAL", 166, 185], ["carboxylic acid", "CHEMICAL", 194, 209], ["methylene", "SIMPLE_CHEMICAL", 58, 67], ["methylene", "SIMPLE_CHEMICAL", 176, 185], ["carboxylic acid", "SIMPLE_CHEMICAL", 194, 209], ["E. faecium", "ORGANISM", 254, 264], ["MRSA", "CANCER", 269, 273], ["E. faecium", "SPECIES", 254, 264], ["MRSA", "SPECIES", 269, 273], ["E. faecium", "SPECIES", 254, 264], ["an exocyclic methylene group", "TREATMENT", 45, 73], ["the cytotoxic effect", "PROBLEM", 78, 98], ["our study", "TEST", 120, 129], ["the exocyclic methylene", "TREATMENT", 162, 185], ["the carboxylic acid group", "TREATMENT", 190, 215], ["E. faecium", "PROBLEM", 254, 264], ["MRSA", "PROBLEM", 269, 273], ["the antifungal activity", "TREATMENT", 340, 363], ["the two natural products", "TREATMENT", 367, 391], ["their derivatives", "TREATMENT", 396, 413], ["MRSA", "OBSERVATION", 269, 273]]], ["For T. mentagrophytes, the picture was somehow similar to the antibacterial assays, where the best antifungal activity was achieved when both an exocylic methylene group and a carboxylic acid were present.", [["methylene", "CHEMICAL", 154, 163], ["carboxylic acid", "CHEMICAL", 176, 191], ["exocylic methylene", "CHEMICAL", 145, 163], ["carboxylic acid", "CHEMICAL", 176, 191], ["T. mentagrophytes", "ORGANISM", 4, 21], ["exocylic methylene", "SIMPLE_CHEMICAL", 145, 163], ["a carboxylic acid", "SIMPLE_CHEMICAL", 174, 191], ["T. mentagrophytes", "SPECIES", 4, 21], ["T. mentagrophytes", "SPECIES", 4, 21], ["T. mentagrophytes", "PROBLEM", 4, 21], ["the antibacterial assays", "TEST", 58, 82], ["an exocylic methylene group", "TREATMENT", 142, 169], ["a carboxylic acid", "TREATMENT", 174, 191]]], ["In contrast, the presence of an carboxyl group was not required for activity against C. neoformans and T. rubrum, as displayed by the similar IC50 values of 1, 1a and 1b.", [["carboxyl", "CHEMICAL", 32, 40], ["C. neoformans", "ORGANISM", 85, 98], ["T. rubrum", "ORGANISM", 103, 112], ["C. neoformans", "SPECIES", 85, 98], ["T. rubrum", "SPECIES", 103, 112], ["C. neoformans", "SPECIES", 85, 98], ["T. rubrum", "SPECIES", 103, 112], ["an carboxyl group", "TREATMENT", 29, 46], ["C. neoformans", "PROBLEM", 85, 98], ["T. rubrum", "TEST", 103, 112], ["the similar IC50 values", "TEST", 130, 153]]], ["However, the low IC50 value of compound 1c clearly shows that at least the methylene group is crucial for the effect.ConclusionBesides gaining further insights into differential biological activities and some SARs for copaiba diterpenoids, we present a novel semi-synthetic derivative of (\u2212)-polyalthic acid.", [["methylene", "CHEMICAL", 75, 84], ["copaiba diterpenoids", "CHEMICAL", 218, 238], ["methylene", "CHEMICAL", 75, 84], ["copaiba diterpenoids", "CHEMICAL", 218, 238], ["(\u2212)-polyalthic acid", "CHEMICAL", 288, 307], ["methylene", "SIMPLE_CHEMICAL", 75, 84], ["copaiba diterpenoids", "SIMPLE_CHEMICAL", 218, 238], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 288, 307], ["the methylene group", "TREATMENT", 71, 90], ["some SARs", "PROBLEM", 204, 213], ["copaiba diterpenoids", "PROBLEM", 218, 238], ["polyalthic acid", "TREATMENT", 292, 307], ["low IC50", "OBSERVATION_MODIFIER", 13, 21]]], ["In the course of verifying the relative configuration of the new compound, we discovered ambiguities regarding the stereochemistry of polyalthic acid by two commonly used databases, which also led to incorrect chemical structures in several publications.", [["polyalthic acid", "CHEMICAL", 134, 149], ["polyalthic acid", "CHEMICAL", 134, 149], ["polyalthic acid", "SIMPLE_CHEMICAL", 134, 149], ["polyalthic acid", "PROBLEM", 134, 149], ["incorrect chemical structures", "PROBLEM", 200, 229], ["new", "OBSERVATION_MODIFIER", 61, 64], ["compound", "OBSERVATION_MODIFIER", 65, 73], ["several", "OBSERVATION_MODIFIER", 233, 240], ["publications", "OBSERVATION", 241, 253]]], ["We thus suggest to only use the terms (+)- and (\u2212)-polyalthic acid to differentiate between the two enantiomers in order to hopefully avoid such mistakes in future publications.", [["(+)- and (\u2212)-polyalthic acid", "CHEMICAL", 38, 66], ["(\u2212)-polyalthic acid", "SIMPLE_CHEMICAL", 47, 66], ["polyalthic acid", "TREATMENT", 51, 66], ["such mistakes", "PROBLEM", 140, 153]]]], "PMC7381859": [["Development of Microdevices for Detection/Diagnosis of the Disease ::: Development of Computer Models and Apps for Managing the PandemicTripathy and Singh (2020) described a method for detection of the SARS-CoV-2 virus using a device that is hand-held and affordable.", [["SARS-CoV-2 virus", "ORGANISM", 202, 218], ["CoV-2 virus", "SPECIES", 207, 218], ["SARS-CoV-2 virus", "SPECIES", 202, 218], ["the SARS", "PROBLEM", 198, 206], ["CoV-2 virus", "TREATMENT", 207, 218], ["a device", "TREATMENT", 225, 233], ["Microdevices", "OBSERVATION", 15, 27]]], ["The proposed method based on electrochemical transduction is label-free.", [["electrochemical transduction", "TREATMENT", 29, 57], ["free", "OBSERVATION_MODIFIER", 67, 71]]], ["Murugan et al. (2020) proposed a portable plasmonic fiber-optic absorbance biosensor (P-FAB) platform for detection of SARS-CoV-2 virus in saliva samples with a very little effort in the sample pre-processing.", [["samples", "ANATOMY", 146, 153], ["SARS-CoV-2 virus", "ORGANISM", 119, 135], ["saliva", "ORGANISM", 139, 145], ["CoV-2 virus", "SPECIES", 124, 135], ["SARS-CoV-2 virus", "SPECIES", 119, 135], ["a portable plasmonic fiber", "TEST", 31, 57], ["optic absorbance biosensor", "TEST", 58, 84], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["2 virus", "PROBLEM", 128, 135], ["saliva samples", "TEST", 139, 153]]], ["Tripathi and Agrawal (2020) proposed engineering of the blood plasma separation microdevice for detecting relevant anti-bodies in blood.", [["blood plasma", "ANATOMY", 56, 68], ["blood", "ANATOMY", 130, 135], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["the blood plasma separation microdevice", "TREATMENT", 52, 91], ["relevant anti-bodies in blood", "PROBLEM", 106, 135]]], ["Chatterjee and Bandyopadhyay (2020) developed a technique for detecting taste-contributing agents that is envisaged to have application in the detection of COVID-19.", [["a technique", "TREATMENT", 46, 57], ["agents", "TREATMENT", 91, 97], ["COVID", "TEST", 156, 161]]], ["Paul et al. (2020) proposed a diagnostic test based on a paper fluidic device.", [["a diagnostic test", "TEST", 28, 45], ["a paper fluidic device", "TREATMENT", 55, 77]]], ["The device could diagnose bacterial infections through molecular tests.", [["bacterial infections", "DISEASE", 26, 46], ["The device", "TREATMENT", 0, 10], ["diagnose bacterial infections", "PROBLEM", 17, 46], ["molecular tests", "TEST", 55, 70], ["bacterial", "OBSERVATION_MODIFIER", 26, 35], ["infections", "OBSERVATION", 36, 46]]], ["Nag et al. (2020) provided an overview of evanescent wave absorbance and localized surface plasmon resonance-based optic fiber platform for potential screening of COVID-19.Development of Microdevices for Detection/Diagnosis of the Disease ::: Development of Computer Models and Apps for Managing the PandemicSince one of the symptoms for identification of COVID-19 seems to be inability to smell, Gandhi et al. (2020) developed a device based on olfactory sense detection for detecting the disease.", [["olfactory", "ANATOMY", 446, 455], ["COVID-19", "CHEMICAL", 163, 171], ["COVID-19", "DNA", 163, 171], ["evanescent wave absorbance", "TEST", 42, 68], ["localized surface plasmon resonance", "TEST", 73, 108], ["potential screening", "TEST", 140, 159], ["COVID", "TEST", 163, 168], ["the symptoms", "PROBLEM", 321, 333], ["COVID", "TEST", 356, 361], ["inability to smell", "PROBLEM", 377, 395], ["a device", "TREATMENT", 428, 436], ["olfactory sense detection", "TEST", 446, 471], ["the disease", "PROBLEM", 486, 497], ["Microdevices", "OBSERVATION", 187, 199], ["disease", "OBSERVATION", 490, 497]]], ["The device generates precise level of smell digitally and repeatedly in a contactless manner.", [["The device", "TREATMENT", 0, 10]]], ["Roy et al. (2020) came up with an idea of using a lung-on-chip platform to study the SARS-CoV-2 pathogenesis in humans, with drug toxicity testing claimed to have potential in providing meaningful insights into antigen\u2013antibody interactions.", [["lung", "ANATOMY", 50, 54], ["SARS", "DISEASE", 85, 89], ["toxicity", "DISEASE", 130, 138], ["lung", "ORGAN", 50, 54], ["CoV-2", "ORGANISM", 90, 95], ["humans", "ORGANISM", 112, 118], ["humans", "SPECIES", 112, 118], ["SARS-CoV", "SPECIES", 85, 93], ["humans", "SPECIES", 112, 118], ["the SARS", "PROBLEM", 81, 89], ["CoV", "PROBLEM", 90, 93], ["drug toxicity testing", "TEST", 125, 146], ["lung", "ANATOMY", 50, 54]]], ["Jain and Muralidhar (2020) proposed an electrowetting-on-dielectric based technology to merge a liquid drop of possibly infected sample with another drop of a reagent for the purpose of testing.Systems for Containment of the Virus and for Disinfecting Surfaces and Objects ::: Development of Computer Models and Apps for Managing the PandemicDiwan et al. (2020) described a numerical tool for simulating the cloud of fluid ejected during coughing and sneezing.", [["sample", "ANATOMY", 129, 135], ["fluid", "ANATOMY", 417, 422], ["coughing", "DISEASE", 438, 446], ["sneezing", "DISEASE", 451, 459], ["fluid", "ORGANISM_SUBSTANCE", 417, 422], ["an electrowetting", "TEST", 36, 53], ["infected sample", "PROBLEM", 120, 135], ["a reagent", "TREATMENT", 157, 166], ["testing", "TEST", 186, 193], ["the Virus", "TREATMENT", 221, 230], ["fluid ejected", "PROBLEM", 417, 430], ["coughing", "PROBLEM", 438, 446], ["sneezing", "PROBLEM", 451, 459], ["possibly", "UNCERTAINTY", 111, 119], ["infected", "OBSERVATION", 120, 128], ["fluid ejected", "OBSERVATION", 417, 430]]], ["The authors considered coughing and sneezing flows as a problem of fluid dynamics of a transient turbulent jet/puff with buoyancy, laden with evaporating droplets carrying the pathogen.", [["coughing", "DISEASE", 23, 31], ["sneezing", "DISEASE", 36, 44], ["coughing", "PROBLEM", 23, 31], ["sneezing flows", "PROBLEM", 36, 50], ["fluid dynamics", "PROBLEM", 67, 81], ["a transient turbulent jet", "PROBLEM", 85, 110], ["coughing", "OBSERVATION", 23, 31], ["turbulent jet", "OBSERVATION", 97, 110], ["buoyancy", "OBSERVATION_MODIFIER", 121, 129], ["evaporating droplets", "OBSERVATION", 142, 162]]], ["They have developed a direct numerical simulation code and arrived at the time duration over which the cough flow can persist after the coughing has ceased.", [["cough", "DISEASE", 103, 108], ["coughing", "DISEASE", 136, 144], ["the cough flow", "PROBLEM", 99, 113], ["the coughing", "PROBLEM", 132, 144]]], ["These simulations claimed to have potential in devising accurate guidelines for separation distances between neighbors within a group, design better masks, and minimize the spread of the disease.", [["the disease", "PROBLEM", 183, 194], ["disease", "OBSERVATION", 187, 194]]], ["Singh and Tripathi (2020) proposed to study ventilation design of a room for effective transportation of coughing- and sneezing-generated pathogen aerosols.", [["coughing", "DISEASE", 105, 113], ["coughing", "PROBLEM", 105, 113], ["sneezing", "PROBLEM", 119, 127], ["pathogen aerosols", "TREATMENT", 138, 155]]], ["Joshi (2020) developed an innovative chamber christened as COVid SAmple Collection Kiosk (COVSACK) to protect the healthcare provider from getting infected while collecting samples.", [["samples", "ANATOMY", 173, 180], ["an innovative chamber", "TREATMENT", 23, 44], ["COVid SAmple Collection Kiosk (COVSACK)", "TREATMENT", 59, 98]]], ["COVSACK has been designed based on CFD simulations for effective spread of disinfectant in fine droplet form.", [["COVSACK", "CHEMICAL", 0, 7], ["CFD simulations", "TEST", 35, 50]]], ["The kiosk was built using lightweight composite that is capable of sustaining extreme weather conditions and can be sanitized in three minutes after sample collection.", [["sample", "ANATOMY", 149, 155], ["lightweight composite", "TREATMENT", 26, 47], ["sample collection", "TEST", 149, 166]]], ["After its deployment in hospitals and diagnostic centers, it has changed the way that testing is being done in the country with a drastic reduction in the use of personal protection equipment.", [["testing", "TEST", 86, 93], ["a drastic reduction", "TREATMENT", 128, 147], ["personal protection equipment", "TREATMENT", 162, 191], ["drastic", "OBSERVATION_MODIFIER", 130, 137], ["reduction", "OBSERVATION_MODIFIER", 138, 147]]], ["Rao and Rao (2020) developed a \u2018Aerosol Containment Box\u2019 for safeguarding health care providers against infection during intubation procedure and sample collection.", [["infection", "DISEASE", 104, 113], ["a \u2018Aerosol Containment Box", "TREATMENT", 29, 55], ["infection", "PROBLEM", 104, 113], ["intubation procedure", "TREATMENT", 121, 141], ["sample collection", "TEST", 146, 163]]], ["Maurya et al. (2020) developed a tunnel for disinfecting objects employing three different disinfectant strategies.", [["a tunnel", "TREATMENT", 31, 39], ["disinfecting objects", "TREATMENT", 44, 64], ["three different disinfectant strategies", "TREATMENT", 75, 114], ["tunnel", "OBSERVATION", 33, 39]]], ["The tunnel is fully automatic, modular and portable.", [["modular and portable", "TEST", 31, 51], ["tunnel", "OBSERVATION", 4, 10], ["fully", "OBSERVATION_MODIFIER", 14, 19], ["automatic", "OBSERVATION", 20, 29], ["modular", "OBSERVATION_MODIFIER", 31, 38]]], ["Krishnan et al. (2020) described the design and construction of \u2018Chitra Disinfection Gateway\u2019, a walkthrough tunnel, meant to be installed in public places for disinfecting personnel passing through it.", [["\u2018Chitra Disinfection", "TREATMENT", 64, 84], ["a walkthrough tunnel", "TREATMENT", 95, 115]]], ["Murthy (2020) elaborated a tunnel-based system for disinfecting luggages and packages, which can be installed in airports and bus/train stations.", [["a tunnel-based system", "TREATMENT", 25, 46], ["disinfecting luggages and packages", "TREATMENT", 51, 85]]], ["Kumar et al. (2020) demonstrated a portable disinfectant device developed under Industry-Academia collaboration.", [["a portable disinfectant device", "TREATMENT", 33, 63], ["Academia collaboration", "OBSERVATION", 89, 111]]], ["The device effectively combined two disinfection strategies: spraying of sanitizing liquid and UV light.", [["The device", "TREATMENT", 0, 10], ["two disinfection strategies", "TREATMENT", 32, 59], ["sanitizing liquid", "TREATMENT", 73, 90], ["UV light", "TREATMENT", 95, 103]]], ["Neelakandan et al. (2020) proposed a system for disinfecting face masks, with emphasis on utilization of local resources.", [["disinfecting face masks", "TREATMENT", 48, 71], ["local resources", "TREATMENT", 105, 120]]], ["This unique mobile laboratory helps in conducting real-time reverse polymerase chain reaction (rRT-PCR) test for diagnosing Covid-19, virus culturing for drug screening, convalescent plasma-derived therapy, and will aid in the development of vaccine and diagnostic kits.", [["plasma", "ANATOMY", 183, 189], ["plasma", "ORGANISM_SUBSTANCE", 183, 189], ["Covid-19", "SPECIES", 124, 132], ["reverse polymerase chain reaction", "PROBLEM", 60, 93], ["rRT-PCR", "TEST", 95, 102], ["Covid", "TEST", 124, 129], ["virus culturing", "TEST", 134, 149], ["drug screening", "TEST", 154, 168], ["convalescent plasma-derived therapy", "TREATMENT", 170, 205], ["vaccine", "TREATMENT", 242, 249], ["diagnostic kits", "TEST", 254, 269]]], ["This mobile laboratory has been developed as per WHO and ICMR bio-safety standard BSL-3.", [["BSL-3", "GENE_OR_GENE_PRODUCT", 82, 87]]], ["It is heartening to learn that the technology developed for containerization of ground support equipment and clean rooms technology adopted for integration of high precision missile components with high safety standards has been utilized very effectively for establishing COVID-19 diagnostic laboratory.Systems for Containment of the Virus and for Disinfecting Surfaces and Objects ::: Development of Computer Models and Apps for Managing the PandemicSharma and Sharma (2020) narrated a plasma sterilization system employing UV, ozone and short-lived molecules produced during discharges.", [["plasma", "ANATOMY", 487, 493], ["UV", "CHEMICAL", 525, 527], ["ozone", "CHEMICAL", 529, 534], ["ozone", "CHEMICAL", 529, 534], ["plasma", "ORGANISM_SUBSTANCE", 487, 493], ["ozone", "SIMPLE_CHEMICAL", 529, 534], ["ground support equipment", "TREATMENT", 80, 104], ["clean rooms technology", "TREATMENT", 109, 131], ["high precision missile components", "TREATMENT", 159, 192], ["the Virus", "TREATMENT", 330, 339], ["a plasma sterilization system", "TREATMENT", 485, 514]]], ["The system is portable and can be used for sterilization and treatment of garments and used disposable protective gears.", [["sterilization", "TREATMENT", 43, 56], ["treatment of garments", "TREATMENT", 61, 82], ["disposable protective gears", "TREATMENT", 92, 119]]], ["Kar et al. (2020) tweaked two different cold plasma devices for the purpose of pathogenic inactivation.", [["plasma", "ANATOMY", 45, 51], ["plasma", "ORGANISM_SUBSTANCE", 45, 51], ["two different cold plasma devices", "TREATMENT", 26, 59], ["pathogenic inactivation", "PROBLEM", 79, 102], ["pathogenic inactivation", "OBSERVATION", 79, 102]]], ["Mahapatra et al. (2020) proposed to combine anti-viral action with liquid-repelling properties to enhance the functionality of personal protective equipments (PPEs).", [["anti-viral action", "TREATMENT", 44, 61], ["liquid-repelling properties", "TREATMENT", 67, 94]]], ["Kashyap and Saha (2020) came up with novel idea of employing a high voltage charge generator from a very low DC source to eliminate the virus from the surface of PPE, with the aim of sanitizing it before and after use.", [["DC", "ANATOMY", 109, 111], ["surface", "ANATOMY", 151, 158], ["a high voltage charge generator", "TREATMENT", 61, 92], ["a very low DC source", "PROBLEM", 98, 118], ["the virus", "PROBLEM", 132, 141], ["sanitizing", "TREATMENT", 183, 193]]], ["Siddiquie et al. (2020) proposed reduction in contact of viruses with surfaces by employing hydrophobic surfaces by texturing them.", [["viruses", "OBSERVATION", 57, 64]]], ["Alternatively, fullerene-coated surfaces could be employed for this purpose.", [["fullerene", "CHEMICAL", 15, 24], ["fullerene", "CHEMICAL", 15, 24], ["fullerene", "SIMPLE_CHEMICAL", 15, 24], ["fullerene-coated surfaces", "TREATMENT", 15, 40]]], ["Sarada et al. (2020) also employed a combination of strategies for disinfecting places and surfaces effectively.", [["strategies", "TREATMENT", 52, 62], ["disinfecting places", "TREATMENT", 67, 86]]], ["Towards this, they combined physical, thermal and chemical processes to design a UVC based disinfection trolley.", [["UVC", "CHEMICAL", 81, 84], ["a UVC based disinfection trolley", "TREATMENT", 79, 111], ["UVC", "OBSERVATION", 81, 84], ["disinfection trolley", "OBSERVATION", 91, 111]]], ["The trolley comprises honeycomb air heater and a fogging chamber using UVC germicidal lamps, dry heat sterilization, and hypochlorous acid based chemical disinfectant to provide rapid and effective inactivation of microorganisms.Development of Ventilators, Face Masks, and Drugs ::: Development of Computer Models and Apps for Managing the PandemicIndian Space Research Organization (ISRO) team (Design and Development Team 2020) developed three low cost ventilators, with unique characteristics.", [["UVC", "CHEMICAL", 71, 74], ["hypochlorous acid", "CHEMICAL", 121, 138], ["hypochlorous acid", "CHEMICAL", 121, 138], ["hypochlorous acid", "SIMPLE_CHEMICAL", 121, 138], ["honeycomb air heater", "TREATMENT", 22, 42], ["a fogging chamber", "TREATMENT", 47, 64], ["UVC germicidal lamps", "TREATMENT", 71, 91], ["dry heat sterilization", "TREATMENT", 93, 115], ["hypochlorous acid", "TREATMENT", 121, 138], ["chemical disinfectant", "TREATMENT", 145, 166], ["microorganisms", "PROBLEM", 214, 228], ["Ventilators", "TREATMENT", 244, 255], ["three low cost ventilators", "TREATMENT", 440, 466], ["honeycomb", "OBSERVATION_MODIFIER", 22, 31], ["air heater", "OBSERVATION", 32, 42], ["UVC", "ANATOMY", 71, 74], ["germicidal lamps", "OBSERVATION", 75, 91], ["Ventilators", "ANATOMY", 244, 255]]], ["Tests were carried out on prototypes of these ventilators and critical mechanical and electronic parameters were established to ensure satisfactory performance of the developed systems.", [["Tests", "TEST", 0, 5], ["these ventilators", "TREATMENT", 40, 57], ["electronic parameters", "TEST", 86, 107]]], ["Johar and Kuldeep 2020) developed micro-controller operated solenoid valve based ventilator for stand-alone and hospital-use.", [["micro-controller operated solenoid valve", "TREATMENT", 34, 74], ["solenoid valve", "OBSERVATION", 60, 74]]], ["Their ventilator has been successfully demonstrated to various hospitals.", [["Their ventilator", "TREATMENT", 0, 16]]], ["Tharion et al. (2020) designed a ventilator using readily available materials, which can be assembled in a short time.", [["a ventilator", "TREATMENT", 31, 43]]], ["Singh and Sardana (2020) designed a BiPAP, which is a mode of ventilation whereby positive pressure is maintained for air intake, and a low pressure for expiration.", [["BiPAP", "CHEMICAL", 36, 41], ["BiPAP", "SIMPLE_CHEMICAL", 36, 41], ["a BiPAP", "TREATMENT", 34, 41], ["ventilation", "TREATMENT", 62, 73], ["positive pressure", "TREATMENT", 82, 99], ["positive pressure", "OBSERVATION", 82, 99]]], ["Sarkar et al. (2020) proposed a novel three-layered face mask with a hydrophilic layer sandwiched between two hydrophobic layers.", [["a novel three-layered face mask", "TREATMENT", 30, 61], ["a hydrophilic layer", "TREATMENT", 67, 86], ["hydrophilic layer", "OBSERVATION_MODIFIER", 69, 86], ["hydrophobic layers", "OBSERVATION", 110, 128]]], ["Simple tests on the developed mask show a better performance than commercial surgical masks in arresting droplet transmission, thereby reducing the chances of infection.Development of Ventilators, Face Masks, and Drugs ::: Development of Computer Models and Apps for Managing the PandemicSingh and Vijayan (2020) conducted a review on the use of chloroquine as a potential drug for the treatment of COVID-19.", [["infection", "DISEASE", 159, 168], ["chloroquine", "CHEMICAL", 346, 357], ["chloroquine", "CHEMICAL", 346, 357], ["COVID-19", "CHEMICAL", 399, 407], ["chloroquine", "SIMPLE_CHEMICAL", 346, 357], ["Simple tests", "TEST", 0, 12], ["mask", "TREATMENT", 30, 34], ["commercial surgical masks", "TREATMENT", 66, 91], ["arresting droplet transmission", "TREATMENT", 95, 125], ["infection", "PROBLEM", 159, 168], ["Ventilators", "TREATMENT", 184, 195], ["chloroquine", "TREATMENT", 346, 357], ["COVID", "TEST", 399, 404], ["infection", "OBSERVATION", 159, 168], ["Ventilators", "ANATOMY", 184, 195]]], ["They explain how chloroquine and hydroxychloroquine mediates anti-viral effect in both prophylactic and therapeutic settings.", [["chloroquine", "CHEMICAL", 17, 28], ["hydroxychloroquine", "CHEMICAL", 33, 51], ["chloroquine", "CHEMICAL", 17, 28], ["hydroxychloroquine", "CHEMICAL", 33, 51], ["chloroquine", "SIMPLE_CHEMICAL", 17, 28], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 33, 51], ["chloroquine", "TREATMENT", 17, 28], ["hydroxychloroquine", "TREATMENT", 33, 51], ["anti-viral effect", "TREATMENT", 61, 78], ["therapeutic settings", "TREATMENT", 104, 124]]], ["Madhavan and Mustafa (2020) suggested the existence of antigenic mimicry between SARS-CoV-2 and host proteins, which could have therapeutic applications.", [["SARS-CoV-2", "ORGANISM", 81, 91], ["SARS-CoV-2 and host proteins", "PROTEIN", 81, 109], ["SARS-CoV", "SPECIES", 81, 89], ["Madhavan", "TREATMENT", 0, 8], ["antigenic mimicry", "PROBLEM", 55, 72], ["host proteins", "TREATMENT", 96, 109], ["therapeutic applications", "TREATMENT", 128, 152]]], ["Biswas et al. (2020) developed a risk assessment score to predict the severity of the disease of suspected patients.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["a risk assessment score", "TEST", 31, 54], ["the disease", "PROBLEM", 82, 93], ["disease", "OBSERVATION", 86, 93]]], ["This helps in providing early attention and management before the availability of the RT-PCR test for confirmation.", [["management", "TREATMENT", 44, 54], ["the RT-PCR test", "TEST", 82, 97], ["confirmation", "TEST", 102, 114]]], ["Patel et al. (2020) proposed a unique five-layer body bag for the deceased.", [["body", "ANATOMY", 49, 53], ["a unique five-layer body bag", "TREATMENT", 29, 57]]], ["The body bag is leak-proof, strong enough for handling and transport, and has provision to view the face of the dead body by family members before cremation/burial.Development of Ventilators, Face Masks, and Drugs ::: Development of Computer Models and Apps for Managing the PandemicThe scale of the pandemic has increased manifold between conceiving of this SI to its appearance.", [["body", "ANATOMY", 4, 8], ["body", "ANATOMY", 117, 121], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["The body bag", "TREATMENT", 0, 12], ["leak", "PROBLEM", 16, 20], ["Ventilators", "TREATMENT", 179, 190], ["body bag", "OBSERVATION", 4, 12], ["leak", "OBSERVATION", 16, 20], ["Ventilators", "ANATOMY", 179, 190], ["increased", "OBSERVATION_MODIFIER", 313, 322]]], ["Several of us were not even aware that such alternate approaches exist, and that somebody else is already trying to use the other approaches for fighting the biggest danger posed to mankind.Development of Ventilators, Face Masks, and Drugs ::: Development of Computer Models and Apps for Managing the PandemicWe therefore hope that the articles in the SI will enrich the readers, and provide them with additional ideas and tools.", [["Ventilators", "TREATMENT", 205, 216], ["Managing the PandemicWe", "TREATMENT", 288, 311], ["Ventilators", "ANATOMY", 205, 216]]], ["As the President, INAE said in his Foreword (Mishra 2020), we will consider the SI a success only when teams having novel ideas, proposed and partial/full solutions come together and quickly work out collaborations to produce a marketable product at a reasonable cost and reliability which is of utmost importance in diagnosis and treatment.Development of Ventilators, Face Masks, and Drugs ::: Development of Computer Models and Apps for Managing the PandemicProf.", [["partial/full solutions", "TREATMENT", 142, 164], ["treatment", "TREATMENT", 331, 340], ["Ventilators", "TREATMENT", 356, 367], ["Ventilators", "ANATOMY", 356, 367]]], ["K. Bhanu Sankara Rao, Editor-in-Chief of Transactions of INAE showed unabated interest and rendered much needed support and invaluable guidance at all the stages for realizing this rare and timely issue.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["K", "TEST", 0, 1]]]], "278346f96e825556eda1be7ff6bd64de6b314a9f": [["S-3Human neutrophil elastase (HNE): 4 To 970 \uf06dL of 0.1 M HEPES/0.5 M NaCl pH 7.26, 10 uL 1.75 x 10 -3 M of inhibitor (DMSO for control) and 10 \uf06dL of 3.077 x 10 -5 M of HNE were added, mixed, and incubated for 30 minutes.", [["NaCl", "CHEMICAL", 69, 73], ["DMSO", "CHEMICAL", 118, 122], ["HNE", "CHEMICAL", 168, 171], ["HEPES", "CHEMICAL", 57, 62], ["NaCl", "CHEMICAL", 69, 73], ["DMSO", "CHEMICAL", 118, 122], ["HNE", "CHEMICAL", 168, 171], ["S-3Human neutrophil elastase", "GENE_OR_GENE_PRODUCT", 0, 28], ["HNE", "SIMPLE_CHEMICAL", 30, 33], ["DMSO", "SIMPLE_CHEMICAL", 118, 122], ["HNE", "SIMPLE_CHEMICAL", 168, 171], ["3Human neutrophil elastase", "TEST", 2, 28], ["HEPES", "TEST", 57, 62], ["NaCl pH", "TEST", 69, 76], ["uL", "TEST", 86, 88], ["inhibitor (DMSO", "TREATMENT", 107, 122], ["HNE", "TREATMENT", 168, 171], ["neutrophil elastase", "OBSERVATION", 9, 28]]], ["To it, 10 \uf06dL of 0.07 M substrate (MeO-Suc-Ala-Ala-Pro-Val-pNa) was added, and the samples were monitored at \uf06c = 410 nm, T = 25\uf0b0C, for 120 seconds. for 30 minutes then 10 \uf06dL of 0.02 M substrate (N-p-tosyl-Gly-Pro-Lys-pNa) was added, and the samples were monitored at \uf06c = 410 nm, T = 25\uf0b0C for 120 seconds.", [["samples", "ANATOMY", 82, 89], ["samples", "ANATOMY", 240, 247], ["MeO-Suc-Ala-Ala-Pro-Val-pNa", "CHEMICAL", 34, 61], ["N-p-tosyl-Gly-Pro-Lys-pNa", "CHEMICAL", 194, 219], ["MeO-Suc-Ala-Ala-Pro-Val-pNa", "CHEMICAL", 34, 61], ["N-p-tosyl-Gly-Pro-Lys-pNa", "CHEMICAL", 194, 219], ["MeO-Suc-Ala-Ala-Pro-Val-pNa", "SIMPLE_CHEMICAL", 34, 61], ["N-p-tosyl-Gly-Pro-Lys-pNa", "SIMPLE_CHEMICAL", 194, 219], ["MeO", "TEST", 34, 37], ["Ala-Ala-Pro-Val-pNa)", "TREATMENT", 42, 62], ["the samples", "TEST", 78, 89], ["T", "TEST", 120, 121], ["0.02 M substrate (N-p-tosyl-Gly-Pro-Lys-pNa)", "TREATMENT", 176, 220], ["the samples", "TEST", 236, 247], ["T", "TEST", 278, 279]]], ["The blank consisted of 980 \uf06dL of 0.1 M Tris-HCl/0.5 M NaCl, pH 7.5, and 20 \uf06dL DMSO.", [["Tris-HCl", "CHEMICAL", 39, 47], ["NaCl", "CHEMICAL", 54, 58], ["DMSO", "CHEMICAL", 78, 82], ["Tris-HCl", "CHEMICAL", 39, 47], ["NaCl", "CHEMICAL", 54, 58], ["DMSO", "CHEMICAL", 78, 82], ["Tris-HCl", "SIMPLE_CHEMICAL", 39, 47], ["NaCl", "TEST", 54, 58], ["pH", "TEST", 60, 62]]], ["The percent inhibition was calculated by taking the percent difference between the hydrolysis slope and the inhibition slope.", [["The percent inhibition", "TREATMENT", 0, 22], ["the hydrolysis slope", "TREATMENT", 79, 99], ["the inhibition slope", "TREATMENT", 104, 124], ["hydrolysis slope", "OBSERVATION", 83, 99]]], ["DMF (10 mL).", [["DMF", "CHEMICAL", 0, 3], ["DMF", "CHEMICAL", 0, 3], ["DMF", "SIMPLE_CHEMICAL", 0, 3]]], ["The solution was stirred at 25 o C and dry CH 2 Cl 2 (25 mL) was added, and the resulting solution was stirred for 18 h.", [["CH 2 Cl", "CHEMICAL", 43, 50], ["CH 2 Cl 2", "CHEMICAL", 43, 52], ["The solution", "TREATMENT", 0, 12], ["dry CH 2 Cl", "TREATMENT", 39, 50], ["the resulting solution", "TREATMENT", 76, 98]]], ["The reaction was partitioned between water (150 mL) and CH 2 Cl 2 (150 mL).", [["CH 2 Cl", "CHEMICAL", 56, 63], ["CH 2 Cl 2", "CHEMICAL", 56, 65], ["water", "SIMPLE_CHEMICAL", 37, 42], ["The reaction", "PROBLEM", 0, 12]]], ["The pH of the aqueous layer was adjusted to 3 using 2 N HCl.", [["aqueous layer", "ANATOMY", 14, 27], ["N HCl", "CHEMICAL", 54, 59], ["HCl", "CHEMICAL", 56, 59], ["The pH", "TEST", 0, 6], ["the aqueous layer", "TREATMENT", 10, 27], ["aqueous", "OBSERVATION_MODIFIER", 14, 21], ["layer", "OBSERVATION_MODIFIER", 22, 27]]], ["The organic layer was removed, and the aqueous layer was extracted twice with CH 2 Cl 2 (150 mL each).", [["aqueous layer", "ANATOMY", 39, 52], ["CH 2 Cl", "CHEMICAL", 78, 85], ["CH 2 Cl 2", "CHEMICAL", 78, 87], ["aqueous layer", "ORGANISM_SUBSTANCE", 39, 52], ["The organic layer", "TREATMENT", 0, 17], ["the aqueous layer", "TREATMENT", 35, 52], ["CH 2 Cl", "TREATMENT", 78, 85], ["organic", "OBSERVATION_MODIFIER", 4, 11], ["layer", "OBSERVATION_MODIFIER", 12, 17], ["removed", "OBSERVATION", 22, 29], ["aqueous", "OBSERVATION_MODIFIER", 39, 46], ["layer", "OBSERVATION_MODIFIER", 47, 52]]], ["The combined organic layers were dried (anhydrous MgSO 4 ), filtered and concentrated to yield a sticky solid which was purified by silica gel chromatography (30:1 CH 2 Cl 2 :MeOH) to yield compound 11, 1.6 g (72% yield) as a white solid, mp 70 -73 o C. 1 H NMR \u03b4 7.84 (d, J = 7.03 Hz, 1H), 6.96 (br. s., 1H), 5.18 (d, J = 8.59 Hz, 1H), 1H), 1H) Hz, 3H, CH 3 ); 13 C NMR \u03b4 180.0, 173.", [["anhydrous MgSO 4", "CHEMICAL", 40, 56], ["silica gel", "CHEMICAL", 132, 142], ["30:1 CH 2 Cl 2 :MeOH", "CHEMICAL", 159, 179], ["anhydrous MgSO 4", "CHEMICAL", 40, 56], ["silica gel", "CHEMICAL", 132, 142], ["CH 2 Cl 2", "CHEMICAL", 164, 173], ["MeOH", "CHEMICAL", 175, 179], ["H", "CHEMICAL", 256, 257], ["1H", "CHEMICAL", 286, 288], ["1H", "CHEMICAL", 305, 307], ["1H", "CHEMICAL", 332, 334], ["1H", "CHEMICAL", 337, 339], ["1H", "CHEMICAL", 342, 344], ["3H", "CHEMICAL", 350, 352], ["CH", "CHEMICAL", 354, 356], ["13 C", "CHEMICAL", 362, 366], ["silica", "SIMPLE_CHEMICAL", 132, 138], ["The combined organic layers", "TREATMENT", 0, 27], ["dried (anhydrous MgSO", "TREATMENT", 33, 54], ["a sticky solid", "PROBLEM", 95, 109], ["silica gel chromatography", "TEST", 132, 157], ["compound", "TEST", 190, 198], ["a white solid", "TEST", 224, 237], ["mp", "TEST", 239, 241], ["NMR", "TEST", 258, 261], ["J", "TEST", 273, 274], ["Hz", "TEST", 282, 284], ["Hz", "TEST", 346, 348], ["3H", "TEST", 350, 352], ["CH", "TEST", 354, 356], ["NMR \u03b4", "TEST", 367, 372], ["organic", "OBSERVATION_MODIFIER", 13, 20], ["layers", "OBSERVATION_MODIFIER", 21, 27]]], ["6, 172.5, 155.9, 80.0, 53.0, 52.6, 51.3, 42.5, 40.7, 38.5, 33.3, 28.5, 28.3, 24.8, 23.1, 22.4 ; MS, m/z 422.3 (M+Na) + .V.2.", [["Na", "CHEMICAL", 113, 115], ["Na", "CHEMICAL", 113, 115], ["MS", "TEST", 96, 98], ["m", "TEST", 100, 101], ["z", "TEST", 102, 103], ["M+Na", "TEST", 111, 115]]], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (14).", [["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 142], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 142], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "SIMPLE_CHEMICAL", 0, 142], ["Benzyloxycarbonylamino-3-naphthalen-1", "TREATMENT", 8, 45], ["propionylamino)", "TREATMENT", 49, 64], ["-methylpentanoylamino", "TREATMENT", 66, 87], ["propionic acid methyl ester", "TREATMENT", 115, 142]]], ["GeneralProcedure: Compound 11 (1 mmol) was dissolved in 10% TFA/CH 2 Cl 2 (5 mL) and stirred at 25 o C for 4 h.", [["Compound 11", "CHEMICAL", 18, 29], ["TFA/CH 2 Cl", "CHEMICAL", 60, 71], ["TFA", "CHEMICAL", 60, 63], ["CH 2 Cl 2", "CHEMICAL", 64, 73], ["TFA", "SIMPLE_CHEMICAL", 60, 63]]], ["The solvent was removed on a rotary evaporator to yield a sticky oil that was redissolved in chloroform followed by removal of the solvent once again on the rotary evaporator to yield a semi-solid material.", [["oil", "ANATOMY", 65, 68], ["chloroform", "CHEMICAL", 93, 103], ["oil", "ORGANISM_SUBSTANCE", 65, 68], ["chloroform", "SIMPLE_CHEMICAL", 93, 103], ["The solvent", "TREATMENT", 0, 11], ["a rotary evaporator", "TREATMENT", 27, 46], ["a sticky oil", "TREATMENT", 56, 68], ["chloroform", "TREATMENT", 93, 103], ["removal of the solvent", "TREATMENT", 116, 138], ["the rotary evaporator", "TREATMENT", 153, 174], ["semi-solid material", "OBSERVATION", 186, 205]]], ["After sitting under high vacuum for 0.5 h, a white solid (the Boc S-5 group was removed) was obtained in quantitative yield.", [["Boc S-5", "CHEMICAL", 62, 69], ["Boc", "CHEMICAL", 62, 65], ["high vacuum", "TREATMENT", 20, 31], ["a white solid (the Boc S-5 group", "TREATMENT", 43, 75]]], ["To this solid (1 mmol) was added (S)-N-Cbz-1-naphthylalanine (12b) (1 mmol), EDCI (2 mmol) and DMAP (2 mmol) followed by dry CH 2 Cl 2 (15 mL) and the resulting solution was stirred at 25 o C for 18 h under argon atmosphere.V.2.", [["S)-N-Cbz-1-naphthylalanine", "CHEMICAL", 34, 60], ["EDCI", "CHEMICAL", 77, 81], ["DMAP", "CHEMICAL", 95, 99], ["CH 2 Cl", "CHEMICAL", 125, 132], ["(S)-N-Cbz-1-naphthylalanine", "CHEMICAL", 33, 60], ["EDCI", "CHEMICAL", 77, 81], ["DMAP", "CHEMICAL", 95, 99], ["CH 2 Cl 2", "CHEMICAL", 125, 134], ["(S)-N-Cbz-1-naphthylalanine (12b", "SIMPLE_CHEMICAL", 33, 65], ["EDCI", "SIMPLE_CHEMICAL", 77, 81], ["DMAP", "SIMPLE_CHEMICAL", 95, 99], ["V.2", "PROTEIN", 224, 227], ["Cbz", "TREATMENT", 39, 42], ["naphthylalanine", "TREATMENT", 45, 60], ["EDCI", "TREATMENT", 77, 81], ["DMAP", "TREATMENT", 95, 99]]], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (14).", [["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 142], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 142], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "SIMPLE_CHEMICAL", 0, 142], ["Benzyloxycarbonylamino-3-naphthalen-1", "TREATMENT", 8, 45], ["propionylamino)", "TREATMENT", 49, 64], ["-methylpentanoylamino", "TREATMENT", 66, 87], ["propionic acid methyl ester", "TREATMENT", 115, 142]]], ["GeneralThe reaction mixture was partitioned between water (150 mL) and CH 2 Cl 2 (150 mL), the aqueous layer was acidified to pH = 2 using 2 N HCl, and extracted three times with CH 2 Cl 2 (150 mL each).", [["aqueous layer", "ANATOMY", 95, 108], ["CH 2 Cl", "CHEMICAL", 71, 78], ["N HCl", "CHEMICAL", 141, 146], ["CH 2 Cl", "CHEMICAL", 179, 186], ["CH 2 Cl 2", "CHEMICAL", 71, 80], ["HCl", "CHEMICAL", 143, 146], ["CH 2 Cl 2", "CHEMICAL", 179, 188], ["water", "SIMPLE_CHEMICAL", 52, 57], ["The reaction mixture", "TREATMENT", 7, 27], ["2 N HCl", "TREATMENT", 139, 146]]], ["The combined organic layers were dried (anhydrous MgSO 4 ), filtered, and concentrated to yield a solid which was purified by silica gel chromatography ( 7, 172.4, 171.4, 156.3, 136.3, 134.1, 132.9, 132.3, 129.1, 128.7, 128.4, 128.2, 128.0, 127.8, 126.6, 126.0, 125.5, 123.8, 67.2, 55.9, 52.6, 51.9, 51.4, 42.2, 40.8, 38.6, 35.5, 33.3, 28.2, 24.8, 23.1, 22.3 ; MS, m/z 653.2 (M+Na) + .V.3.", [["anhydrous MgSO 4", "CHEMICAL", 40, 56], ["silica gel", "CHEMICAL", 126, 136], ["Na", "CHEMICAL", 378, 380], ["anhydrous MgSO 4", "CHEMICAL", 40, 56], ["silica gel", "CHEMICAL", 126, 136], ["Na", "CHEMICAL", 378, 380], ["silica", "SIMPLE_CHEMICAL", 126, 132], ["The combined organic layers", "TREATMENT", 0, 27], ["dried (anhydrous MgSO", "TREATMENT", 33, 54], ["silica gel chromatography", "TEST", 126, 151], ["MS", "TEST", 361, 363], ["m", "TEST", 365, 366], ["z", "TEST", 367, 368], ["M+Na", "TEST", 376, 380], ["organic", "OBSERVATION_MODIFIER", 13, 20], ["layers", "OBSERVATION_MODIFIER", 21, 27]]], ["2-[2-(2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (13).The procedure was the same as for compound 14 except (S)-N-Cbz-phenylalanine (12a) was used in place of (S)-N-Cbz-1-naphthylalanine (12b) 2, 136.6, 136.4, 129.6, 128.8, 128.4, 128.2, 127.1, 67.3, 56.2, 52.6, 51.8, 51.4, 42.2, 40.7, 38.6, 38.4, 33.2, 28.2, 24.8, 23.1, 22.3 ; MS, m/z 603.2 (M+Na) + .V.4.", [["2-[2-(2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 133], ["S)-N-Cbz-phenylalanine", "CHEMICAL", 193, 215], ["Cbz-1-naphthylalanine", "CHEMICAL", 249, 270], ["Na", "CHEMICAL", 431, 433], ["2-[2-(2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 133], ["(S)-N-Cbz-phenylalanine", "CHEMICAL", 192, 215], ["(S)-N-Cbz-1-naphthylalanine", "CHEMICAL", 243, 270], ["Na", "CHEMICAL", 431, 433], ["2-[2-(2-Benzyloxycarbonylamino-3-phenyl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "SIMPLE_CHEMICAL", 0, 133], ["(S)-N-Cbz-phenylalanine", "SIMPLE_CHEMICAL", 192, 215], ["(S)-N-Cbz-1-naphthylalanine", "SIMPLE_CHEMICAL", 243, 270], ["Benzyloxycarbonylamino", "TREATMENT", 8, 30], ["phenyl-propionylamino)-4-methylpentanoylamino", "TREATMENT", 33, 78], ["propionic acid methyl ester", "TREATMENT", 106, 133], ["The procedure", "TREATMENT", 139, 152], ["N-Cbz-phenylalanine", "TREATMENT", 196, 215], ["Cbz", "TEST", 249, 252], ["naphthylalanine", "TEST", 255, 270], ["MS", "TEST", 414, 416], ["z", "TEST", 420, 421], ["M+Na", "TEST", 429, 433]]], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (15).The procedure was the same as for compound 14 except (R)-N-Cbz-1-naphthylalanine (12c) was used in place of (S)-N-Cbz-1-naphthylalanine (12b) 6, 172.2, 171.0, 156.2, 136.5, 134.1, 133.0, 132.3, 129.0, 128.7, 128.4, 128.3, 128.1, 128.0, 126.7, 126.0, 125.7, 123.9, 67.15, 56.4, 52.5, 51.9, 51.7, 41.5, 40.7, 38.8, 36.2, 32.9, 28.5, 24.5, 23V.6.", [["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 142], ["R)-N-Cbz-1-naphthylalanine", "CHEMICAL", 202, 228], ["Cbz-1-naphthylalanine", "CHEMICAL", 262, 283], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 142], ["(R)-N-Cbz-1-naphthylalanine", "CHEMICAL", 201, 228], ["(S)-N-Cbz-1-naphthylalanine", "CHEMICAL", 256, 283], ["2-[2-(2-Benzyloxycarbonylamino-3-naphthalen-1-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "SIMPLE_CHEMICAL", 0, 142], ["(R)-N-Cbz-1-naphthylalanine (12c", "SIMPLE_CHEMICAL", 201, 233], ["(S)-N-Cbz-1-naphthylalanine", "SIMPLE_CHEMICAL", 256, 283], ["Benzyloxycarbonylamino-3-naphthalen-1", "TREATMENT", 8, 45], ["propionylamino)", "TREATMENT", 49, 64], ["-methylpentanoylamino", "TREATMENT", 66, 87], ["propionic acid methyl ester", "TREATMENT", 115, 142], ["The procedure", "TREATMENT", 148, 161], ["compound", "TEST", 182, 190], ["Cbz", "TEST", 207, 210], ["naphthylalanine", "TREATMENT", 213, 228], ["Cbz", "TEST", 262, 265], ["naphthylalanine", "TEST", 268, 283]]], ["2-[2-(2-Benzyloxycarbonylamino-3-biphenyl-4-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester (17).The procedure was the same as for compound 14 except (S)-N-Cbz-(4-phenyl)phenylalanine (12e) was used in place of (S)-N-Cbz-1-napthylalanine (12b) 2, 140.8, 140.3, 136.3, 134.8, 130.0, 129.0, 128.8, 128.5, 128.3, 127.6, 127.5, 127.1, 67.4, 54.9, 37.6 ; MS, m/z 398.0 (M+Na) + .V.8.", [["2-[2-(2-Benzyloxycarbonylamino-3-biphenyl-4-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 140], ["S)-N-Cbz-(4-phenyl)phenylalanine", "CHEMICAL", 200, 232], ["Cbz-1-napthylalanine", "CHEMICAL", 266, 286], ["Na", "CHEMICAL", 416, 418], ["2-[2-(2-Benzyloxycarbonylamino-3-biphenyl-4-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "CHEMICAL", 0, 140], ["(S)-N-Cbz-(4-phenyl)phenylalanine", "CHEMICAL", 199, 232], ["(S)-N-Cbz-1-napthylalanine", "CHEMICAL", 260, 286], ["Na", "CHEMICAL", 416, 418], ["2-[2-(2-Benzyloxycarbonylamino-3-biphenyl-4-yl-propionylamino)-4-methylpentanoylamino]-3-(2-oxo-pyrrolidin-3-yl)-propionic acid methyl ester", "SIMPLE_CHEMICAL", 0, 140], ["(S)-N-Cbz-(4-phenyl)phenylalanine", "SIMPLE_CHEMICAL", 199, 232], ["(S)-N-Cbz-1-napthylalanine", "SIMPLE_CHEMICAL", 260, 286], ["Benzyloxycarbonylamino", "TREATMENT", 8, 30], ["propionylamino)-4-methylpentanoylamino", "TREATMENT", 47, 85], ["propionic acid methyl ester", "TREATMENT", 113, 140], ["The procedure", "TREATMENT", 146, 159], ["compound", "TEST", 180, 188], ["Cbz-(4-phenyl)phenylalanine (12e)", "TREATMENT", 205, 238], ["Cbz", "TEST", 266, 269], ["napthylalanine", "TREATMENT", 272, 286], ["MS", "TEST", 399, 401], ["z", "TEST", 405, 406], ["M+Na", "TEST", 414, 418]]], ["(1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (2).", [["1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester", "CHEMICAL", 1, 137], ["(1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester", "CHEMICAL", 0, 137], ["1-{3-Methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester", "SIMPLE_CHEMICAL", 1, 137], ["Methyl", "TEST", 6, 12], ["oxo", "TREATMENT", 18, 21], ["oxo", "TREATMENT", 27, 30], ["pyrrolidin", "TREATMENT", 31, 41], ["ethylcarbamoyl", "TREATMENT", 54, 68], ["butylcarbamoyl}-2", "TREATMENT", 70, 87], ["carbamic acid benzyl ester", "TREATMENT", 111, 137]]], ["GeneralProcedure: To a solution of ester 14 (0.63 mmol) in CH 2 Cl 2 /MeOH (1:1) (8 mL) at 0 o C was added NaBH 4 (5.6 mmol) in small portions over a period of 4 h.", [["ester 14", "CHEMICAL", 35, 43], ["CH 2 Cl 2 /MeOH", "CHEMICAL", 59, 74], ["NaBH", "CHEMICAL", 107, 111], ["ester 14", "CHEMICAL", 35, 43], ["CH 2 Cl 2", "CHEMICAL", 59, 68], ["MeOH", "CHEMICAL", 70, 74], ["NaBH 4", "CHEMICAL", 107, 113], ["ester 14", "SIMPLE_CHEMICAL", 35, 43], ["a solution of ester", "TREATMENT", 21, 40]]], ["The reaction was quenched with water (0.5 mL) and diluted with 100 mL of CH 2 Cl 2 .", [["CH 2 Cl", "CHEMICAL", 73, 80], ["CH 2 Cl 2", "CHEMICAL", 73, 82], ["water", "SIMPLE_CHEMICAL", 31, 36], ["The reaction", "PROBLEM", 0, 12]]], ["The solution was passed through a short plug of silica gel and the organic material washed thoroughly with 30:1 CH 2 Cl 2 /MeOH (100 mL).", [["silica gel", "CHEMICAL", 48, 58], ["30:1 CH 2 Cl 2 /MeOH", "CHEMICAL", 107, 127], ["silica", "CHEMICAL", 48, 54], ["CH 2 Cl 2", "CHEMICAL", 112, 121], ["MeOH", "CHEMICAL", 123, 127], ["The solution", "TREATMENT", 0, 12], ["a short plug of silica gel", "TREATMENT", 32, 58], ["the organic material", "TREATMENT", 63, 83]]], ["The filtrate was concentrated to yield a solid which was dissolved in distilled CH 2 Cl 2 (15 mL) and treated with Dess-Martin periodinane (DMP) for 2 h at 25 o C. The reaction mixture was filtered and the filtrate was concentrated and purified by silica gel chromatography using a gradient solvent elution of 25% acetone/CH 2 Cl 2 to 100% acetone.", [["CH 2 Cl 2", "CHEMICAL", 80, 89], ["Dess-Martin periodinane", "CHEMICAL", 115, 138], ["DMP", "CHEMICAL", 140, 143], ["silica gel", "CHEMICAL", 248, 258], ["acetone", "CHEMICAL", 314, 321], ["CH 2 Cl", "CHEMICAL", 322, 329], ["acetone", "CHEMICAL", 340, 347], ["CH 2 Cl 2", "CHEMICAL", 80, 89], ["periodinane", "CHEMICAL", 127, 138], ["DMP", "CHEMICAL", 140, 143], ["silica gel", "CHEMICAL", 248, 258], ["acetone", "CHEMICAL", 314, 321], ["CH 2 Cl 2", "CHEMICAL", 322, 331], ["acetone", "CHEMICAL", 340, 347], ["Dess-Martin periodinane", "SIMPLE_CHEMICAL", 115, 138], ["DMP", "SIMPLE_CHEMICAL", 140, 143], ["silica", "SIMPLE_CHEMICAL", 248, 254], ["acetone", "SIMPLE_CHEMICAL", 314, 321], ["acetone", "SIMPLE_CHEMICAL", 340, 347], ["The filtrate", "TREATMENT", 0, 12], ["Dess-Martin periodinane (DMP)", "TREATMENT", 115, 144], ["the filtrate", "TREATMENT", 202, 214], ["silica gel chromatography", "TEST", 248, 273], ["a gradient solvent elution", "TREATMENT", 280, 306], ["25% acetone/CH", "TREATMENT", 310, 324], ["filtrate", "OBSERVATION", 4, 12]]], ["The fractions containing the product were combined and concentrated to give a white solid to which was added CHCl 3 (20 mL).", [["CHCl 3", "CHEMICAL", 109, 115], ["fractions", "OBSERVATION_MODIFIER", 4, 13]]], ["After sitting for 10 min the mixture was filtered through a glass frit funnel (fine) and the filtrate was concentrated to provide aldehyde 2 (90% yield) as a white solid, mp 85 -88 o C. 2, 180.1, 173.2, 171.4, 156.4, 136.2, 134.1, 132.8, 132.3, 129.1, 128.8, 128.5, 128.2, 128.1, 127.9, 126.7, 126.0, 125.6, 123.8, 67.3, 57.8, 56.0, 52.0, 41.9, 40.8, 38.4, 35.4, 30.0, 28.7, 25 1, 180.2, 173.3, 171.3, 156.4, 136.5, 136.3, 129.6, 128.8, 128.7, 128.5, 128.2, 127.3, 67.4, 57.6, 56.3, 52.0, 42.0, 40.8, 38.3, 38.2, 30.0, 28.5, 25 .", [["aldehyde", "CHEMICAL", 130, 138], ["aldehyde", "CHEMICAL", 130, 138], ["aldehyde", "SIMPLE_CHEMICAL", 130, 138], ["a glass frit funnel", "TREATMENT", 58, 77], ["the filtrate", "TREATMENT", 89, 101], ["a white solid", "TEST", 156, 169], ["mp", "TEST", 171, 173]]], ["4, 180.0, 173.3, 171.2, 156.4, 136.4, 134.1, 133.0, 132.4, 129.0, 128.8, 128.5, 128.4, 128.3, 128.0, 126.6, 126.0, 125.7, 124.0, 67.2, 58.3, 56.5, 51.8, 41.2, S-9 40.", [["S", "TEST", 159, 160]]], ["(2-Biphenyl-4-yl-1-{3-methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-ethyl)-carbamic acid benzyl ester (5) .", [["2-Biphenyl-4-yl-1-{3-methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-ethyl)-carbamic acid benzyl ester", "CHEMICAL", 1, 135], ["(2-Biphenyl-4-yl-1-{3-methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-ethyl)-carbamic acid benzyl ester", "CHEMICAL", 0, 135], ["(2-Biphenyl-4-yl-1-{3-methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-ethyl)-carbamic acid benzyl ester", "SIMPLE_CHEMICAL", 0, 135], ["Biphenyl", "TEST", 3, 11], ["methyl-1-[2-oxo-1-(2-oxo-pyrrolidin-3-ylmethyl)-ethylcarbamoyl]-butylcarbamoyl}-ethyl", "TREATMENT", 22, 107], ["carbamic acid benzyl ester", "TREATMENT", 109, 135]]], ["Followed the same procedure as for compound 2 but started with ester 17 to give compound 5 (79% yield) as a NMR \u03b4 199.9, 180.2, 173.3, 171.2, 156.4, 140.8, 140.1, 136.2, 135.5, 130.0, 129.0, 128.8, 128.5, 128.3, 127.6, 127.5, 127.1, 67.4, 58.0, 56.3, 52.1, 41.9, 40.8, 38.5, 37.8, 29.9, 28.8, 25.3-methyl-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester (6).Isopropylisocyanide (0.067 mmol) was added to a solution of aldehyde 2 (67 \uf06dmol) in distilled EtOAc (2 mL) and AcOH (1 drop) and the resulting solution stirred at 25 o C for 18 h.", [["ester 17", "CHEMICAL", 63, 71], ["25.3-methyl-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester", "CHEMICAL", 293, 372], ["Isopropylisocyanide", "CHEMICAL", 377, 396], ["aldehyde", "CHEMICAL", 437, 445], ["distilled EtOAc", "CHEMICAL", 461, 476], ["AcOH", "CHEMICAL", 488, 492], ["ester", "CHEMICAL", 63, 68], ["25.3-methyl-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester", "CHEMICAL", 293, 372], ["Isopropylisocyanide", "CHEMICAL", 377, 396], ["aldehyde", "CHEMICAL", 437, 445], ["EtOAc", "CHEMICAL", 471, 476], ["AcOH", "CHEMICAL", 488, 492], ["ester 17", "SIMPLE_CHEMICAL", 63, 71], ["25.3-methyl-butylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid benzyl ester", "SIMPLE_CHEMICAL", 293, 372], ["Isopropylisocyanide", "SIMPLE_CHEMICAL", 377, 396], ["aldehyde 2", "SIMPLE_CHEMICAL", 437, 447], ["AcOH", "SIMPLE_CHEMICAL", 488, 492], ["the same procedure", "TREATMENT", 9, 27], ["a NMR", "TEST", 106, 111], ["methyl", "TEST", 298, 304], ["carbamic acid benzyl ester", "TREATMENT", 346, 372], ["Isopropylisocyanide", "TREATMENT", 377, 396], ["a solution of aldehyde", "TREATMENT", 423, 445], ["AcOH", "TREATMENT", 488, 492], ["the resulting solution stirred", "TREATMENT", 506, 536]]], ["The solvent was removed in vacuo and the residue was dissolved in a 1:1 solution of MeOH/H 2 O (5 mL) and", [["H 2 O", "CHEMICAL", 89, 94], ["MeOH", "CHEMICAL", 84, 88], ["H 2 O", "CHEMICAL", 89, 94], ["MeOH", "SIMPLE_CHEMICAL", 84, 88], ["H 2 O", "SIMPLE_CHEMICAL", 89, 94], ["The solvent", "TREATMENT", 0, 11], ["vacuo", "TREATMENT", 27, 32], ["a 1:1 solution of MeOH/H", "TREATMENT", 66, 90]]]], "PMC7345222": [], "PMC1288026": [["IntroductionThe epidemiological responsibility to forecast disease outbreaks is an onerous one.", [["forecast disease outbreaks", "PROBLEM", 50, 76]]], ["Because of the devastating consequences and high costs of disease, predicting outbreaks is a chief goal for public-health planning and emergency preparedness.", [["the devastating consequences", "PROBLEM", 11, 39], ["disease", "PROBLEM", 58, 65], ["public-health planning", "TREATMENT", 108, 130], ["emergency preparedness", "TREATMENT", 135, 157], ["devastating", "OBSERVATION_MODIFIER", 15, 26], ["high", "OBSERVATION_MODIFIER", 44, 48]]], ["Thus, quantitative forecasting and development of early warning systems (EWSs) for disease outbreak is a high priority for research and development [1].", [["early warning systems", "PROBLEM", 50, 71], ["disease outbreak", "PROBLEM", 83, 99], ["early", "OBSERVATION_MODIFIER", 50, 55]]], ["Intuition suggests that for directly transmissible diseases, the magnitude of the outbreak will be extremely difficult to predict because of the stochastic process of infectious contacts [2,3].", [["transmissible diseases", "DISEASE", 37, 59], ["directly transmissible diseases", "PROBLEM", 28, 59], ["infectious", "OBSERVATION", 167, 177]]], ["This idea is consistent with the recent finding of Sultan et al. [4] that although the timing of annual meningitis outbreaks in West Africa was highly predictable, the final outbreak size varied greatly from year to year.", [["meningitis", "DISEASE", 104, 114], ["annual meningitis outbreaks", "PROBLEM", 97, 124], ["consistent with", "UNCERTAINTY", 13, 28], ["meningitis", "OBSERVATION", 104, 114], ["size", "OBSERVATION_MODIFIER", 183, 187]]], ["Here I study fundamental limits to forecast precision for (eventually) controlled outbreaks, first theoretically, then using nine well-studied infectious diseases as examples.", [["infectious diseases", "DISEASE", 143, 162]]], ["Finally, I consider a new model that more realistically represents actual outbreaks of emerging infections.IntroductionThe reason that final outbreak size is generally not predictable is that the eventual dynamics of the outbreak are highly sensitive to the seemingly random sequence of infectious contacts and removal of infectious individuals in the early, typically unobserved stages of the outbreak [3].", [["infections", "DISEASE", 96, 106], ["emerging infections", "PROBLEM", 87, 106], ["infectious contacts", "PROBLEM", 287, 306], ["removal", "TREATMENT", 311, 318], ["infectious individuals", "PROBLEM", 322, 344], ["infections", "OBSERVATION", 96, 106], ["size", "OBSERVATION_MODIFIER", 150, 154], ["infectious", "OBSERVATION", 287, 297], ["infectious", "OBSERVATION_MODIFIER", 322, 332]]], ["Clearly, the final size of an outbreak depends on numerous aspects of the social structure of the population, the environment, and disease- or strain-specific characteristics.", [["disease", "PROBLEM", 131, 138], ["final", "OBSERVATION_MODIFIER", 13, 18], ["size", "OBSERVATION_MODIFIER", 19, 23], ["outbreak", "OBSERVATION", 30, 38], ["numerous", "OBSERVATION_MODIFIER", 50, 58]]], ["Among the more important factors are seasonal climate fluctuations, transmissibility and virulence of the pathogen, population dynamics and structure of the host population, physiological and immunological status of potential hosts, and the social networks of contacts between infectious and susceptible individuals [5\u20138].", [["seasonal climate fluctuations", "PROBLEM", 37, 66], ["the pathogen", "PROBLEM", 102, 114]]], ["Accordingly, the deterministic approach to epidemic modeling regards the spread of infectious diseases as completely determined by the average effects of these factors on the basic reproductive ratio (R0) together with initial conditions.", [["infectious diseases", "DISEASE", 83, 102], ["infectious diseases", "PROBLEM", 83, 102], ["these factors", "PROBLEM", 154, 167], ["infectious", "OBSERVATION", 83, 93]]], ["Deterministic models of epidemics have provided insight into such important topics as the design of vaccination campaigns and the effect of age structure on epidemic dynamics [5].", [["epidemics", "PROBLEM", 24, 33], ["vaccination campaigns", "TREATMENT", 100, 121]]], ["From the perspective of EWSs, the timing and average severity of outbreaks also might be modeled quite accurately with deterministic models.", [["outbreaks", "PROBLEM", 65, 74]]], ["However, for emerging diseases or for diseases prone to sudden outbreak, numerical predictions of final outbreak size derived from deterministic models will often deviate substantially from the observed outbreak size [3,9].IntroductionIn contrast, the stochastic theory of epidemics represents the population as a statistical ensemble with constant or regular average properties but probabilistic changes in disease status for individuals.", [["emerging diseases", "PROBLEM", 13, 30], ["diseases", "PROBLEM", 38, 46], ["sudden outbreak", "PROBLEM", 56, 71], ["epidemics", "PROBLEM", 273, 282], ["probabilistic changes in disease status", "PROBLEM", 383, 422], ["individuals", "PROBLEM", 427, 438], ["size", "OBSERVATION_MODIFIER", 212, 216]]], ["As a result, properties of the ensemble, such as the final epidemic size, are probabilistic as well [10\u201314].", [["size", "OBSERVATION_MODIFIER", 68, 72]]], ["Thus, stochastic models quantify the likelihood of outbreaks that deviate from the expected final size [9,15].", [["outbreaks", "PROBLEM", 51, 60], ["outbreaks", "OBSERVATION", 51, 60], ["size", "OBSERVATION_MODIFIER", 98, 102]]], ["Such information about the variation in final outbreak size\u2014its predictability\u2014is crucial if disease forecasting is to be relied upon for planning interventions.IntroductionThe stochastic theory of epidemics can therefore be used to understand the theoretical limits to forecasting precision for disease outbreaks, including EWSs or forecasts based on the developing epidemic curve as case reports accumulate.", [["interventions", "TREATMENT", 147, 160], ["epidemics", "PROBLEM", 198, 207], ["disease outbreaks", "PROBLEM", 296, 313]]], ["I studied how precision in the forecasted final outbreak size for transmissible diseases depends on two dynamical features of outbreaks: the contact rate (\u03b2) and the rate of removal (\u03b3) in the simple stochastic epidemic.", [["transmissible diseases", "DISEASE", 66, 88], ["transmissible diseases", "PROBLEM", 66, 88], ["removal", "TREATMENT", 174, 181], ["size", "OBSERVATION_MODIFIER", 57, 61]]], ["Next, I developed models of forecast precision for nine outbreak-prone diseases (chicken pox, diphtheria, measles, mumps, poliomyelitis, rubella, scarlet fever, smallpox, and whooping cough) and used removal rate as a control parameter to relate intervention effectiveness to final outbreak size and forecast precision.", [["chicken pox", "DISEASE", 81, 92], ["diphtheria", "DISEASE", 94, 104], ["measles", "DISEASE", 106, 113], ["mumps", "DISEASE", 115, 120], ["poliomyelitis", "DISEASE", 122, 135], ["rubella", "DISEASE", 137, 144], ["scarlet fever", "DISEASE", 146, 159], ["smallpox", "DISEASE", 161, 169], ["whooping cough", "DISEASE", 175, 189], ["chicken", "ORGANISM", 81, 88], ["pox", "ORGANISM_SUBDIVISION", 89, 92], ["chicken", "SPECIES", 81, 88], ["pox", "SPECIES", 89, 92], ["chicken", "SPECIES", 81, 88], ["prone diseases", "PROBLEM", 65, 79], ["chicken pox", "TREATMENT", 81, 92], ["diphtheria", "PROBLEM", 94, 104], ["measles", "PROBLEM", 106, 113], ["mumps", "PROBLEM", 115, 120], ["poliomyelitis", "PROBLEM", 122, 135], ["rubella", "PROBLEM", 137, 144], ["scarlet fever", "PROBLEM", 146, 159], ["smallpox", "PROBLEM", 161, 169], ["whooping cough", "PROBLEM", 175, 189], ["removal rate", "TREATMENT", 200, 212], ["a control parameter", "TREATMENT", 216, 235], ["intervention effectiveness", "TREATMENT", 246, 272], ["size", "OBSERVATION_MODIFIER", 291, 295]]], ["Finally, I developed a new model to understand how delays in implementing interventions affect final outbreak size and forecast prevision.Model ::: MethodsThe simplest realistic model for outbreaks with a small number of initially infectious individuals is the simple stochastic epidemic with contact rate \u03b2 and removal rate \u03b3, which do not change appreciably over the time scale of the outbreak [15,16].", [["Methods", "TREATMENT", 148, 155], ["initially infectious individuals", "PROBLEM", 221, 253], ["removal rate", "TREATMENT", 312, 324], ["size", "OBSERVATION_MODIFIER", 110, 114], ["small", "OBSERVATION_MODIFIER", 205, 210], ["infectious", "OBSERVATION", 231, 241]]], ["This model is a good approximation if the outbreak meets the following criteria, which are reasonable for modern outbreaks that are rapidly controlled.", [["modern outbreaks", "PROBLEM", 106, 122], ["good", "OBSERVATION_MODIFIER", 16, 20]]], ["First, we assume that infectious contacts and removal of infectious individuals are approximately independent in time so that the outbreak is Markovian (compare [17\u201319]).", [["removal", "TREATMENT", 46, 53], ["infectious", "OBSERVATION", 22, 32]]], ["Second, the rate at which infectious individuals are removed from the population exceeds the rate at which infectious contacts occur (\u03b2 < \u03b3).", [["individuals", "ORGANISM", 37, 48], ["infectious", "OBSERVATION", 26, 36], ["infectious", "OBSERVATION", 107, 117]]], ["Finally, the population is sufficiently large that the number of individuals ultimately infected is not more than a negligible fraction of the susceptible population (i.e., per capita transmission rates are approximately independent of the density of infected individuals).", [["the susceptible population", "PROBLEM", 139, 165], ["sufficiently", "OBSERVATION_MODIFIER", 27, 39], ["large", "OBSERVATION_MODIFIER", 40, 45], ["infected", "OBSERVATION", 88, 96], ["susceptible", "OBSERVATION_MODIFIER", 143, 154], ["population", "OBSERVATION", 155, 165], ["infected", "OBSERVATION", 251, 259]]], ["Then, the outbreak is a homogeneous birth\u2013death process (the simple stochastic epidemic) with mean (M) and variance (V) of the final outbreak size given by [10]:Model ::: Methods", [["a homogeneous birth\u2013death process", "PROBLEM", 22, 55], ["size", "OBSERVATION_MODIFIER", 142, 146]]]], "bfa16bbe1eca8deca15fc08f8b472b123d6a3b1f": [["P hylogenetic analyses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suggest virus emergence weeks, if not months, before the World Health Organization was notified of the original cluster of cases in Wuhan, China (1).", [["acute respiratory syndrome coronavirus", "DISEASE", 33, 71], ["SARS-CoV-2", "ORGANISM", 75, 85], ["severe acute respiratory syndrome coronavirus", "SPECIES", 26, 71], ["SARS-CoV-2", "SPECIES", 75, 85], ["P hylogenetic analyses", "TEST", 0, 22], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 26, 71], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory syndrome", "OBSERVATION", 39, 59]]], ["These analyses have estimated that SARS-CoV-2 emerged from October 6, 2019, through December 11, 2019 (2) .", [["These analyses", "TEST", 0, 14], ["CoV", "TEST", 40, 43]]], ["Given this timeline, interest in retrospectively identifying patient zero in different geographic areas has been growing, to better determine the spread of SARS-CoV-2 and to inform current and future surveillance strategies for emerging infectious diseases.", [["SARS", "DISEASE", 156, 160], ["infectious diseases", "DISEASE", 237, 256], ["patient", "ORGANISM", 61, 68], ["SARS-CoV-2", "ORGANISM", 156, 166], ["patient", "SPECIES", 61, 68], ["SARS-CoV", "SPECIES", 156, 164], ["emerging infectious diseases", "PROBLEM", 228, 256], ["infectious", "OBSERVATION", 237, 247]]]], "e8562c5a4d3ffe1940993a2778c550bf7b1a49f8": [["IntroductionFirstly informed to World Health Organization (WHO) on 31 December 2019, the current outbreak of Coronavirus Disease (COVID- 19) involves 78,811 confirmed cases over 28 countries as of 23 February 2020 [1] .", [["Coronavirus Disease", "DISEASE", 109, 128], ["Coronavirus Disease", "PROBLEM", 109, 128], ["Coronavirus Disease", "OBSERVATION", 109, 128]]], ["The majority of COVID-19 patients had pneumonia and showed symptoms include fever and cough [2, 3] .", [["pneumonia", "DISEASE", 38, 47], ["fever", "DISEASE", 76, 81], ["cough", "DISEASE", 86, 91], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["COVID", "TEST", 16, 21], ["pneumonia", "PROBLEM", 38, 47], ["symptoms", "PROBLEM", 59, 67], ["fever", "PROBLEM", 76, 81], ["cough", "PROBLEM", 86, 91], ["pneumonia", "OBSERVATION", 38, 47]]], ["The genome sequence of causative novel coronavirus was shared through Global Initiative on Sharing All Influenza Data (GISAID) platform from 12 January 2020.", [["coronavirus", "ORGANISM", 39, 50], ["causative novel coronavirus", "PROBLEM", 23, 50]]], ["The sequences of novel coronavirus (CoV) showed close similarity to that of severe acute respiratory syndrome-related coronaviruses (SARSr-CoV) and the virus uses ACE2 as the entry receptor like SARS-CoV [4] [5] [6] .", [["acute respiratory syndrome", "DISEASE", 83, 109], ["novel coronavirus", "ORGANISM", 17, 34], ["CoV", "ORGANISM", 36, 39], ["severe acute respiratory syndrome-related coronaviruses", "ORGANISM", 76, 131], ["SARSr-CoV", "ORGANISM", 133, 142], ["ACE2", "GENE_OR_GENE_PRODUCT", 163, 167], ["ACE2", "PROTEIN", 163, 167], ["entry receptor", "PROTEIN", 175, 189], ["CoV", "SPECIES", 36, 39], ["severe acute respiratory syndrome-related coronaviruses", "SPECIES", 76, 131], ["SARSr-CoV", "SPECIES", 133, 142], ["novel coronavirus (CoV)", "TEST", 17, 40], ["severe acute respiratory syndrome", "PROBLEM", 76, 109], ["coronaviruses", "PROBLEM", 118, 131], ["SARSr", "TEST", 133, 138], ["the virus", "PROBLEM", 148, 157], ["ACE2", "TREATMENT", 163, 167], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["respiratory syndrome", "OBSERVATION", 89, 109]]], ["The Coronavirus Study Group of the International Committee on Taxonomy of Viruses designated the virus as SARS-CoV-2 [7] .IntroductionMolecular diagnosis of COVID-19 is currently carried out by one-step quantitative RT-PCR (qRT-PCR) targetting SARS-CoV-2 by which primers and probes being suggested by institutes of China, Germany, Hong Kong, Japan, Thailand, and USA were posted through WHO [8] [9] [10] .", [["COVID-19", "DNA", 157, 165], ["SARS-CoV-2", "DNA", 244, 254], ["SARS-CoV", "SPECIES", 106, 114], ["The Coronavirus Study", "TEST", 0, 21], ["Viruses", "TREATMENT", 74, 81], ["COVID", "TEST", 157, 162], ["PCR", "TEST", 219, 222], ["qRT", "TEST", 224, 227], ["PCR", "TEST", 228, 231], ["SARS", "TEST", 244, 248], ["CoV", "TEST", 249, 252]]], ["Clinical diagnosis methods including CT scan are also utilized to identify COVID-19 cases in Hubei province, China, from 13 February 2020 [11] .", [["Clinical diagnosis methods", "TEST", 0, 26], ["CT scan", "TEST", 37, 44], ["COVID", "TEST", 75, 80]]], ["Although qRT-PCR assay served as a gold-standard method to detect respiratory infectious viruses such as SARS-CoV and MERS-CoV [12] [13] [14] [15] , current qRT-PCR assays targetting SARS-CoV-2 have some caveats.", [["respiratory infectious viruses", "DISEASE", 66, 96], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 118, 126], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 183, 193], ["qRT", "DNA", 9, 12], ["SARS-CoV-2", "DNA", 183, 193], ["SARS-CoV", "SPECIES", 105, 113], ["MERS-CoV", "SPECIES", 118, 126], ["qRT", "TEST", 9, 12], ["PCR assay", "TEST", 13, 22], ["respiratory infectious viruses", "PROBLEM", 66, 96], ["SARS", "PROBLEM", 105, 109], ["CoV", "TEST", 110, 113], ["MERS", "TEST", 118, 122], ["CoV", "TEST", 123, 126], ["current qRT", "TEST", 149, 160], ["PCR assays", "TEST", 161, 171], ["SARS", "TEST", 183, 187], ["CoV", "TEST", 188, 191], ["respiratory", "ANATOMY", 66, 77], ["infectious", "OBSERVATION", 78, 88]]], ["First, due to the high similarity of SARS-CoV-2 to SARS-CoV, primer-probe sets would cross-react.", [["SARS", "DISEASE", 37, 41], ["SARS", "DISEASE", 51, 55], ["SARS-CoV-2", "ORGANISM", 37, 47], ["SARS-CoV", "ORGANISM", 51, 59], ["SARS-CoV", "DNA", 51, 59], ["primer-probe sets", "DNA", 61, 78], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 51, 59], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["SARS", "PROBLEM", 51, 55], ["primer", "TEST", 61, 67], ["SARS", "OBSERVATION", 37, 41]]], ["Second, the sensitivity of the assays may not enough to confirm suspicious patients in early time points after admission.", [["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["the assays", "TEST", 27, 37]]], ["Indeed, cases of positive CT scan results and negative RT-PCR results at initial presentation were reported [16] .", [["positive CT scan", "TEST", 17, 33], ["PCR", "TEST", 58, 61]]], ["The performance of molecular diagnosis might be dependent on primers, probes, and reagents.", [["dependent on primers", "PROBLEM", 48, 68]]], ["There have been no comparative results of the current qRT-PCR analysis for the molecular diagnosis of SARS-CoV-2.IntroductionIn this present study, the qRT-PCR analysis was performed with previously reported primer-probe sets targeting RdRp/Orf1 and N region of SARS-CoV-2.", [["SARS", "DISEASE", 102, 106], ["SARS-CoV-2", "ORGANISM", 102, 112], ["Orf1", "GENE_OR_GENE_PRODUCT", 241, 245], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 262, 272], ["qRT", "DNA", 54, 57], ["qRT", "DNA", 152, 155], ["RdRp", "PROTEIN", 236, 240], ["Orf1", "PROTEIN", 241, 245], ["N region", "PROTEIN", 250, 258], ["SARS-CoV-2", "DNA", 262, 272], ["SARS-CoV", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 262, 270], ["the current qRT", "TEST", 42, 57], ["PCR analysis", "TEST", 58, 70], ["SARS", "PROBLEM", 102, 106], ["CoV", "TEST", 107, 110], ["this present study", "TEST", 128, 146], ["the qRT-PCR analysis", "TEST", 148, 168], ["RdRp/Orf1", "TREATMENT", 236, 245], ["SARS", "PROBLEM", 262, 266], ["CoV", "TEST", 267, 270]]], ["This is the first comparative analysis of various primer-probe sets for the laboratory confirmation of SARS-CoV-2.Primer Information of qPCRFor the comparative analysis of laboratory confirmation for SARS-CoV-2, ten primer-probe sets were selected based on sequence information from the six different national institutions; the Centers for Disease Control and Figure 1 and Table 1 .", [["SARS", "DISEASE", 103, 107], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 103, 113], ["qPCRFor", "DNA", 136, 143], ["SARS-CoV-2", "DNA", 200, 210], ["SARS-CoV", "SPECIES", 103, 111], ["SARS-CoV", "SPECIES", 200, 208], ["the laboratory confirmation", "TEST", 72, 99], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["laboratory confirmation", "TEST", 172, 195], ["SARS", "TEST", 200, 204], ["CoV", "TEST", 205, 208], ["Disease Control", "TREATMENT", 340, 355]]], ["Seven of the ten sets were derived from the N gene, and the other three sets were derived from Orf1 gene (RdRp, ORF 1b-Nsp14, and ORF 1-Nsp10).", [["Orf1", "GENE_OR_GENE_PRODUCT", 95, 99], ["RdRp", "GENE_OR_GENE_PRODUCT", 106, 110], ["ORF 1b", "GENE_OR_GENE_PRODUCT", 112, 118], ["Nsp14", "GENE_OR_GENE_PRODUCT", 119, 124], ["ORF 1-Nsp10", "GENE_OR_GENE_PRODUCT", 130, 141], ["N gene", "DNA", 44, 50], ["Orf1 gene", "DNA", 95, 104], ["RdRp", "DNA", 106, 110], ["ORF 1b", "DNA", 112, 118], ["Nsp14", "DNA", 119, 124], ["ORF 1", "DNA", 130, 135], ["Nsp10", "DNA", 136, 141], ["RdRp", "TEST", 106, 110], ["ORF 1b", "TEST", 112, 118], ["Nsp14", "TEST", 119, 124], ["ORF", "TEST", 130, 133]]], ["All DNA oligonucleotides were resuspended in nuclease-free water before use.Viral RNA preparationThe infection experiments were performed in a biosafety level-3 (BSL-3) laboratory.", [["infection", "DISEASE", 101, 110], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["nuclease", "PROTEIN", 45, 53], ["All DNA oligonucleotides", "TREATMENT", 0, 24], ["Viral RNA preparation", "TREATMENT", 76, 97], ["The infection experiments", "PROBLEM", 97, 122], ["a biosafety level", "TEST", 141, 158], ["RNA preparation", "OBSERVATION", 82, 97], ["infection", "OBSERVATION", 101, 110]]], ["African green monkey kidney Vero cells (ATCC CCL-81) were infected with a clinical isolate SARS-CoV-2 (BetaCoV/Korea/KCDC03/2020 provided from Korea CDC).", [["kidney Vero cells", "ANATOMY", 21, 38], ["ATCC CCL-81", "ANATOMY", 40, 51], ["monkey", "ORGANISM", 14, 20], ["kidney Vero cells", "CELL", 21, 38], ["ATCC CCL-81", "CELL", 40, 51], ["SARS-CoV-2", "ORGANISM", 91, 101], ["BetaCoV", "ORGANISM", 103, 110], ["African green monkey kidney Vero cells", "CELL_LINE", 0, 38], ["ATCC CCL-81", "CELL_LINE", 40, 51], ["monkey", "SPECIES", 14, 20], ["African green monkey", "SPECIES", 0, 20], ["ATCC CCL-81", "SPECIES", 40, 51], ["SARS-CoV-2 (BetaCoV/Korea/KCDC03/2020", "SPECIES", 91, 128], ["African green monkey kidney Vero cells", "TEST", 0, 38], ["ATCC CCL", "TEST", 40, 48], ["a clinical isolate SARS", "TEST", 72, 95], ["CoV", "TEST", 96, 99], ["kidney", "ANATOMY", 21, 27], ["Vero cells", "OBSERVATION", 28, 38]]], ["After 72 h, the culture medium containing mature infectious virions (virus medium) was collected and viral RNA was isolated from the culture medium using the QIAamp viral RNA extraction Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.Preparation of in vitro transcribed RNA standardThe coding sequence of SARS-CoV-2 Envelope (E) protein, which cloned in pET21a plasmid was PCR amplified with T7 promoter primer (5' -AATACGACTCACTATAG -3', Macrogen Inc., South Korea) and T7 terminator primer (5' -GCTAGTTATTGCTCAGCGG -3', Macrogen) with AccuPower\u00ae PCR PreMix (-dye) kit (Bioneer Inc., South Korea).", [["virions", "ANATOMY", 60, 67], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 332, 342], ["Envelope (E)", "GENE_OR_GENE_PRODUCT", 343, 355], ["pET21a", "GENE_OR_GENE_PRODUCT", 381, 387], ["viral RNA", "RNA", 101, 110], ["SARS-CoV-2 Envelope (E) protein", "PROTEIN", 332, 363], ["pET21a plasmid", "DNA", 381, 395], ["T7 promoter primer", "DNA", 419, 437], ["T7 terminator primer", "DNA", 498, 518], ["Macrogen", "DNA", 549, 557], ["SARS-CoV", "SPECIES", 332, 340], ["the culture medium", "TEST", 12, 30], ["mature infectious virions (virus medium)", "PROBLEM", 42, 82], ["viral RNA", "PROBLEM", 101, 110], ["the culture medium", "TEST", 129, 147], ["the QIAamp viral RNA extraction", "TREATMENT", 154, 185], ["The coding sequence", "TEST", 309, 328], ["SARS", "TEST", 332, 336], ["CoV", "TEST", 337, 340], ["PCR", "TEST", 400, 403], ["T7 promoter primer", "TREATMENT", 419, 437], ["AATACGACTCACTATAG", "TEST", 443, 460], ["T7 terminator primer", "TREATMENT", 498, 518], ["GCTAGTTATTGCTCAGCGG", "TEST", 524, 543], ["Macrogen", "TREATMENT", 549, 557], ["AccuPower\u00ae PCR PreMix", "TREATMENT", 564, 585], ["infectious virions", "OBSERVATION", 49, 67], ["T7", "ANATOMY", 498, 500]]], ["PCR product was then used as in vitro transcription template using MEGAscript\u2122 T7 Transcription Kit (Invitrogen Inc., CA, USA).", [["PCR product", "TREATMENT", 0, 11], ["MEGAscript\u2122 T7", "TREATMENT", 67, 81]]], ["The copy number of in vitro transcribed RNA was calculated from RNA concentration measured with Quantus\u2122 Fluorometer (Promega Inc., WI, USA).", [["in vitro transcribed RNA", "RNA", 19, 43], ["RNA concentration", "TEST", 64, 81]]], ["Standardized amounts of in vitro produced RNA were used E primer and qRT-PCR to produce a standard curve.Confirmatory qRT-PCR in RdRp and NExtracted nucleic acid samples were tested for comparative analysis of SARS-CoV-2 by qRT-PCR.", [["nucleic acid samples", "ANATOMY", 149, 169], ["nucleic acid", "CHEMICAL", 149, 161], ["RdRp", "ORGANISM", 129, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 210, 220], ["E primer", "DNA", 56, 64], ["SARS-CoV", "SPECIES", 210, 218], ["vitro produced RNA", "TREATMENT", 27, 45], ["E primer", "TREATMENT", 56, 64], ["qRT", "TEST", 69, 72], ["PCR", "TEST", 73, 76], ["a standard curve", "TEST", 88, 104], ["Confirmatory qRT", "TEST", 105, 121], ["PCR", "TEST", 122, 125], ["RdRp", "PROBLEM", 129, 133], ["NExtracted nucleic acid samples", "TEST", 138, 169], ["comparative analysis", "TEST", 186, 206], ["SARS", "TEST", 210, 214], ["CoV", "TEST", 215, 218], ["qRT", "TEST", 224, 227], ["PCR", "TEST", 228, 231], ["amounts", "OBSERVATION_MODIFIER", 13, 20]]], ["The Orf1 and N region of SARS-CoV-2 were used as the target sequences for SARS-CoV-2 specific gene.", [["Orf1", "GENE_OR_GENE_PRODUCT", 4, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 84], ["Orf1 and N region", "DNA", 4, 21], ["SARS-CoV-2", "DNA", 25, 35], ["target sequences", "DNA", 53, 69], ["SARS-CoV-2 specific gene", "DNA", 74, 98], ["SARS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 74, 82], ["The Orf1", "TREATMENT", 0, 8], ["SARS-CoV", "TEST", 25, 33], ["the target sequences", "TEST", 49, 69], ["SARS", "TEST", 74, 78], ["CoV", "TEST", 79, 82]]], ["Briefly, 10 \u03bcL of purified viral RNA was amplified in a 20 \u03bcL reaction solution containing 1X 1 step RT-PCR mix (WELLS BIO INC., South Korea), and 300 nM of primers and probes for the target detection.", [["viral RNA", "RNA", 27, 36], ["purified viral RNA", "TREATMENT", 18, 36], ["a 20 \u03bcL reaction solution", "TREATMENT", 54, 79], ["1 step RT", "TREATMENT", 94, 103], ["primers", "TEST", 157, 164], ["the target detection", "TEST", 180, 200], ["viral RNA", "OBSERVATION", 27, 36]]], ["The qRT-PCR was performed with a CFX 96 touch real-time PCR detection system (Bio-rad, Hercules, CA, USA).", [["qRT", "DNA", 4, 7], ["The qRT-PCR", "TEST", 0, 11], ["a CFX", "TEST", 31, 36], ["Bio", "TEST", 78, 81]]], ["The qRT-PCR conditions applied in this study were programmed as follows: UNG incubation, RT incubation, and enzyme activation were serially performed at 25 \u00b0C for 2 minutes, at 55 \u00b0C for 10 minutes, at 94 \u00b0C for 3 minutes respectively.", [["The qRT-PCR conditions", "TEST", 0, 22], ["this study", "TEST", 34, 44], ["UNG incubation", "TREATMENT", 73, 87], ["RT incubation", "TEST", 89, 102], ["enzyme activation", "TEST", 108, 125]]], ["Thermal cycling was then performed at 94 \u00b0C for 15 seconds (denaturation), and at 60 \u00b0C for 30 seconds (annealing and amplification) for forty-five cycles.Validation of qRT-PCR assayThe Ct value was not produced from negative control, indicating the reaction was done aseptically.", [["qRT", "DNA", 169, 172], ["denaturation", "TEST", 60, 72], ["qRT", "TEST", 169, 172], ["The Ct value", "TEST", 182, 194], ["the reaction", "PROBLEM", 246, 258]]], ["The standard curve from E gene primer-probe set also showed the reaction was done accordingly.", [["E gene primer", "DNA", 24, 37], ["The standard curve from E gene primer", "TEST", 0, 37], ["the reaction", "PROBLEM", 60, 72]]], ["The R 2 value of the standard curve was 0.999 and the calculated amplification efficiency was 101.6%.", [["the standard curve", "TEST", 17, 35], ["the calculated amplification efficiency", "TEST", 50, 89]]], ["These indicated that the qRT-PCR reaction was done in optimal condition.", [["qRT", "DNA", 25, 28], ["the qRT-PCR reaction", "TEST", 21, 41]]], ["The viral concentration of supernatant and cell lysate was determined by E gene-based assay ( Table 2) .RdRp/Orf1 AssaysThe Ct value of RdRp_SARSr (Germany), HKU-ORF1b-nsp14 (Hong Kong), and ORF1ab (China) from low concentration (15 copies/reaction) were 43.00, 38.97, and 36.85, respectively ( Table 2)", [["supernatant", "ANATOMY", 27, 38], ["cell lysate", "ANATOMY", 43, 54], ["cell", "CELL", 43, 47], ["Orf1", "GENE_OR_GENE_PRODUCT", 109, 113], ["HKU-ORF1b-nsp14", "GENE_OR_GENE_PRODUCT", 158, 173], ["E gene", "DNA", 73, 79], ["RdRp", "PROTEIN", 104, 108], ["Orf1", "PROTEIN", 109, 113], ["ORF1b", "PROTEIN", 162, 167], ["nsp14", "PROTEIN", 168, 173], ["ORF1ab", "PROTEIN", 191, 197], ["The viral concentration of supernatant and cell lysate", "TREATMENT", 0, 54], ["Orf1 Assays", "TEST", 109, 120], ["The Ct value", "TEST", 120, 132], ["HKU", "TEST", 158, 161], ["viral concentration", "OBSERVATION", 4, 23], ["cell lysate", "OBSERVATION", 43, 54]]]], "225ee16d130872aa6ade326d6342def4dafe7f37": [["INTRODUCTIONThe covalent modification of target proteins by ubiquitin (Ub), a small 76 residue protein, occurs in various linkage types and can produce many different outcomes.", [["ubiquitin", "GENE_OR_GENE_PRODUCT", 60, 69], ["Ub", "GENE_OR_GENE_PRODUCT", 71, 73], ["target proteins", "PROTEIN", 41, 56], ["ubiquitin", "PROTEIN", 60, 69], ["Ub", "PROTEIN", 71, 73], ["small 76 residue protein", "PROTEIN", 78, 102], ["a small 76 residue protein", "PROBLEM", 76, 102], ["small", "OBSERVATION_MODIFIER", 78, 83], ["residue protein", "OBSERVATION", 87, 102]]], ["Processes as diverse as cell-cycle regulation, receptor trafficking, signal transduction, epigenetic regulation of gene expression, DNA repair, regulated proteolysis, and destruction of the target protein by the proteasome are under the control of Ub addition (Glickman and Ciechanover, 2002; Schnell and Hicke, 2003) .", [["cell", "ANATOMY", 24, 28], ["cell", "CELL", 24, 28], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["Ub", "GENE_OR_GENE_PRODUCT", 248, 250], ["target protein", "PROTEIN", 190, 204], ["proteasome", "PROTEIN", 212, 222], ["Ub", "PROTEIN", 248, 250], ["cell-cycle regulation", "TREATMENT", 24, 45], ["receptor trafficking", "TREATMENT", 47, 67], ["signal transduction", "TREATMENT", 69, 88], ["gene expression", "TREATMENT", 115, 130], ["DNA repair", "TREATMENT", 132, 142], ["regulated proteolysis", "PROBLEM", 144, 165], ["destruction of the target protein", "PROBLEM", 171, 204], ["the proteasome", "TREATMENT", 208, 222], ["DNA repair", "OBSERVATION", 132, 142]]], ["Moreover, the processing of pathogen-derived proteins by the Ub/proteasome pathway is a prerequisite for their display to the immune system to initiate the host's defense (York and Rock, 1996) .INTRODUCTIONUbiquitination, like many other posttranslational modifications, is a reversible process, allowing regulation of the balance between the unmodified and modified states of the target protein.", [["immune system", "ANATOMY", 126, 139], ["Ub", "GENE_OR_GENE_PRODUCT", 61, 63], ["pathogen-derived proteins", "PROTEIN", 28, 53], ["Ub", "PROTEIN", 61, 63], ["proteasome", "PROTEIN", 64, 74], ["target protein", "PROTEIN", 381, 395], ["a reversible process", "PROBLEM", 274, 294], ["posttranslational modifications", "OBSERVATION", 238, 269], ["reversible", "OBSERVATION_MODIFIER", 276, 286], ["process", "OBSERVATION", 287, 294]]], ["Different collections of enzymes are responsible for driving either the forward or the reverse reaction, providing dynamic control of the modification state.", [["enzymes", "PROTEIN", 25, 32], ["Different collections of enzymes", "PROBLEM", 0, 32], ["the reverse reaction", "PROBLEM", 83, 103], ["collections", "OBSERVATION", 10, 21]]], ["A significant portion of the genome is invested in the process of Ub addition and removal: there are $500 Ub ligases in the human genome catalyzing the forward reaction in conjunction with one Ub-activating (E1) and several Ub-conjugating enzymes (E2s), whereas $100 deubiquitinating enzymes (DUBs) are currently predicted through bioinformatics (Nijman et al., 2005) .INTRODUCTIONAll viral pathogens and many intracellular bacteria rely critically on the host synthetic machinery for their propagation.", [["intracellular", "ANATOMY", 410, 423], ["Ub", "GENE_OR_GENE_PRODUCT", 66, 68], ["human", "ORGANISM", 124, 129], ["Ub", "GENE_OR_GENE_PRODUCT", 224, 226], ["DUBs", "GENE_OR_GENE_PRODUCT", 293, 297], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 410, 423], ["Ub", "PROTEIN", 66, 68], ["Ub ligases", "PROTEIN", 106, 116], ["human genome", "DNA", 124, 136], ["E1", "PROTEIN", 208, 210], ["Ub", "PROTEIN", 224, 226], ["conjugating enzymes", "PROTEIN", 227, 246], ["E2s", "PROTEIN", 248, 251], ["deubiquitinating enzymes", "PROTEIN", 267, 291], ["DUBs", "PROTEIN", 293, 297], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129], ["removal", "TREATMENT", 82, 89], ["$500 Ub ligases", "TREATMENT", 101, 116], ["several Ub", "TEST", 216, 226], ["viral pathogens", "PROBLEM", 385, 400], ["many intracellular bacteria", "PROBLEM", 405, 432], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["portion", "OBSERVATION_MODIFIER", 14, 21], ["genome", "OBSERVATION", 29, 35], ["forward reaction", "OBSERVATION", 152, 168]]], ["Accordingly, these pathogens have learned to exploit or subvert to their own advantage the cellular enzymatic machinery that could otherwise be deployed against them.", [["cellular", "ANATOMY", 91, 99], ["cellular", "CELL", 91, 99], ["these pathogens", "PROBLEM", 13, 28]]], ["A number of these pathogens have thus evolved an elaborate molecular armory that includes pathogen-encoded ubiquitinating and deubiquitinating activities, as well as proteins capable of manipulating/hijacking the host's Ub machinery.", [["Ub", "GENE_OR_GENE_PRODUCT", 220, 222], ["Ub", "PROTEIN", 220, 222], ["these pathogens", "PROBLEM", 12, 27], ["pathogen", "PROBLEM", 90, 98], ["pathogens", "OBSERVATION", 18, 27], ["molecular armory", "OBSERVATION", 59, 75]]], ["The known functions of these pathogen-encoded activities are quite diverse.", [["these pathogen", "PROBLEM", 23, 37]]], ["Regulation of the cell cycle, activation or suppression of the NF-kB pathway, destruction of the class I MHC glycoprotein, and regulation of intracellular trafficking are but a few examples (Gao and Luo [2006] and references cited therein).INTRODUCTIONHow can we detect Ub-related activities that relate to host-pathogen interactions?", [["cell", "ANATOMY", 18, 22], ["intracellular", "ANATOMY", 141, 154], ["cell", "CELL", 18, 22], ["NF-kB", "GENE_OR_GENE_PRODUCT", 63, 68], ["class I MHC glycoprotein", "GENE_OR_GENE_PRODUCT", 97, 121], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 141, 154], ["Ub", "GENE_OR_GENE_PRODUCT", 270, 272], ["NF-kB", "PROTEIN", 63, 68], ["class I MHC glycoprotein", "PROTEIN", 97, 121], ["Ub", "PROTEIN", 270, 272], ["the cell cycle", "TREATMENT", 14, 28], ["the NF-kB pathway", "TREATMENT", 59, 76], ["cell cycle", "OBSERVATION", 18, 28], ["intracellular trafficking", "OBSERVATION", 141, 166]]], ["A functional proteomic approach-where active DUBs are targeted selectively in crude cell extracts with epitope-tagged, Ub-based suicide substrates, retrieved by immunoprecipitation, and identified by mass spectrometry-has proved particularly useful in identifying new deubiquitinating enzymes (Borodovsky et al., 2002; Ovaa et al., 2004) .", [["cell extracts", "ANATOMY", 84, 97], ["DUBs", "GENE_OR_GENE_PRODUCT", 45, 49], ["cell extracts", "ORGANISM_SUBSTANCE", 84, 97], ["Ub", "GENE_OR_GENE_PRODUCT", 119, 121], ["DUBs", "PROTEIN", 45, 49], ["Ub", "PROTEIN", 119, 121], ["deubiquitinating enzymes", "PROTEIN", 268, 292], ["A functional proteomic approach", "TREATMENT", 0, 31], ["active DUBs", "PROBLEM", 38, 49], ["epitope", "TEST", 103, 110], ["suicide substrates", "TREATMENT", 128, 146], ["mass spectrometry", "TEST", 200, 217]]], ["Using this approach, we identified a unique deubiquitinating activity present in herpes simplex virus-1 (HSV-1/a subfamily)infected cells .", [["cells", "ANATOMY", 132, 137], ["herpes simplex", "DISEASE", 81, 95], ["herpes simplex virus-1", "ORGANISM", 81, 103], ["HSV-1", "ORGANISM", 105, 110], ["cells", "CELL", 132, 137], ["infected cells", "CELL_TYPE", 123, 137], ["herpes simplex virus-1", "SPECIES", 81, 103], ["HSV-1", "SPECIES", 105, 110], ["herpes simplex virus-1", "SPECIES", 81, 103], ["HSV-1", "SPECIES", 105, 110], ["this approach", "TREATMENT", 6, 19], ["herpes simplex virus", "TEST", 81, 101], ["HSV", "TEST", 105, 108], ["infected cells", "PROBLEM", 123, 137], ["deubiquitinating activity", "OBSERVATION", 44, 69], ["infected cells", "OBSERVATION", 123, 137]]], ["The DUB activity mapped to the N-terminal portion of UL36, a large (3156 residues) and presumably multifunctional protein of the a-herpesvirus HSV-1.", [["DUB", "GENE_OR_GENE_PRODUCT", 4, 7], ["UL36", "GENE_OR_GENE_PRODUCT", 53, 57], ["a-herpesvirus HSV-1", "ORGANISM", 129, 148], ["DUB", "PROTEIN", 4, 7], ["N-terminal portion", "PROTEIN", 31, 49], ["UL36", "PROTEIN", 53, 57], ["multifunctional protein", "PROTEIN", 98, 121], ["a-herpesvirus HSV-1", "PROTEIN", 129, 148], ["HSV-1", "SPECIES", 143, 148], ["a large (3156 residues", "PROBLEM", 59, 81], ["the a-herpesvirus HSV", "TEST", 125, 146], ["DUB activity", "OBSERVATION", 4, 16], ["large", "OBSERVATION_MODIFIER", 61, 66], ["multifunctional protein", "OBSERVATION", 98, 121]]], ["UL36 is a constituent of the amorphous proteinaceous layer located between the nucleocapsid and the envelope of the herpesvirus particle, referred to as tegument.", [["tegument", "ANATOMY", 153, 161], ["UL36", "CHEMICAL", 0, 4], ["UL36", "GENE_OR_GENE_PRODUCT", 0, 4], ["nucleocapsid", "CELLULAR_COMPONENT", 79, 91], ["herpesvirus", "ORGANISM", 116, 127], ["tegument", "CELLULAR_COMPONENT", 153, 161], ["UL36", "PROTEIN", 0, 4], ["the amorphous proteinaceous layer", "PROBLEM", 25, 58], ["the nucleocapsid", "PROBLEM", 75, 91], ["constituent", "OBSERVATION_MODIFIER", 10, 21], ["amorphous", "OBSERVATION_MODIFIER", 29, 38], ["proteinaceous", "OBSERVATION_MODIFIER", 39, 52], ["layer", "OBSERVATION_MODIFIER", 53, 58], ["nucleocapsid", "OBSERVATION", 79, 91], ["herpesvirus particle", "OBSERVATION", 116, 136]]], ["All known herpesviruses sequenced to date contain homologs of this large tegument protein.", [["herpesviruses", "ORGANISM", 10, 23], ["tegument protein", "PROTEIN", 73, 89], ["All known herpesviruses", "PROBLEM", 0, 23], ["this large tegument protein", "PROBLEM", 62, 89], ["herpesviruses", "OBSERVATION", 10, 23]]], ["The putative key catalytic residues of the protease domain found in UL36 are conserved throughout all herpesviridae subfamilies: a, b, and g (Schlieker et al., 2005) .", [["UL36", "GENE_OR_GENE_PRODUCT", 68, 72], ["catalytic residues", "PROTEIN", 17, 35], ["protease domain", "PROTEIN", 43, 58], ["UL36", "PROTEIN", 68, 72], ["herpesviridae subfamilies", "PROTEIN", 102, 127], ["the protease domain", "PROBLEM", 39, 58], ["catalytic residues", "OBSERVATION", 17, 35]]], ["Deubiquitinating activity was confirmed for the UL36 homologs of murine cytomegalovirus (MCMV/b subfamily), human cytomegalovirus (HCMV/b subfamily), and Epstein-Barr virus (EBV/g subfamily), M48, UL48, and BPLF1, respectively (Schlieker et al., 2005; Wang et al., 2006) .", [["UL36", "GENE_OR_GENE_PRODUCT", 48, 52], ["murine cytomegalovirus", "ORGANISM", 65, 87], ["MCMV/b subfamily", "ORGANISM", 89, 105], ["human", "ORGANISM", 108, 113], ["cytomegalovirus", "ORGANISM", 114, 129], ["HCMV", "ORGANISM", 131, 135], ["/b subfamily", "ORGANISM", 135, 147], ["Epstein-Barr virus", "ORGANISM", 154, 172], ["EBV", "ORGANISM", 174, 177], ["M48", "GENE_OR_GENE_PRODUCT", 192, 195], ["UL48", "GENE_OR_GENE_PRODUCT", 197, 201], ["BPLF1", "GENE_OR_GENE_PRODUCT", 207, 212], ["UL36 homologs", "PROTEIN", 48, 61], ["murine", "SPECIES", 65, 71], ["human", "SPECIES", 108, 113], ["MCMV", "SPECIES", 89, 93], ["human cytomegalovirus", "SPECIES", 108, 129], ["HCMV", "SPECIES", 131, 135], ["Epstein-Barr virus", "SPECIES", 154, 172], ["murine cytomegalovirus", "PROBLEM", 65, 87], ["human cytomegalovirus", "PROBLEM", 108, 129], ["HCMV/b subfamily", "TEST", 131, 147], ["Epstein", "TEST", 154, 161], ["EBV/g subfamily", "TEST", 174, 189], ["M48", "TEST", 192, 195], ["UL48", "TEST", 197, 201], ["BPLF1", "TEST", 207, 212], ["cytomegalovirus", "OBSERVATION", 114, 129]]], ["Although the in vivo function of this activity is currently unknown, its strict conservation through all herpesvirus subfamilies suggests an important role in their biology.", [["herpesvirus", "ORGANISM", 105, 116]]], ["To gain insights into the structural and functional properties of this activity, we set out to determine the structure of this enzyme.INTRODUCTIONWe report the crystal structure of the Ub-specific protease (USP) domain of MCMV (M48 USP ) in a covalent complex with a Ub-based suicide inhibitor, Ub vinylmethylester (UbVME).", [["Ub vinylmethylester", "CHEMICAL", 295, 314], ["UbVME", "CHEMICAL", 316, 321], ["Ub vinylmethylester", "CHEMICAL", 295, 314], ["UbVME", "CHEMICAL", 316, 321], ["Ub", "GENE_OR_GENE_PRODUCT", 185, 187], ["MCMV", "ORGANISM", 222, 226], ["M48 USP", "GENE_OR_GENE_PRODUCT", 228, 235], ["Ub", "GENE_OR_GENE_PRODUCT", 267, 269], ["Ub vinylmethylester", "SIMPLE_CHEMICAL", 295, 314], ["UbVME", "SIMPLE_CHEMICAL", 316, 321], ["enzyme", "PROTEIN", 127, 133], ["Ub-specific protease (USP) domain", "PROTEIN", 185, 218], ["MCMV", "PROTEIN", 222, 226], ["M48 USP", "PROTEIN", 228, 235], ["covalent complex", "PROTEIN", 243, 259], ["Ub", "PROTEIN", 267, 269], ["MCMV", "SPECIES", 222, 226], ["this enzyme", "TEST", 122, 133], ["the Ub", "TEST", 181, 187], ["MCMV", "TEST", 222, 226], ["a Ub-based suicide inhibitor", "TREATMENT", 265, 293]]], ["A comparison of the M48 USP topology to eukaryotic DUBs and other proteases established that M48 USP is the founding member of a structurally distinct class of deubiquitinating enzymes, which we designate herpesvirus tegument USPs (htUSPs).", [["DUBs", "GENE_OR_GENE_PRODUCT", 51, 55], ["M48 USP", "GENE_OR_GENE_PRODUCT", 93, 100], ["herpesvirus", "ORGANISM", 205, 216], ["tegument", "ORGANISM", 217, 225], ["USPs", "GENE_OR_GENE_PRODUCT", 226, 230], ["htUSPs", "GENE_OR_GENE_PRODUCT", 232, 238], ["M48 USP topology", "PROTEIN", 20, 36], ["eukaryotic DUBs", "PROTEIN", 40, 55], ["proteases", "PROTEIN", 66, 75], ["M48 USP", "PROTEIN", 93, 100], ["deubiquitinating enzymes", "PROTEIN", 160, 184], ["herpesvirus tegument USPs", "PROTEIN", 205, 230], ["htUSPs", "PROTEIN", 232, 238], ["other proteases", "TEST", 60, 75], ["deubiquitinating enzymes", "TEST", 160, 184]]], ["The presence of this family of cysteine proteases has implications for its possible role as a target to manipulate the interaction of MCMV and by inference, other herpesviruses, with their host.RESULTS AND DISCUSSIONConstruct Design and Enzymatic Properties of M48 USP A 205 residue module in the N-terminal portion of MCMV M48 and EBV BPLF1 is necessary and sufficient for deubiquitinating activity and Ub specificity (Schlieker et al., 2005) .", [["cysteine", "CHEMICAL", 31, 39], ["N", "CHEMICAL", 297, 298], ["cysteine", "AMINO_ACID", 31, 39], ["MCMV", "ORGANISM", 134, 138], ["MCMV", "ORGANISM", 319, 323], ["M48", "GENE_OR_GENE_PRODUCT", 324, 327], ["EBV", "ORGANISM", 332, 335], ["BPLF1", "GENE_OR_GENE_PRODUCT", 336, 341], ["Ub", "GENE_OR_GENE_PRODUCT", 404, 406], ["cysteine proteases", "PROTEIN", 31, 49], ["N-terminal portion", "PROTEIN", 297, 315], ["MCMV M48", "PROTEIN", 319, 327], ["EBV BPLF1", "PROTEIN", 332, 341], ["Ub", "PROTEIN", 404, 406], ["MCMV", "SPECIES", 134, 138], ["MCMV", "SPECIES", 319, 323], ["EBV", "SPECIES", 332, 335], ["cysteine proteases", "TREATMENT", 31, 49], ["EBV BPLF1", "TEST", 332, 341], ["MCMV", "OBSERVATION", 319, 323]]], ["The proposed catalytic triad and oxyanion residues of this cysteine protease module are conserved in all herpesviruses.", [["cysteine", "CHEMICAL", 59, 67], ["cysteine", "AMINO_ACID", 59, 67], ["herpesviruses", "ORGANISM", 105, 118], ["cysteine protease module", "PROTEIN", 59, 83], ["The proposed catalytic triad and oxyanion residues", "TREATMENT", 0, 50], ["this cysteine protease module", "TREATMENT", 54, 83], ["catalytic triad", "OBSERVATION", 13, 28], ["oxyanion residues", "OBSERVATION", 33, 50]]], ["The tegument protease domains otherwise display only moderate sequence conservation (%12% identity between representatives of a, b, and g subfamilies) yet share a high degree of structural similarity according to secondary structure predictions (Schlieker et al., 2005) .", [["tegument protease domains", "PROTEIN", 4, 29], ["The tegument protease domains", "TEST", 0, 29], ["moderate sequence conservation", "PROBLEM", 53, 83], ["a high degree of structural similarity", "PROBLEM", 161, 199], ["high degree", "OBSERVATION_MODIFIER", 163, 174]]], ["Neither BLAST searches (Altschul et al., 1997) nor threading programs that employ sequence alignment and protein-fold recognition algorithms (McGuffin et al., 2000) uncovered homologs other than herpesvirus tegument proteins (data not shown).", [["herpesvirus", "ORGANISM", 195, 206], ["herpesvirus tegument proteins", "PROTEIN", 195, 224], ["sequence alignment", "TEST", 82, 100], ["protein", "TEST", 105, 112], ["herpesvirus tegument proteins", "TEST", 195, 224]]], ["This suggested that htUSPs have structural properties that are distinct from known DUBs and other cysteine proteases Sulea et al., 2006) .", [["cysteine", "CHEMICAL", 98, 106], ["htUSPs", "GENE_OR_GENE_PRODUCT", 20, 26], ["DUBs", "GENE_OR_GENE_PRODUCT", 83, 87], ["htUSPs", "PROTEIN", 20, 26], ["DUBs", "PROTEIN", 83, 87], ["cysteine proteases", "PROTEIN", 98, 116], ["structural properties", "PROBLEM", 32, 53]]], ["Accordingly, UL36 USP and its homologs represent an independent family (C76) in the CA clan of proteases in the MEROPS peptidase database (Rawlings et al., 2004) .", [["UL36 USP", "GENE_OR_GENE_PRODUCT", 13, 21], ["MEROPS peptidase", "GENE_OR_GENE_PRODUCT", 112, 128], ["UL36 USP", "PROTEIN", 13, 21], ["C76", "PROTEIN", 72, 75], ["CA clan", "PROTEIN", 84, 91], ["proteases", "PROTEIN", 95, 104], ["MEROPS peptidase", "PROTEIN", 112, 128]]], ["To explore the structural and mechanistic properties of htUSPs, we expressed an N-terminal fragment encompassing residues 1-236 of the MCMV M48 tegument protein (M48 USP ), which likely comprises the entire USP domain of M48, because it is followed by an $70 residue region that is likely unstructured according to secondary structure predictions.", [["N", "CHEMICAL", 80, 81], ["htUSPs", "GENE_OR_GENE_PRODUCT", 56, 62], ["MCMV", "ORGANISM", 135, 139], ["M48 USP", "GENE_OR_GENE_PRODUCT", 162, 169], ["M48", "GENE_OR_GENE_PRODUCT", 221, 224], ["htUSPs", "PROTEIN", 56, 62], ["N-terminal fragment", "PROTEIN", 80, 99], ["MCMV M48 tegument protein", "PROTEIN", 135, 160], ["M48 USP", "PROTEIN", 162, 169], ["USP domain", "PROTEIN", 207, 217], ["M48", "PROTEIN", 221, 224], ["an N-terminal fragment encompassing residues", "PROBLEM", 77, 121], ["terminal", "OBSERVATION_MODIFIER", 82, 90], ["fragment", "OBSERVATION", 91, 99], ["secondary structure", "OBSERVATION", 315, 334]]], ["To confirm that this domain is a functional deubiquitinating enzyme, we first tested the ability of M48 USP to hydrolyze the fluorogenic substrate Ub C-terminal 7-amido-4-methylcoumarin (UbAMC).", [["Ub C-terminal 7-amido-4-methylcoumarin", "CHEMICAL", 147, 185], ["Ub C-terminal 7-amido-4-methylcoumarin", "CHEMICAL", 147, 185], ["UbAMC", "CHEMICAL", 187, 192], ["M48 USP", "GENE_OR_GENE_PRODUCT", 100, 107], ["Ub C-terminal 7-amido-4-methylcoumarin", "SIMPLE_CHEMICAL", 147, 185], ["UbAMC", "SIMPLE_CHEMICAL", 187, 192], ["deubiquitinating enzyme", "PROTEIN", 44, 67], ["M48 USP", "PROTEIN", 100, 107], ["C-terminal", "TEST", 150, 160], ["amido", "TEST", 163, 168], ["methylcoumarin (UbAMC)", "TREATMENT", 171, 193]]], ["UbAMC hydrolysis followed Michaelis-Menten kinetics, with k cat / K M = 9.17 3 10 6 M \u00c01 s \u00c01 (data not shown).", [["UbAMC", "CHEMICAL", 0, 5], ["UbAMC", "SIMPLE_CHEMICAL", 0, 5], ["UbAMC hydrolysis", "TEST", 0, 16], ["Michaelis", "TEST", 26, 35], ["k cat", "TEST", 58, 63], ["K M", "TEST", 66, 69]]], ["To determine whether M48 USP can cleave true isopeptide-linked Ub chains, we examined its ability to attack K48-linked or K63-linked diUb by using a 500-fold excess of substrate over enzyme.", [["isopeptide", "CHEMICAL", 45, 55], ["K48", "CHEMICAL", 108, 111], ["M48 USP", "GENE_OR_GENE_PRODUCT", 21, 28], ["Ub", "GENE_OR_GENE_PRODUCT", 63, 65], ["K48", "SIMPLE_CHEMICAL", 108, 111], ["K63", "SIMPLE_CHEMICAL", 122, 125], ["diUb", "GENE_OR_GENE_PRODUCT", 133, 137], ["M48 USP", "PROTEIN", 21, 28], ["Ub chains", "PROTEIN", 63, 72], ["K48", "PROTEIN", 108, 111], ["K63", "PROTEIN", 122, 125], ["diUb", "PROTEIN", 133, 137], ["enzyme", "PROTEIN", 183, 189], ["K48", "TEST", 108, 111], ["K63", "TEST", 122, 125], ["substrate over enzyme", "TREATMENT", 168, 189]]], ["Both adducts were converted to free monomeric Ub, albeit with $5-fold slower kinetics for K63-linked compared to K48-linked diUb ( Figure 1A) .RESULTS AND DISCUSSIONCan M48 USP also cleave Ub conjugates found in living cells?", [["cells", "ANATOMY", 219, 224], ["K63", "CHEMICAL", 90, 93], ["K48", "CHEMICAL", 113, 116], ["Ub", "GENE_OR_GENE_PRODUCT", 46, 48], ["K63", "SIMPLE_CHEMICAL", 90, 93], ["K48", "SIMPLE_CHEMICAL", 113, 116], ["Ub", "GENE_OR_GENE_PRODUCT", 189, 191], ["cells", "CELL", 219, 224], ["monomeric Ub", "PROTEIN", 36, 48], ["K63", "PROTEIN", 90, 93], ["K48", "PROTEIN", 113, 116], ["diUb", "PROTEIN", 124, 128], ["Figure 1A", "PROTEIN", 131, 140], ["Ub", "PROTEIN", 189, 191], ["living cells", "CELL_TYPE", 212, 224], ["K63", "TEST", 90, 93], ["K48", "TEST", 113, 116]]], ["To address this issue, 293T cells were transiently transfected with HA-tagged Ub and treated with a proteasome inhibitor, ZL 3 VS (Bogyo et al., 1997) , to allow accumulation of (poly)-ubiquitinated species.", [["293T cells", "ANATOMY", 23, 33], ["293T cells", "CELL", 23, 33], ["Ub", "GENE_OR_GENE_PRODUCT", 78, 80], ["293T cells", "CELL_LINE", 23, 33], ["HA", "PROTEIN", 68, 70], ["Ub", "PROTEIN", 78, 80], ["HA", "PROBLEM", 68, 70], ["a proteasome inhibitor", "TREATMENT", 98, 120], ["accumulation of (poly)-ubiquitinated species", "PROBLEM", 162, 206], ["ubiquitinated species", "OBSERVATION", 185, 206]]], ["Cell lysates were prepared and incubated in the absence and presence of M48 USP or its catalytically inactive counterpart, M48 USP -C23A (Schlieker et al., 2005) , and subjected to SDS-PAGE and immunoblotting ( Figure 1B ).", [["Cell lysates", "ANATOMY", 0, 12], ["Cell lysates", "CELL", 0, 12], ["M48 USP", "GENE_OR_GENE_PRODUCT", 72, 79], ["M48 USP", "PROTEIN", 72, 79], ["Cell lysates", "TEST", 0, 12]]], ["Both free Ub and Ub conjugates were readily detectable, the latter being more prominent in samples derived from ZL 3 VS-treated cells.", [["samples", "ANATOMY", 91, 98], ["cells", "ANATOMY", 128, 133], ["ZL 3 VS", "CHEMICAL", 112, 119], ["Ub", "GENE_OR_GENE_PRODUCT", 10, 12], ["Ub conjugates", "SIMPLE_CHEMICAL", 17, 30], ["cells", "CELL", 128, 133], ["Ub", "PROTEIN", 10, 12], ["Ub", "PROTEIN", 17, 19], ["ZL 3 VS-treated cells", "CELL_LINE", 112, 133], ["Both free Ub and Ub conjugates", "TEST", 0, 30], ["free", "OBSERVATION_MODIFIER", 5, 9], ["Ub", "ANATOMY_MODIFIER", 10, 12], ["more prominent", "OBSERVATION_MODIFIER", 73, 87]]], ["Upon exposure to nanomolar concentrations of M48 USP , the majority of cellular Ub conjugates were deubiquitinated, as judged by the near-complete elimination of high molecular weight, anti-HA-reactive material and a corresponding increase in free Ub.", [["cellular", "ANATOMY", 71, 79], ["M48 USP", "GENE_OR_GENE_PRODUCT", 45, 52], ["cellular", "CELL", 71, 79], ["Ub", "GENE_OR_GENE_PRODUCT", 80, 82], ["anti-HA", "PROTEIN", 185, 192], ["nanomolar concentrations", "TEST", 17, 41], ["cellular Ub conjugates", "TEST", 71, 93], ["anti-HA-reactive material", "PROBLEM", 185, 210], ["a corresponding increase in free Ub.", "PROBLEM", 215, 251], ["reactive material", "OBSERVATION", 193, 210], ["increase", "OBSERVATION_MODIFIER", 231, 239]]], ["For comparison, we also tested the homologous EBV-derived protease BPLF1 USP and observed similar deubiquitinating activity ( Figure 1B) , confirming that the activity exerted on poly-Ub adducts is conserved among herpesviruses.Structure Determination and Overall Structure of M48 USPHaving demonstrated the activity of M48 USP , we initiated crystallization trials for M48 USP and BPLF1 USP , neither of which yielded diffraction-quality crystals.", [["poly-Ub", "CHEMICAL", 179, 186], ["EBV", "ORGANISM", 46, 49], ["BPLF1 USP", "GENE_OR_GENE_PRODUCT", 67, 76], ["poly-Ub", "SIMPLE_CHEMICAL", 179, 186], ["herpesviruses", "ORGANISM", 214, 227], ["protease", "PROTEIN", 58, 66], ["BPLF1 USP", "PROTEIN", 67, 76], ["M48 USPHaving", "PROTEIN", 277, 290], ["M48 USP", "PROTEIN", 320, 327], ["BPLF1 USP", "PROTEIN", 382, 391], ["the homologous EBV", "TEST", 31, 49], ["poly-Ub adducts", "TREATMENT", 179, 194], ["Structure Determination", "TEST", 228, 251], ["crystallization trials", "TREATMENT", 343, 365], ["BPLF1 USP", "TEST", 382, 391], ["deubiquitinating activity", "OBSERVATION", 98, 123]]], ["We crystallized M48 USP in a covalent complex with UbVME, a suicide inhibitor that forms a thioether bond with the active-site cysteine of DUBs (Borodovsky et al., 2002; Misaghi et al., 2005) .", [["UbVME", "CHEMICAL", 51, 56], ["thioether", "CHEMICAL", 91, 100], ["UbVME", "CHEMICAL", 51, 56], ["thioether", "CHEMICAL", 91, 100], ["cysteine", "CHEMICAL", 127, 135], ["UbVME", "SIMPLE_CHEMICAL", 51, 56], ["cysteine", "AMINO_ACID", 127, 135], ["M48 USP", "PROTEIN", 16, 23], ["DUBs", "PROTEIN", 139, 143], ["UbVME", "TREATMENT", 51, 56], ["a suicide inhibitor", "TREATMENT", 58, 77], ["active", "OBSERVATION_MODIFIER", 115, 121]]], ["The structure was determined by using crystals of SeMet-labeled M48 USP covalently bound to UbVME in a single-wavelength anomalous dispersion (SAD) experiment.", [["SeMet", "CHEMICAL", 50, 55], ["UbVME", "CHEMICAL", 92, 97], ["SeMet", "CHEMICAL", 50, 55], ["UbVME", "CHEMICAL", 92, 97], ["SeMet", "SIMPLE_CHEMICAL", 50, 55], ["M48 USP", "SIMPLE_CHEMICAL", 64, 71], ["UbVME", "SIMPLE_CHEMICAL", 92, 97], ["M48 USP", "PROTEIN", 64, 71], ["UbVME", "PROTEIN", 92, 97], ["SeMet", "TEST", 50, 55], ["a single-wavelength anomalous dispersion", "TREATMENT", 101, 141]]], ["Continuous electron density was observed for residues 1-232 of the two M48 USP molecules and all residues of the two UbVME molecules in the asymmetric unit.", [["UbVME", "CHEMICAL", 117, 122], ["electron", "SIMPLE_CHEMICAL", 11, 19], ["M48 USP molecules", "PROTEIN", 71, 88], ["UbVME molecules", "PROTEIN", 117, 132], ["density", "OBSERVATION", 20, 27], ["asymmetric", "OBSERVATION_MODIFIER", 140, 150]]], ["The final model was refined to 1.8 \u00c5 resolution to an R factor of 15.8% (R free = 21.4%) (see Table 1 for data collection and refinement statistics).", [["an R factor", "TEST", 51, 62], ["data collection", "TEST", 106, 121]]], ["Because the Ca atoms of both complexes can be superimposed with 0.3 \u00c5 rootmean-square deviation (rmsd), we limit our discussion to a single complex of M48 USP with UbVME (chains A and C).Structure Determination and Overall Structure of M48 USPThe M48 USP structure is organized around a bifurcated antiparallel b sheet flanked on either side by a helices to 678 Molecular Cell 25, 677-687, March 9, 2007 \u00aa2007 Elsevier Inc.Molecular Cellform an a-b-a sandwich structure ( Figure 2A ).", [["Ca", "CHEMICAL", 12, 14], ["Ca", "CHEMICAL", 12, 14], ["Ca atoms", "SIMPLE_CHEMICAL", 12, 20], ["UbVME", "SIMPLE_CHEMICAL", 164, 169], ["M48 USP", "PROTEIN", 151, 158], ["UbVME", "PROTEIN", 164, 169], ["chains A and C", "PROTEIN", 171, 185], ["bifurcated antiparallel b sheet", "PROTEIN", 287, 318], ["Structure Determination", "TEST", 187, 210], ["a bifurcated antiparallel b sheet flanked", "TREATMENT", 285, 326], ["Molecular Cell", "TEST", 362, 376], ["bifurcated", "OBSERVATION_MODIFIER", 287, 297]]], ["The extended C terminus of UbVME lies in the deep catalytic cleft between a helix A and the b sheet of M48 USP , with the active-site cysteine in thioether linkage to the former VME moiety ( Figures 2B and 2C ).", [["cysteine", "CHEMICAL", 134, 142], ["thioether", "CHEMICAL", 146, 155], ["C", "CHEMICAL", 13, 14], ["cysteine", "CHEMICAL", 134, 142], ["thioether", "CHEMICAL", 146, 155], ["VME", "CHEMICAL", 178, 181], ["UbVME", "GENE_OR_GENE_PRODUCT", 27, 32], ["M48 USP", "GENE_OR_GENE_PRODUCT", 103, 110], ["cysteine", "AMINO_ACID", 134, 142], ["C terminus", "PROTEIN", 13, 23], ["UbVME", "PROTEIN", 27, 32], ["helix A", "PROTEIN", 76, 83], ["b sheet", "PROTEIN", 92, 99], ["M48 USP", "PROTEIN", 103, 110], ["The extended C terminus of UbVME", "PROBLEM", 0, 32], ["deep", "ANATOMY_MODIFIER", 45, 49], ["catalytic", "ANATOMY_MODIFIER", 50, 59], ["cleft", "OBSERVATION", 60, 65], ["active", "OBSERVATION_MODIFIER", 122, 128]]], ["As detailed below, the M48 USP fold, although it has similarities to several cysteine proteases, is distinct from all other known DUB structures.Molecular CellCharge and Surface Complementarity Yield an Intimate M48 USP -Ub Interface UbVME undergoes only minimal conformational changes upon binding to M48 USP , as reflected by 0.33 \u00c5 rmsd over all Ca atoms when free Ub (Vijay-Kumar et al., 1987) and M48 USP -bound UbVME are superimposed.", [["Ca", "CHEMICAL", 349, 351], ["cysteine", "CHEMICAL", 77, 85], ["Ca", "CHEMICAL", 349, 351], ["M48 USP", "GENE_OR_GENE_PRODUCT", 23, 30], ["DUB", "GENE_OR_GENE_PRODUCT", 130, 133], ["M48 USP", "GENE_OR_GENE_PRODUCT", 302, 309], ["UbVME", "GENE_OR_GENE_PRODUCT", 417, 422], ["M48 USP fold", "PROTEIN", 23, 35], ["cysteine proteases", "PROTEIN", 77, 95], ["DUB structures", "PROTEIN", 130, 144], ["Intimate M48 USP -Ub Interface UbVME", "PROTEIN", 203, 239], ["M48 USP", "PROTEIN", 302, 309], ["UbVME", "PROTEIN", 417, 422], ["the M48 USP fold", "TEST", 19, 35], ["several cysteine proteases", "PROBLEM", 69, 95], ["minimal conformational changes", "PROBLEM", 255, 285], ["several", "OBSERVATION_MODIFIER", 69, 76], ["cysteine proteases", "OBSERVATION", 77, 95], ["distinct", "OBSERVATION_MODIFIER", 100, 108], ["DUB", "OBSERVATION", 130, 133], ["Surface", "OBSERVATION_MODIFIER", 170, 177], ["minimal", "OBSERVATION_MODIFIER", 255, 262], ["conformational", "OBSERVATION", 263, 277]]], ["Electron density indicates a 1.9 \u00c5 covalent bond between the M48 USP C23 Sg atom and the Cb-carbon atom of the former VME moiety that replaces the C-terminal G76 of wild-type Ub ( Figure 2C ), reminiscent of the covalent complex between UbVME and UCH-L3 (Misaghi et al., 2005) .", [["Sg atom", "CHEMICAL", 73, 80], ["VME", "CHEMICAL", 118, 121], ["C23", "CHEMICAL", 69, 72], ["Sg", "CHEMICAL", 73, 75], ["Cb-carbon", "CHEMICAL", 89, 98], ["VME", "CHEMICAL", 118, 121], ["C", "CHEMICAL", 147, 148], ["Sg atom", "SIMPLE_CHEMICAL", 73, 80], ["VME moiety", "SIMPLE_CHEMICAL", 118, 128], ["Ub", "GENE_OR_GENE_PRODUCT", 175, 177], ["C-terminal G76", "PROTEIN", 147, 161], ["wild-type Ub", "PROTEIN", 165, 177], ["Figure 2C", "PROTEIN", 180, 189], ["covalent complex", "PROTEIN", 212, 228], ["UbVME", "PROTEIN", 237, 242], ["UCH", "PROTEIN", 247, 250], ["Electron density", "TEST", 0, 16], ["density", "OBSERVATION", 9, 16], ["1.9 \u00c5", "OBSERVATION_MODIFIER", 29, 34], ["C23", "ANATOMY", 69, 72], ["carbon atom", "OBSERVATION", 92, 103], ["L3", "ANATOMY", 251, 253]]], ["Complex formation buries 1840 \u00c5 2 of solvent-accessible surface area, corresponding to 816 \u00c5 2 (7%) and 1024 \u00c5 2 (21%) of the total solvent-accessible surface area of free M48 USP and UbVME, respectively.", [["surface area", "ANATOMY", 56, 68], ["surface area", "ANATOMY", 151, 163], ["UbVME", "PROTEIN", 184, 189], ["Complex formation buries", "PROBLEM", 0, 24], ["the total solvent", "TEST", 122, 139]]], ["The size of this interface is comparable to the corresponding ones in UCH enzymes, e.g., 2300 A 2 in UCH-L3 (Misaghi et al., 2005) , but smaller than in HAUSP (3600 \u00c5 2 ) (Hu et al., 2002) and other USPs.", [["UCH enzymes", "GENE_OR_GENE_PRODUCT", 70, 81], ["UCH enzymes", "PROTEIN", 70, 81], ["UCH enzymes", "TEST", 70, 81], ["HAUSP", "TEST", 153, 158], ["Hu et al.", "TEST", 172, 181], ["other USPs", "TEST", 193, 203], ["size", "OBSERVATION_MODIFIER", 4, 8], ["interface", "OBSERVATION", 17, 26], ["L3", "ANATOMY", 105, 107], ["smaller", "OBSERVATION_MODIFIER", 137, 144]]], ["Electrostatic surface potential calculations show a high degree of charge complementarity: positively charged surface regions of the extended Ub C terminus (residues 71-75) are deeply buried in the largely acidic cleft of M48 USP ( Figure 2B ).", [["residues 71-75", "CHEMICAL", 157, 171], ["C", "CHEMICAL", 145, 146], ["positively charged surface regions", "PROTEIN", 91, 125], ["Ub C terminus", "PROTEIN", 142, 155], ["residues 71-75", "PROTEIN", 157, 171], ["M48 USP", "PROTEIN", 222, 229], ["Figure 2B", "PROTEIN", 232, 241], ["Electrostatic surface potential calculations", "TEST", 0, 44], ["a high degree of charge complementarity", "PROBLEM", 50, 89], ["high degree", "OBSERVATION_MODIFIER", 52, 63], ["charge complementarity", "OBSERVATION", 67, 89], ["acidic", "OBSERVATION_MODIFIER", 206, 212], ["cleft", "OBSERVATION", 213, 218]]], ["The backbone of the Ub C terminus adopts an extended b conformation and is extensively coordinated by seven salt bridges and hydrogen bonds to residues lining the M48 USP cleft, conferring sequence specificity for the Ub C terminus ( Figure 3A ).", [["C", "CHEMICAL", 23, 24], ["hydrogen", "CHEMICAL", 125, 133], ["Ub", "GENE_OR_GENE_PRODUCT", 20, 22], ["Ub C terminus", "PROTEIN", 20, 33], ["M48 USP cleft", "PROTEIN", 163, 176], ["Ub C terminus", "PROTEIN", 218, 231], ["Figure 3A", "PROTEIN", 234, 243], ["an extended b conformation", "TREATMENT", 41, 67], ["backbone", "ANATOMY_MODIFIER", 4, 12], ["Ub", "ANATOMY_MODIFIER", 20, 22]]], ["In addition, a hydrophobic pocket lined by M48 USP V140 and Y192 accommodates the Ub L73 side chain (Figures 2B and 3A) .", [["Y192", "AMINO_ACID", 60, 64], ["Ub L73 side chain", "PROTEIN", 82, 99], ["Figures 2B and 3A", "PROTEIN", 101, 118], ["a hydrophobic pocket", "PROBLEM", 13, 33]]], ["Binding of the C-terminal Ub segment in an extended conformation in the active-site cleft is a common feature of DUBs, as observed in the crystal structures of Ub derivatives in complex with UCH-L3, HAUSP, USP2, and USP14 (Hu et al., 2002 (Hu et al., , 2005 Misaghi et al., 2004; Renatus et al., 2006) .Molecular CellApart from contacts with the C-terminal Ub stretch, there are a number of additional interactions between Ub and M48 USP .", [["Ub", "GENE_OR_GENE_PRODUCT", 26, 28], ["DUBs", "GENE_OR_GENE_PRODUCT", 113, 117], ["Ub", "GENE_OR_GENE_PRODUCT", 160, 162], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 191, 197], ["HAUSP", "GENE_OR_GENE_PRODUCT", 199, 204], ["USP2", "GENE_OR_GENE_PRODUCT", 206, 210], ["USP14", "GENE_OR_GENE_PRODUCT", 216, 221], ["Ub", "GENE_OR_GENE_PRODUCT", 357, 359], ["Ub", "GENE_OR_GENE_PRODUCT", 423, 425], ["M48 USP", "GENE_OR_GENE_PRODUCT", 430, 437], ["C-terminal Ub segment", "PROTEIN", 15, 36], ["DUBs", "PROTEIN", 113, 117], ["Ub derivatives", "PROTEIN", 160, 174], ["UCH", "PROTEIN", 191, 194], ["USP2", "PROTEIN", 206, 210], ["C-terminal Ub", "PROTEIN", 346, 359], ["Ub", "PROTEIN", 423, 425], ["M48 USP", "PROTEIN", 430, 437], ["Binding of the C-terminal Ub segment", "PROBLEM", 0, 36], ["DUBs", "PROBLEM", 113, 117], ["UCH", "TEST", 191, 194], ["HAUSP", "TEST", 199, 204], ["USP2", "TEST", 206, 210], ["C-terminal Ub", "ANATOMY_MODIFIER", 15, 28], ["segment", "ANATOMY_MODIFIER", 29, 36], ["extended", "OBSERVATION_MODIFIER", 43, 51], ["conformation", "OBSERVATION", 52, 64], ["active", "OBSERVATION_MODIFIER", 72, 78], ["cleft", "OBSERVATION", 84, 89], ["DUBs", "OBSERVATION", 113, 117], ["Ub derivatives", "OBSERVATION", 160, 174], ["L3", "ANATOMY", 195, 197]]], ["Most notably, an exposed b hairpin, formed by M48 USP b strands 5 and 6 and located in line with the central eight-stranded b sheet, contacts the Ub core domain (Figure 2A ).", [["M48 USP b strands 5 and 6", "DNA", 46, 71], ["central eight-stranded b sheet", "PROTEIN", 101, 131], ["Ub core domain", "PROTEIN", 146, 160], ["Figure 2A", "PROTEIN", 162, 171], ["an exposed b hairpin", "TREATMENT", 14, 34], ["hairpin", "OBSERVATION", 27, 34], ["central", "ANATOMY_MODIFIER", 101, 108]]], ["The hydrophobic patch formed by Ub residues L8, R42, I44, H68, and V70 contacts the (A) Hydrolysis of isopeptide-linked diUb by M48 USP .", [["isopeptide", "CHEMICAL", 102, 112], ["Ub", "GENE_OR_GENE_PRODUCT", 32, 34], ["diUb", "SIMPLE_CHEMICAL", 120, 124], ["Ub", "PROTEIN", 32, 34], ["diUb", "PROTEIN", 120, 124], ["M48 USP", "PROTEIN", 128, 135], ["The hydrophobic patch", "TREATMENT", 0, 21], ["hydrophobic patch", "OBSERVATION", 4, 21], ["Ub", "ANATOMY_MODIFIER", 32, 34], ["residues", "ANATOMY_MODIFIER", 35, 43], ["L8", "ANATOMY", 44, 46]]], ["K48-or K63-linked diUb (5 mM) was incubated with M48 USP (10 nM) at 37 C, stopped at the indicated time points by addition of 23 tris/tricine sample buffer, subjected to a tris/tricine gel, and stained by colloidal blue.", [["colloidal blue", "CHEMICAL", 205, 219], ["diUb", "CHEMICAL", 18, 22], ["tris", "CHEMICAL", 172, 176], ["K48", "SIMPLE_CHEMICAL", 0, 3], ["K63", "SIMPLE_CHEMICAL", 7, 10], ["diUb", "SIMPLE_CHEMICAL", 18, 22], ["tricine", "SIMPLE_CHEMICAL", 177, 184], ["K48", "PROTEIN", 0, 3], ["diUb", "PROTEIN", 18, 22], ["K48", "TEST", 0, 3], ["K63", "TEST", 7, 10], ["23 tris/tricine sample buffer", "TREATMENT", 126, 155], ["a tris/tricine gel", "TREATMENT", 170, 188], ["colloidal blue", "OBSERVATION", 205, 219]]], ["A densiometric quantification for these time courses (see Experimental Procedures) yields rate constants of 0.102 and 0.021/min for K48-and K63-linked diUb, respectively.", [["K48", "SIMPLE_CHEMICAL", 132, 135], ["K63", "SIMPLE_CHEMICAL", 140, 143], ["diUb", "GENE_OR_GENE_PRODUCT", 151, 155], ["K48", "PROTEIN", 132, 135], ["K63", "PROTEIN", 140, 143], ["diUb", "PROTEIN", 151, 155], ["A densiometric quantification", "TEST", 0, 29], ["rate constants", "TEST", 90, 104], ["K48", "TEST", 132, 135], ["K63", "TEST", 140, 143]]], ["(B) M48 USP cleaves cellular Ub conjugates to yield free Ub.", [["cellular", "ANATOMY", 20, 28], ["cellular", "CELL", 20, 28], ["M48 USP", "PROTEIN", 4, 11]]], ["293T cells were transiently transfected with HA-Ub or pcDNA3.1+ as control.Molecular CellTo enrich for polyubiquitinated species, cells were exposed to the proteasome inhibitor ZL 3 VS 1 hr prior to cell lysis where indicated.", [["293T cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 130, 135], ["cell", "ANATOMY", 199, 203], ["293T cells", "CELL", 0, 10], ["HA-Ub", "GENE_OR_GENE_PRODUCT", 45, 50], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 54, 60], ["cells", "CELL", 130, 135], ["cell", "CELL", 199, 203], ["293T cells", "CELL_LINE", 0, 10], ["HA", "PROTEIN", 45, 47], ["Ub", "PROTEIN", 48, 50], ["pcDNA3", "DNA", 54, 60], ["proteasome", "PROTEIN", 156, 166], ["HA-Ub", "TREATMENT", 45, 50], ["pcDNA3", "TREATMENT", 54, 60], ["polyubiquitinated species", "PROBLEM", 103, 128], ["cells", "PROBLEM", 130, 135], ["the proteasome inhibitor ZL", "TREATMENT", 152, 179], ["cell lysis", "TREATMENT", 199, 209], ["polyubiquitinated species", "OBSERVATION", 103, 128], ["cell lysis", "OBSERVATION", 199, 209]]], ["Soluble cell extracts were prepared 24 hr posttransfection, incubated for 1 hr in the absence or presence of enzymes, and subjected to SDS-PAGE and immunoblotting.", [["cell extracts", "ANATOMY", 8, 21], ["cell extracts", "ORGANISM_SUBSTANCE", 8, 21], ["enzymes", "PROTEIN", 109, 116], ["Soluble cell extracts", "TREATMENT", 0, 21], ["enzymes", "TEST", 109, 116], ["immunoblotting", "TEST", 148, 162]]], ["HA-Ub was detected by using 12CA5 (anti-HA) as primary antibody.Molecular Cellb hairpin residues L110, Y113, and C115 ( Figure 3B ).", [["HA-Ub", "GENE_OR_GENE_PRODUCT", 0, 5], ["12CA5", "SIMPLE_CHEMICAL", 28, 33], ["anti-HA", "GENE_OR_GENE_PRODUCT", 35, 42], ["HA", "PROTEIN", 0, 2], ["Ub", "PROTEIN", 3, 5], ["12CA5", "PROTEIN", 28, 33], ["anti", "PROTEIN", 35, 39], ["HA", "PROTEIN", 40, 42], ["primary antibody", "PROTEIN", 47, 63], ["Molecular Cellb hairpin residues", "TEST", 64, 96], ["Y113", "TEST", 103, 107], ["Ub", "ANATOMY_MODIFIER", 3, 5], ["hairpin residues", "OBSERVATION", 80, 96]]], ["In addition, several hydrogen bonds are formed between backbone atoms of the two proteins ( Figure 3B ).Molecular CellMembers of the UCH family like UCH-L3 and Yuh1 lack an additional Ub-interacting subdomain beyond the active-site cleft that accommodates the C-terminal Ub residues.", [["hydrogen", "CHEMICAL", 21, 29], ["UCH", "GENE_OR_GENE_PRODUCT", 133, 136], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 149, 155], ["Yuh1", "GENE_OR_GENE_PRODUCT", 160, 164], ["Ub", "GENE_OR_GENE_PRODUCT", 184, 186], ["Ub", "GENE_OR_GENE_PRODUCT", 271, 273], ["Figure 3B", "PROTEIN", 92, 101], ["UCH family", "PROTEIN", 133, 143], ["UCH", "PROTEIN", 149, 152], ["L3", "PROTEIN", 153, 155], ["Yuh1", "PROTEIN", 160, 164], ["Ub", "PROTEIN", 184, 186], ["interacting subdomain", "PROTEIN", 187, 208], ["C-terminal Ub residues", "PROTEIN", 260, 282], ["several hydrogen bonds", "PROBLEM", 13, 35], ["an additional Ub", "PROBLEM", 170, 186], ["the active-site cleft", "PROBLEM", 216, 237], ["the C-terminal Ub residues", "PROBLEM", 256, 282], ["hydrogen bonds", "OBSERVATION", 21, 35], ["L3", "ANATOMY", 153, 155], ["active", "OBSERVATION_MODIFIER", 220, 226], ["cleft", "OBSERVATION", 232, 237], ["C-terminal Ub residues", "OBSERVATION", 260, 282]]], ["Other important contacts are formed to two loop regions (residues 8-9 and 39-42) neighboring this C-terminal Ub stretch (Johnston et al., 1999; Misaghi et al., 2005) .", [["C", "CHEMICAL", 98, 99], ["loop regions", "PROTEIN", 43, 55], ["C-terminal Ub", "PROTEIN", 98, 111]]], ["This binding pattern allows significant conformational freedom of Ub when bound to UCH-L3 (Misaghi et al., 2005) .", [["Ub", "GENE_OR_GENE_PRODUCT", 66, 68], ["Ub", "PROTEIN", 66, 68], ["UCH", "PROTEIN", 83, 86], ["This binding pattern", "PROBLEM", 0, 20], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["L3", "ANATOMY", 87, 89]]], ["In contrast, extensive interactions mediated by the M48 USP b hairpin likely restrain movement of Ub relative to the M48 protease domain, as suggested from the two structurally very similar M48 USP -Ub complexes in the asymmetric unit (see above).Molecular CellOverall, the Ub-M48 USP interaction is very intimate, as indicated by shape complementarity (S c ) calculations, which yield a high S c of 0.77 compared to an average of 0.70-0.74 for oligomeric interfaces (Lawrence and Colman, 1993) .", [["Ub", "GENE_OR_GENE_PRODUCT", 98, 100], ["USP -Ub", "GENE_OR_GENE_PRODUCT", 194, 201], ["Ub", "GENE_OR_GENE_PRODUCT", 274, 276], ["M48 USP b hairpin", "PROTEIN", 52, 69], ["Ub", "PROTEIN", 98, 100], ["M48 protease domain", "PROTEIN", 117, 136], ["M48 USP -Ub complexes", "PROTEIN", 190, 211], ["Ub", "PROTEIN", 274, 276], ["M48", "PROTEIN", 277, 280], ["the M48 USP b hairpin", "TREATMENT", 48, 69], ["the M48 protease domain", "TEST", 113, 136], ["calculations", "TEST", 360, 372], ["a high S c", "TEST", 386, 396], ["asymmetric", "OBSERVATION_MODIFIER", 219, 229], ["Ub", "ANATOMY_MODIFIER", 274, 276]]], ["The surface complementarity also results in exclusion of water molecules from the interface, which contrasts with DUBs of the USP family such as HAUSP or USP2 (Hu et al., 2002; Renatus et al., 2006) .", [["surface", "ANATOMY", 4, 11], ["surface", "CELLULAR_COMPONENT", 4, 11], ["DUBs", "GENE_OR_GENE_PRODUCT", 114, 118], ["USP", "GENE_OR_GENE_PRODUCT", 126, 129], ["HAUSP", "GENE_OR_GENE_PRODUCT", 145, 150], ["water molecules", "PROTEIN", 57, 72], ["DUBs", "PROTEIN", 114, 118], ["USP family", "PROTEIN", 126, 136], ["HAUSP", "PROTEIN", 145, 150], ["USP2", "PROTEIN", 154, 158], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["complementarity", "OBSERVATION", 12, 27], ["water molecules", "OBSERVATION", 57, 72]]], ["In both USP-Ub complexes, $20 water molecules are coordinated in the interface between the USP finger domain and the Ub core domain, and Ub specificity is therefore dictated by several water-mediated contacts (Hu et al., 2002; Renatus et al., 2006) .Active-Site ConformationThe active site that surrounds the covalent bond between the catalytic C23 and the former VME moiety of UbVME is canopied by the Y76 and V140 side chains forming a van der Waals interaction above the active site ( Figure 3A) .", [["UbVME", "CHEMICAL", 378, 383], ["C23", "CHEMICAL", 345, 348], ["VME", "CHEMICAL", 364, 367], ["UbVME", "CHEMICAL", 378, 383], ["Y76", "CHEMICAL", 403, 406], ["V140", "CHEMICAL", 411, 415], ["USP-Ub", "GENE_OR_GENE_PRODUCT", 8, 14], ["Ub", "GENE_OR_GENE_PRODUCT", 117, 119], ["Ub", "GENE_OR_GENE_PRODUCT", 137, 139], ["UbVME", "SIMPLE_CHEMICAL", 378, 383], ["Y76", "SIMPLE_CHEMICAL", 403, 406], ["USP-Ub complexes", "PROTEIN", 8, 24], ["USP finger domain", "PROTEIN", 91, 108], ["Ub core domain", "PROTEIN", 117, 131], ["Ub", "PROTEIN", 137, 139], ["catalytic C23", "PROTEIN", 335, 348], ["VME moiety", "PROTEIN", 364, 374], ["UbVME", "PROTEIN", 378, 383], ["Y76 and V140 side chains", "PROTEIN", 403, 427], ["active site", "PROTEIN", 474, 485], ["$20 water molecules", "TREATMENT", 26, 45], ["The active site", "PROBLEM", 274, 289], ["the catalytic C23", "TREATMENT", 331, 348], ["V140 side chains", "TREATMENT", 411, 427], ["a van der Waals interaction", "TREATMENT", 436, 463], ["Ub", "ANATOMY_MODIFIER", 12, 14], ["complexes", "OBSERVATION", 15, 24], ["USP finger", "ANATOMY", 91, 101], ["active", "OBSERVATION_MODIFIER", 278, 284], ["site", "OBSERVATION", 285, 289], ["covalent bond", "OBSERVATION", 309, 322], ["catalytic", "OBSERVATION_MODIFIER", 335, 344], ["C23", "OBSERVATION_MODIFIER", 345, 348], ["active", "OBSERVATION_MODIFIER", 474, 480]]], ["Consequently, the entry of ubiquitinated substrates into the active site would require a small structural rearrangement around either of these two residues.", [["ubiquitinated substrates", "PROTEIN", 27, 51], ["a small structural rearrangement", "PROBLEM", 87, 119], ["active", "OBSERVATION_MODIFIER", 61, 67], ["small", "OBSERVATION_MODIFIER", 89, 94], ["structural rearrangement", "OBSERVATION", 95, 119]]], ["This is analogous to the USP-Ub structures (Hu et al., 2002 (Hu et al., , 2005 Renatus et al., 2006) but stands in contrast to the UCH family members, which have a long crossover loop that covers the active site (Das et al., 2006; Johnston et al., 1997; Misaghi et al., 2005) .", [["UCH", "GENE_OR_GENE_PRODUCT", 131, 134], ["UCH family members", "PROTEIN", 131, 149], ["a long crossover loop", "TREATMENT", 162, 183]]], ["The exit tunnel ( Figure 2B ) is occupied in our structure by the VME moiety and in the case of bound natural substrates would readily accommodate the isopeptide-linked lysine side chain of the target protein.Active-Site ConformationIn light of the strict conservation of Q10, C23, D156, and H158 throughout all herpesviridae subfamilies ( Figure 4A and Figure S1A , in the Supplemental Data available with this article online; numbering according to M48 sequence), we proposed that these residues are involved in the formation of the oxyanion hole (Q10) and the aspartic acid-histidine-cysteine catalytic triad Schlieker et al., 2005) .", [["lysine", "CHEMICAL", 169, 175], ["Q10", "CHEMICAL", 272, 275], ["Q10", "CHEMICAL", 550, 553], ["aspartic acid-histidine-cysteine", "CHEMICAL", 563, 595], ["VME", "CHEMICAL", 66, 69], ["isopeptide", "CHEMICAL", 151, 161], ["lysine", "CHEMICAL", 169, 175], ["Q10, C23, D156, and H158", "CHEMICAL", 272, 296], ["Q10", "CHEMICAL", 550, 553], ["aspartic acid-histidine", "CHEMICAL", 563, 586], ["cysteine", "CHEMICAL", 587, 595], ["VME", "SIMPLE_CHEMICAL", 66, 69], ["cysteine", "AMINO_ACID", 587, 595], ["VME moiety", "PROTEIN", 66, 76], ["isopeptide-linked lysine side chain", "PROTEIN", 151, 186], ["target protein", "PROTEIN", 194, 208], ["Q10", "DNA", 272, 275], ["C23", "DNA", 277, 280], ["herpesviridae subfamilies", "PROTEIN", 312, 337], ["Figure S1A", "PROTEIN", 354, 364], ["M48 sequence", "DNA", 451, 463], ["The exit tunnel ( Figure 2B )", "TREATMENT", 0, 29], ["bound natural substrates", "PROBLEM", 96, 120], ["the isopeptide-linked lysine side chain", "TREATMENT", 147, 186], ["C23", "TREATMENT", 277, 280], ["the oxyanion hole", "TREATMENT", 531, 548], ["the aspartic acid-histidine", "TREATMENT", 559, 586], ["exit tunnel", "OBSERVATION", 4, 15]]], ["This prediction is unambiguously confirmed for C23, which forms a thioether linkage to the UbVME suicide inhibitor ( Figure 2C ).", [["C23", "CHEMICAL", 47, 50], ["thioether", "CHEMICAL", 66, 75], ["C23", "CHEMICAL", 47, 50], ["thioether", "CHEMICAL", 66, 75], ["C23", "SIMPLE_CHEMICAL", 47, 50], ["UbVME", "SIMPLE_CHEMICAL", 91, 96], ["C23", "PROBLEM", 47, 50], ["a thioether linkage", "PROBLEM", 64, 83], ["the UbVME suicide inhibitor", "TREATMENT", 87, 114]]], ["The addition of C23 to the former VME moiety imposes an sp3 configuration on the VME b carbon atom, thus resembling the tetrahedral reaction intermediate during catalysis, but with the oxyanion replaced by a hydrogen atom.", [["C23", "CHEMICAL", 16, 19], ["VME", "CHEMICAL", 34, 37], ["C23", "CHEMICAL", 16, 19], ["VME", "CHEMICAL", 34, 37], ["VME", "CHEMICAL", 81, 84], ["carbon", "CHEMICAL", 87, 93], ["hydrogen", "CHEMICAL", 208, 216], ["C23", "SIMPLE_CHEMICAL", 16, 19], ["VME b carbon atom", "SIMPLE_CHEMICAL", 81, 98], ["hydrogen atom", "SIMPLE_CHEMICAL", 208, 221], ["C23", "TREATMENT", 16, 19], ["the tetrahedral reaction", "PROBLEM", 116, 140], ["the oxyanion", "TREATMENT", 181, 193], ["a hydrogen atom", "TREATMENT", 206, 221], ["sp3 configuration", "OBSERVATION", 56, 73], ["tetrahedral reaction", "OBSERVATION", 120, 140]]], ["This hydrogen is located in a pocket that is lined by the conserved Q10 and corresponds to the oxyanion hole observed in other cysteine proteases ( Figure 4C ).", [["hydrogen", "CHEMICAL", 5, 13], ["Q10", "CHEMICAL", 68, 71], ["hydrogen", "CHEMICAL", 5, 13], ["Q10", "CHEMICAL", 68, 71], ["cysteine", "CHEMICAL", 127, 135], ["hydrogen", "SIMPLE_CHEMICAL", 5, 13], ["Q10", "PROTEIN", 68, 71], ["cysteine proteases", "PROTEIN", 127, 145], ["a pocket", "PROBLEM", 28, 36], ["the oxyanion hole", "TREATMENT", 91, 108], ["other cysteine proteases", "TREATMENT", 121, 145], ["hydrogen", "OBSERVATION", 5, 13], ["pocket", "OBSERVATION_MODIFIER", 30, 36], ["oxyanion hole", "OBSERVATION", 95, 108]]], ["Thus, the transition-state oxyanion is likely coordinated by the Q10 side chain and the backbone NH groups of Q22 and the catalytically active C23 ( Figure 4C ).", [["Q10", "CHEMICAL", 65, 68], ["Q22", "CHEMICAL", 110, 113], ["oxyanion", "CHEMICAL", 27, 35], ["Q10", "CHEMICAL", 65, 68], ["NH", "CHEMICAL", 97, 99], ["Q22", "CHEMICAL", 110, 113], ["Q22", "SIMPLE_CHEMICAL", 110, 113], ["the transition-state oxyanion", "TREATMENT", 6, 35], ["the Q10 side chain", "TREATMENT", 61, 79], ["the backbone NH groups", "TREATMENT", 84, 106]]], ["Furthermore, the catalytic aspartic acid residue can be assigned to D156 due to its location and distance to the catalytic C23 ( Figure 4B ).", [["aspartic acid", "CHEMICAL", 27, 40], ["aspartic acid", "CHEMICAL", 27, 40], ["aspartic acid", "AMINO_ACID", 27, 40], ["D156", "PROTEIN", 68, 72], ["catalytic C23", "PROTEIN", 113, 126], ["Figure 4B", "PROTEIN", 129, 138], ["the catalytic aspartic acid residue", "PROBLEM", 13, 48]]], ["Consistently, an D156A substitution results in a 180-fold reduction of catalytic activity ( Figure 5A) .Active-Site ConformationSurprisingly, two histidine residues, H141 and H158, are found neighboring the catalytic C23.", [["histidine", "CHEMICAL", 146, 155], ["histidine", "CHEMICAL", 146, 155], ["catalytic C23", "PROTEIN", 207, 220], ["an D156A substitution", "TREATMENT", 14, 35], ["catalytic activity", "OBSERVATION", 71, 89]]], ["H158 is conserved throughout the herpesviridae and forms a hydrogenMolecular Cellbond to the conserved D156 ( Figure 4B ) and for these reasons is the plausible candidate to act as catalytic base.", [["H158", "GENE_OR_GENE_PRODUCT", 0, 4], ["H158", "PROTEIN", 0, 4], ["D156", "DNA", 103, 107]]], ["However, both histidines are >5 \u00c5 from the catalytic C23, resulting in a misaligned catalytic triad ( Figure 4B) .", [["histidines", "CHEMICAL", 14, 24], ["catalytic C23", "PROTEIN", 43, 56], ["catalytic triad", "PROTEIN", 84, 99], ["Figure 4B", "PROTEIN", 102, 111], ["a misaligned catalytic triad", "PROBLEM", 71, 99]]], ["A side-chain rearrangement is required to position either histidine within hydrogen bonding distance to C23 and D156, in order to form a functional proton relay system.", [["histidine", "CHEMICAL", 58, 67], ["histidine", "CHEMICAL", 58, 67], ["hydrogen", "CHEMICAL", 75, 83], ["C23", "CHEMICAL", 104, 107], ["D156", "CHEMICAL", 112, 116], ["histidine", "AMINO_ACID", 58, 67], ["C23", "SIMPLE_CHEMICAL", 104, 107], ["D156", "SIMPLE_CHEMICAL", 112, 116], ["A side-chain rearrangement", "TREATMENT", 0, 26]]], ["Possible scenarios for either rearrangement can be derived from structurally related cysteine proteases.", [["cysteine", "CHEMICAL", 85, 93], ["cysteine proteases", "PROTEIN", 85, 103], ["scenarios", "PROBLEM", 9, 18], ["structurally related cysteine proteases", "PROBLEM", 64, 103]]], ["Figure 4D shows that in superimposed structures of M48 USP and UCH-L3, C23, D156, and H141 correspond to UCH-L3 catalytic triad residues.", [["M48 USP", "GENE_OR_GENE_PRODUCT", 51, 58], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 63, 69], ["C23", "GENE_OR_GENE_PRODUCT", 71, 74], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 105, 111], ["M48 USP", "PROTEIN", 51, 58], ["UCH", "PROTEIN", 63, 66], ["L3", "DNA", 67, 69], ["C23", "DNA", 71, 74], ["D156", "DNA", 76, 80], ["UCH", "PROTEIN", 105, 108], ["Figure 4D", "TEST", 0, 9], ["UCH", "TEST", 63, 66], ["C23", "TEST", 71, 74], ["D156", "TEST", 76, 80], ["UCH", "TEST", 105, 108], ["L3", "ANATOMY", 67, 69], ["L3", "ANATOMY", 109, 111]]], ["Therefore, to form a functional catalytic triad, the M48 USP H141 side chain may adopt a rotamer conformation observed for the corresponding UCH-L3 histidine, as is observed in the vast majority of cysteine proteases.", [["histidine", "CHEMICAL", 148, 157], ["histidine", "CHEMICAL", 148, 157], ["cysteine", "CHEMICAL", 198, 206], ["UCH-L3 histidine", "GENE_OR_GENE_PRODUCT", 141, 157], ["M48 USP H141 side chain", "PROTEIN", 53, 76], ["UCH", "PROTEIN", 141, 144], ["cysteine proteases", "PROTEIN", 198, 216], ["a rotamer conformation", "TREATMENT", 87, 109], ["L3", "ANATOMY", 145, 147]]], ["On the other hand, the conserved M48 USP H158 could instead participate in catalysis after adopting a conformation that corresponds to the unusual histidine alignment found in the catalytic triad of the structurally related human cysteine protease Atg4B ( Figure 4E ).Molecular CellTo address which histidine serves as catalytic base, we exchanged either or both histidine residues to alanine by site-directed mutagenesis.", [["histidine", "CHEMICAL", 147, 156], ["histidine", "CHEMICAL", 299, 308], ["histidine", "CHEMICAL", 363, 372], ["alanine", "CHEMICAL", 385, 392], ["histidine", "CHEMICAL", 147, 156], ["cysteine", "CHEMICAL", 230, 238], ["histidine", "CHEMICAL", 299, 308], ["histidine", "CHEMICAL", 363, 372], ["alanine", "CHEMICAL", 385, 392], ["human", "ORGANISM", 224, 229], ["cysteine protease Atg4B ( Figure 4E", "GENE_OR_GENE_PRODUCT", 230, 265], ["histidine", "AMINO_ACID", 299, 308], ["alanine", "AMINO_ACID", 385, 392], ["M48 USP H158", "DNA", 33, 45], ["catalytic triad", "PROTEIN", 180, 195], ["human cysteine protease", "PROTEIN", 224, 247], ["Atg4B", "PROTEIN", 248, 253], ["Figure 4E", "PROTEIN", 256, 265], ["human", "SPECIES", 224, 229], ["human", "SPECIES", 224, 229], ["the unusual histidine alignment", "PROBLEM", 135, 166], ["human cysteine protease", "TREATMENT", 224, 247], ["both histidine residues", "TREATMENT", 358, 381]]], ["Enzymatic activity was assessed by measuring the hydrolysis of UbAMC.", [["UbAMC", "SIMPLE_CHEMICAL", 63, 68], ["Enzymatic activity", "PROBLEM", 0, 18], ["activity", "OBSERVATION_MODIFIER", 10, 18]]], ["Both sin-gle substitutions remained enzymatically active, with a 3.5-fold and a 146-fold reduction of hydrolytic activity compared to WT enzyme for the H141A and H158A mutants, respectively ( Figure 5A ).", [["WT enzyme", "PROTEIN", 134, 143], ["a 146-fold reduction", "TREATMENT", 78, 98], ["hydrolytic activity", "PROBLEM", 102, 121], ["WT enzyme", "TEST", 134, 143], ["the H141A", "TEST", 148, 157], ["enzymatically", "OBSERVATION_MODIFIER", 36, 49], ["active", "OBSERVATION_MODIFIER", 50, 56], ["hydrolytic activity", "OBSERVATION", 102, 121]]], ["In contrast, the doublemutant protein (H141A/H158A) completely lacked catalytic activity ( Figure 5A ).", [["doublemutant", "GENE_OR_GENE_PRODUCT", 17, 29], ["doublemutant protein", "PROTEIN", 17, 37], ["H141A", "PROTEIN", 39, 44], ["H158A", "PROTEIN", 45, 50], ["the doublemutant protein", "TEST", 13, 37]]], ["However, activity was partially restored in a concentration-dependent manner upon addition of imidazole (data not shown).", [["imidazole", "CHEMICAL", 94, 103], ["imidazole", "CHEMICAL", 94, 103], ["imidazole", "SIMPLE_CHEMICAL", 94, 103], ["imidazole", "TREATMENT", 94, 103]]], ["We conclude that H158 is the principal catalytic histidine as judged by the more pronounced reduction of catalytic activity of the H158A mutant, consistent with H158 being conserved throughout the htUSPs.", [["H158", "CHEMICAL", 17, 21], ["histidine", "CHEMICAL", 49, 58], ["histidine", "CHEMICAL", 49, 58], ["H158", "GENE_OR_GENE_PRODUCT", 17, 21], ["histidine", "AMINO_ACID", 49, 58], ["H158A", "GENE_OR_GENE_PRODUCT", 131, 136], ["H158", "GENE_OR_GENE_PRODUCT", 161, 165], ["htUSPs", "GENE_OR_GENE_PRODUCT", 197, 203], ["H158A mutant", "PROTEIN", 131, 143], ["H158", "PROTEIN", 161, 165], ["htUSPs", "PROTEIN", 197, 203], ["the principal catalytic histidine", "TREATMENT", 25, 58], ["catalytic activity", "OBSERVATION", 105, 123]]], ["Nevertheless, the residual activity of H158A is still substantial at saturating substrate concentrations (k cat = 1.38/min, Figure 5B ).", [["the residual activity of H158A", "PROBLEM", 14, 44], ["k cat", "TEST", 106, 111], ["residual", "OBSERVATION_MODIFIER", 18, 26], ["activity", "OBSERVATION_MODIFIER", 27, 35]]], ["To confirm that the residual catalytic activity observed for H158A indeed involves H141, we mutated H141 to glycine or tyrosine, the corresponding residues in HSV-1 and EBV, respectively ( Figure 4A ), or to glutamine-a conservative replacement-into a H158A background ( Figure 5A ).", [["glycine", "CHEMICAL", 108, 115], ["tyrosine", "CHEMICAL", 119, 127], ["glutamine", "CHEMICAL", 208, 217], ["glycine", "CHEMICAL", 108, 115], ["tyrosine", "CHEMICAL", 119, 127], ["glutamine", "CHEMICAL", 208, 217], ["glycine", "AMINO_ACID", 108, 115], ["tyrosine", "AMINO_ACID", 119, 127], ["HSV-1", "ORGANISM", 159, 164], ["EBV", "ORGANISM", 169, 172], ["glutamine", "AMINO_ACID", 208, 217], ["H158A", "PROTEIN", 61, 66], ["H141", "PROTEIN", 83, 87], ["HSV-1", "SPECIES", 159, 164], ["the residual catalytic activity", "PROBLEM", 16, 47], ["glycine", "TREATMENT", 108, 115], ["tyrosine", "TREATMENT", 119, 127], ["HSV", "TEST", 159, 162], ["EBV", "TEST", 169, 172], ["glutamine", "TREATMENT", 208, 217], ["a conservative replacement", "TREATMENT", 218, 244]]], ["All three double mutants were catalytically inactive, even when tested at 50-fold-higher enzyme and saturating substrate concentrations ( Figure 5B ).", [["saturating substrate concentrations", "PROBLEM", 100, 135]]], ["Therefore, neither glycine, tyrosine, nor glutamine can replace H141 when H158 is changed to alanine.", [["glycine", "CHEMICAL", 19, 26], ["tyrosine", "CHEMICAL", 28, 36], ["glutamine", "CHEMICAL", 42, 51], ["H158", "CHEMICAL", 74, 78], ["alanine", "CHEMICAL", 93, 100], ["glycine", "CHEMICAL", 19, 26], ["tyrosine", "CHEMICAL", 28, 36], ["glutamine", "CHEMICAL", 42, 51], ["alanine", "CHEMICAL", 93, 100], ["glycine", "SIMPLE_CHEMICAL", 19, 26], ["tyrosine", "AMINO_ACID", 28, 36], ["glutamine", "AMINO_ACID", 42, 51], ["alanine", "AMINO_ACID", 93, 100], ["neither glycine", "TREATMENT", 11, 26], ["tyrosine", "TREATMENT", 28, 36], ["glutamine", "TREATMENT", 42, 51], ["alanine", "TREATMENT", 93, 100]]], ["Because the H141Q and H141Y single mutants had 58% and 68% of WT activity, respectively Figure 5A ), the inactivity of the double mutants is unlikely to result from structural distortions, albeit we cannot formally exclude this possibility.Molecular CellIn summary, our structural and mutagenesis data suggest that the conserved H158 is the principal catalytic histidine, whereas H141, only present in M48 USP and not in the other herpesvirus homologs, might participate in catalysis when H158 is absent.", [["histidine", "CHEMICAL", 361, 370], ["histidine", "CHEMICAL", 361, 370], ["H158", "GENE_OR_GENE_PRODUCT", 329, 333], ["histidine", "AMINO_ACID", 361, 370], ["H141", "AMINO_ACID", 380, 384], ["M48 USP", "GENE_OR_GENE_PRODUCT", 402, 409], ["herpesvirus", "ORGANISM", 431, 442], ["double mutants", "PROTEIN", 123, 137], ["H158", "DNA", 329, 333], ["H141", "PROTEIN", 380, 384], ["M48 USP", "PROTEIN", 402, 409], ["herpesvirus homologs", "PROTEIN", 431, 451], ["H158", "PROTEIN", 489, 493], ["WT activity", "TEST", 62, 73], ["the double mutants", "PROBLEM", 119, 137], ["structural distortions", "PROBLEM", 165, 187], ["mutagenesis data", "TEST", 285, 301], ["structural distortions", "OBSERVATION", 165, 187], ["cannot formally exclude this possibility", "UNCERTAINTY", 199, 239], ["absent", "OBSERVATION", 497, 503]]], ["Interestingly, the principal catalytic triad histidine, H158, is located on a secondary structure element different from that in most cysteine proteases, whereas H141 is located on a position homologous to the catalytic triad histidine in papain ( Figure 6 ).", [["histidine", "CHEMICAL", 45, 54], ["H158", "CHEMICAL", 56, 60], ["H141", "CHEMICAL", 162, 166], ["histidine", "CHEMICAL", 226, 235], ["histidine", "CHEMICAL", 45, 54], ["cysteine", "CHEMICAL", 134, 142], ["histidine", "CHEMICAL", 226, 235], ["histidine", "AMINO_ACID", 45, 54], ["H158", "AMINO_ACID", 56, 60], ["histidine", "AMINO_ACID", 226, 235], ["papain", "AMINO_ACID", 239, 245], ["H158", "PROTEIN", 56, 60], ["cysteine proteases", "PROTEIN", 134, 152], ["H141", "PROTEIN", 162, 166], ["catalytic triad histidine", "PROTEIN", 210, 235], ["papain", "PROTEIN", 239, 245], ["a secondary structure element", "PROBLEM", 76, 105], ["secondary structure", "OBSERVATION", 78, 97], ["element", "OBSERVATION_MODIFIER", 98, 105], ["different", "OBSERVATION_MODIFIER", 106, 115], ["most cysteine", "OBSERVATION_MODIFIER", 129, 142]]], ["The presence of two histidines in the M48 USP active site suggests how the location within the tertiary structure of catalytic triad residues might change while the original fold of an enzyme is retained, providing a rationale for the catalytic-site diversity observed in cysteine proteases.Ub Specificity and Ubl DiscriminationA number of DUBs display promiscuity, targeting not only Ub but also some Ub-like modifiers (Ubls).", [["histidines", "CHEMICAL", 20, 30], ["cysteine", "CHEMICAL", 272, 280], ["cysteine proteases", "GENE_OR_GENE_PRODUCT", 272, 290], ["Ub", "GENE_OR_GENE_PRODUCT", 291, 293], ["DUBs", "GENE_OR_GENE_PRODUCT", 340, 344], ["Ub", "GENE_OR_GENE_PRODUCT", 385, 387], ["Ub", "GENE_OR_GENE_PRODUCT", 402, 404], ["Ubls", "GENE_OR_GENE_PRODUCT", 421, 425], ["M48 USP active site", "PROTEIN", 38, 57], ["catalytic triad residues", "PROTEIN", 117, 141], ["enzyme", "PROTEIN", 185, 191], ["cysteine proteases", "PROTEIN", 272, 290], ["Ub", "PROTEIN", 291, 293], ["DUBs", "PROTEIN", 340, 344], ["Ub", "PROTEIN", 385, 387], ["Ub", "PROTEIN", 402, 404], ["Ubls", "PROTEIN", 421, 425], ["two histidines", "TREATMENT", 16, 30], ["catalytic triad residues", "PROBLEM", 117, 141], ["an enzyme", "TEST", 182, 191], ["the catalytic-site diversity", "TREATMENT", 231, 259], ["cysteine proteases", "TREATMENT", 272, 290], ["histidines", "OBSERVATION_MODIFIER", 20, 30], ["catalytic triad", "OBSERVATION", 117, 132], ["cysteine proteases", "OBSERVATION", 272, 290]]], ["For example, USP21 and UCH-L3 can cleave Ub and NEDD8 (Gong et al., 2000; Misaghi et al., 2005; Wada et al., 1998) , whereas USP14 is bispecific for Ub and ISG15 (Hemelaar et al., 2004) .", [["USP21", "GENE_OR_GENE_PRODUCT", 13, 18], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 23, 29], ["Ub", "GENE_OR_GENE_PRODUCT", 41, 43], ["NEDD8", "GENE_OR_GENE_PRODUCT", 48, 53], ["USP14", "GENE_OR_GENE_PRODUCT", 125, 130], ["Ub", "GENE_OR_GENE_PRODUCT", 149, 151], ["ISG15", "GENE_OR_GENE_PRODUCT", 156, 161], ["USP21", "PROTEIN", 13, 18], ["UCH", "PROTEIN", 23, 26], ["L3", "PROTEIN", 27, 29], ["Ub", "PROTEIN", 41, 43], ["NEDD8", "PROTEIN", 48, 53], ["USP14", "PROTEIN", 125, 130], ["Ub", "PROTEIN", 149, 151], ["ISG15", "PROTEIN", 156, 161], ["USP21", "TEST", 13, 18], ["L3", "ANATOMY", 27, 29]]], ["In contrast, M48 USP and its relatives in the herpesvirus family are highly specific for Ub, because NEDD8-, SUMO-, and ISG15-based suicide inhibitors fail to inhibit enzymatic activity, even when present in a 100-fold molar excess over the respective enzyme What is the structural basis for the observed specificity?", [["M48 USP", "GENE_OR_GENE_PRODUCT", 13, 20], ["herpesvirus", "ORGANISM", 46, 57], ["Ub", "GENE_OR_GENE_PRODUCT", 89, 91], ["NEDD8", "GENE_OR_GENE_PRODUCT", 101, 106], ["SUMO", "GENE_OR_GENE_PRODUCT", 109, 113], ["ISG15", "GENE_OR_GENE_PRODUCT", 120, 125], ["M48 USP", "PROTEIN", 13, 20], ["Ub", "PROTEIN", 89, 91], ["NEDD8", "PROTEIN", 101, 106], ["SUMO", "PROTEIN", 109, 113], ["ISG15", "PROTEIN", 120, 125], ["NEDD8", "TEST", 101, 106], ["SUMO", "TEST", 109, 113], ["ISG15-based suicide inhibitors", "TREATMENT", 120, 150], ["enzymatic activity", "PROBLEM", 167, 185], ["fold molar excess", "PROBLEM", 214, 231], ["the respective enzyme", "TEST", 237, 258]]], ["In general, DUBs feature a largely acidic catalytic cleft that accommodates the complementary basic C-terminal Ub stretch ( 71 LRLRGG 76 ), implicating the cleft in substrate recognition and specificity (Hu et al., 2002) .", [["C", "CHEMICAL", 100, 101], ["DUBs", "GENE_OR_GENE_PRODUCT", 12, 16], ["DUBs", "PROTEIN", 12, 16], ["complementary basic C-terminal Ub stretch", "PROTEIN", 80, 121], ["a largely acidic catalytic cleft", "PROBLEM", 25, 57], ["the cleft in substrate recognition", "PROBLEM", 152, 186], ["acidic", "OBSERVATION_MODIFIER", 35, 41], ["catalytic cleft", "OBSERVATION", 42, 57], ["terminal", "ANATOMY_MODIFIER", 102, 110], ["Ub", "ANATOMY_MODIFIER", 111, 113]]], ["For instance, the C-terminal sequence of SUMO ( 72 QEQTGG 76 ) is clearly different and of opposite charge compared to the Ub C terminus, and consequently, SUMO cannot bind to M48 USP .", [["C", "CHEMICAL", 18, 19], ["C", "CHEMICAL", 126, 127], ["SUMO", "GENE_OR_GENE_PRODUCT", 41, 45], ["SUMO", "GENE_OR_GENE_PRODUCT", 156, 160], ["M48 USP", "GENE_OR_GENE_PRODUCT", 176, 183], ["C-terminal sequence", "PROTEIN", 18, 37], ["SUMO", "PROTEIN", 41, 45], ["72 QEQTGG 76", "PROTEIN", 48, 60], ["Ub C terminus", "PROTEIN", 123, 136], ["SUMO", "PROTEIN", 156, 160], ["M48 USP", "PROTEIN", 176, 183], ["the C-terminal sequence of SUMO", "TEST", 14, 45], ["opposite charge", "PROBLEM", 91, 106]]], ["Other Ubls, however, terminate in a sequence similar or identical to Ub ( Figure S1B ).", [["Ubls", "GENE_OR_GENE_PRODUCT", 6, 10], ["Ub", "GENE_OR_GENE_PRODUCT", 69, 71], ["Figure S1B", "GENE_OR_GENE_PRODUCT", 74, 84], ["Ubls", "PROTEIN", 6, 10], ["Ub", "PROTEIN", 69, 71], ["Figure S1B", "PROTEIN", 74, 84]]], ["For example, the ISG15 C-terminal sequence LRLRGG is identical to that of Ub.", [["C", "CHEMICAL", 23, 24], ["ISG15", "GENE_OR_GENE_PRODUCT", 17, 22], ["ISG15 C-terminal sequence", "DNA", 17, 42], ["LRLRGG", "DNA", 43, 49], ["the ISG15 C-terminal sequence LRLRGG", "PROBLEM", 13, 49]]], ["A superposition of the structure of free ISG15 (Narasimhan et al., 2005) on UbVME bound to M48 USP indicates that the ISG15 C terminus would require only minor structural changes to enter the M48 USP active site (data not shown).", [["ISG15", "GENE_OR_GENE_PRODUCT", 41, 46], ["UbVME", "SIMPLE_CHEMICAL", 76, 81], ["M48 USP", "GENE_OR_GENE_PRODUCT", 91, 98], ["ISG15", "GENE_OR_GENE_PRODUCT", 118, 123], ["ISG15", "PROTEIN", 41, 46], ["UbVME", "PROTEIN", 76, 81], ["M48 USP", "PROTEIN", 91, 98], ["ISG15 C terminus", "PROTEIN", 118, 134], ["M48 USP active site", "DNA", 192, 211], ["the ISG15 C terminus", "TREATMENT", 114, 134], ["minor structural changes", "PROBLEM", 154, 178]]], ["However, the M48 USP b hairpin that tightly interacts with the Ub core domain ( Figure 3A ) lacks surface complementarity for the ISG15 core domain (data not shown), suggesting that several unfavorable contacts between the b hairpin of M48 USP and ISG15 mainly account for the discrimination between Ub and ISG15.Ub Specificity and Ubl DiscriminationAs pointed out by Shen and coworkers, free NEDD8 exhibits a different C-terminal conformation compared to free Ub, due to the substitution of R72 for alanine in NEDD8 (Shen et al., 2005) .", [["surface", "ANATOMY", 98, 105], ["alanine", "CHEMICAL", 500, 507], ["C", "CHEMICAL", 420, 421], ["alanine", "CHEMICAL", 500, 507], ["Ub", "GENE_OR_GENE_PRODUCT", 63, 65], ["ISG15", "GENE_OR_GENE_PRODUCT", 130, 135], ["M48 USP", "GENE_OR_GENE_PRODUCT", 236, 243], ["ISG15", "GENE_OR_GENE_PRODUCT", 248, 253], ["Ub", "GENE_OR_GENE_PRODUCT", 300, 302], ["ISG15", "GENE_OR_GENE_PRODUCT", 307, 312], ["Ub", "GENE_OR_GENE_PRODUCT", 313, 315], ["NEDD8", "GENE_OR_GENE_PRODUCT", 393, 398], ["Ub", "GENE_OR_GENE_PRODUCT", 461, 463], ["alanine", "AMINO_ACID", 500, 507], ["NEDD8", "GENE_OR_GENE_PRODUCT", 511, 516], ["M48 USP b hairpin", "DNA", 13, 30], ["Ub core domain", "PROTEIN", 63, 77], ["Figure 3A", "PROTEIN", 80, 89], ["ISG15 core domain", "PROTEIN", 130, 147], ["b hairpin", "PROTEIN", 223, 232], ["M48 USP", "PROTEIN", 236, 243], ["ISG15", "PROTEIN", 248, 253], ["Ub", "PROTEIN", 300, 302], ["ISG15", "PROTEIN", 307, 312], ["Ub", "PROTEIN", 313, 315], ["NEDD8", "PROTEIN", 393, 398], ["C-terminal conformation", "PROTEIN", 420, 443], ["Ub", "PROTEIN", 461, 463], ["NEDD8", "PROTEIN", 511, 516], ["the M48 USP b hairpin", "TREATMENT", 9, 30], ["the ISG15 core domain", "TEST", 126, 147], ["ISG15", "TREATMENT", 248, 253], ["the discrimination between Ub and ISG15", "PROBLEM", 273, 312], ["a different C-terminal conformation", "PROBLEM", 408, 443], ["the substitution of R72", "TREATMENT", 472, 495], ["alanine in NEDD8", "TREATMENT", 500, 516]]], ["This difference was suggested to be crucial for Ub discrimination of the NEDD8-specific protease NEDP1 (Shen et al., 2005) and, by analogy, could also explain why NEDD8 is not a M48 USP substrate.", [["Ub", "GENE_OR_GENE_PRODUCT", 48, 50], ["NEDD8", "GENE_OR_GENE_PRODUCT", 73, 78], ["NEDP1", "GENE_OR_GENE_PRODUCT", 97, 102], ["NEDD8", "GENE_OR_GENE_PRODUCT", 163, 168], ["Ub", "PROTEIN", 48, 50], ["NEDD8", "PROTEIN", 73, 78], ["protease NEDP1", "PROTEIN", 88, 102], ["NEDD8", "PROTEIN", 163, 168], ["M48 USP substrate", "PROTEIN", 178, 195], ["the NEDD8", "TEST", 69, 78]]], ["Interactions between UbVME and M48 USP (A) Stereo view of the extended C terminus and attached VME moiety of Ub in the M48 USP active-site cleft.", [["C", "CHEMICAL", 71, 72], ["VME", "CHEMICAL", 95, 98], ["Ub", "GENE_OR_GENE_PRODUCT", 109, 111], ["C terminus", "PROTEIN", 71, 81], ["VME moiety", "PROTEIN", 95, 105], ["Ub", "PROTEIN", 109, 111], ["M48 USP active-site cleft", "PROTEIN", 119, 144], ["Stereo view", "TEST", 43, 54], ["the extended C terminus", "TREATMENT", 58, 81], ["site cleft", "PROBLEM", 134, 144], ["cleft", "OBSERVATION", 139, 144]]], ["M48 USP and UbVME are in gray and green, respectively.", [["UbVME", "GENE_OR_GENE_PRODUCT", 12, 17], ["M48 USP", "DNA", 0, 7], ["UbVME", "DNA", 12, 17], ["UbVME", "TEST", 12, 17]]], ["Nitrogen atoms are shown in blue, and oxygen atoms in red.Ub Specificity and Ubl DiscriminationDashed lines indicate hydrogen bonds.", [["Nitrogen atoms", "CHEMICAL", 0, 14], ["oxygen", "CHEMICAL", 38, 44], ["Nitrogen", "CHEMICAL", 0, 8], ["oxygen", "CHEMICAL", 38, 44], ["hydrogen", "CHEMICAL", 117, 125], ["Nitrogen atoms", "SIMPLE_CHEMICAL", 0, 14], ["oxygen atoms", "SIMPLE_CHEMICAL", 38, 50], ["Ub", "GENE_OR_GENE_PRODUCT", 58, 60], ["hydrogen bonds", "SIMPLE_CHEMICAL", 117, 131], ["Ub", "PROTEIN", 58, 60], ["Ubl DiscriminationDashed lines", "CELL_LINE", 77, 107], ["Nitrogen atoms", "TREATMENT", 0, 14], ["hydrogen bonds", "PROBLEM", 117, 131], ["blue", "OBSERVATION_MODIFIER", 28, 32], ["oxygen atoms", "OBSERVATION", 38, 50], ["DiscriminationDashed lines", "OBSERVATION", 81, 107], ["hydrogen bonds", "OBSERVATION", 117, 131]]], ["Note that the Ub C terminus features an extended b conformation and is extensively coordinated by several hydrogen bonds to M48 USP residues.", [["C", "CHEMICAL", 17, 18], ["hydrogen", "CHEMICAL", 106, 114], ["M48", "CHEMICAL", 124, 127], ["Ub", "GENE_OR_GENE_PRODUCT", 14, 16], ["Ub C terminus", "PROTEIN", 14, 27]]], ["V140 and Y76 of M48 USP are in van der Waals contact and form a canopy over the active site.", [["M48 USP", "GENE_OR_GENE_PRODUCT", 16, 23], ["V140", "PROTEIN", 0, 4], ["M48 USP", "PROTEIN", 16, 23], ["active site", "OBSERVATION", 80, 91]]], ["(B) Stereo view of the interactions between the Ub core (green) and M48 USP (gray) or its b hairpin (orange).", [["Ub", "GENE_OR_GENE_PRODUCT", 48, 50], ["Ub core", "PROTEIN", 48, 55], ["M48 USP", "PROTEIN", 68, 75]]], ["The gray transparent M48 USP surface highlights the shape complementarity of the interface, which is mainly lined by hydrophobic residues. addition, NEDD8 A72 cannot form the hydrogen bond to M48 USP T80 as observed for Ub R72 ( Figure 3A ).", [["hydrogen", "CHEMICAL", 175, 183], ["NEDD8", "GENE_OR_GENE_PRODUCT", 149, 154], ["NEDD8 A72", "PROTEIN", 149, 158], ["M48 USP T80", "PROTEIN", 192, 203], ["Ub R72", "PROTEIN", 220, 226], ["Figure 3A", "PROTEIN", 229, 238], ["surface", "OBSERVATION_MODIFIER", 29, 36], ["shape", "OBSERVATION_MODIFIER", 52, 57], ["complementarity", "OBSERVATION_MODIFIER", 58, 73], ["interface", "OBSERVATION_MODIFIER", 81, 90], ["hydrophobic residues", "OBSERVATION", 117, 137]]], ["To test whether the NEDD8 A72 indeed determines M48 USP specificity, we generated a NEDD8-based suicide inhibitor (NEDD8-VME) and its mutant derivative (NEDD8 A72R -VME).", [["NEDD8", "GENE_OR_GENE_PRODUCT", 20, 25], ["M48 USP", "GENE_OR_GENE_PRODUCT", 48, 55], ["NEDD8", "GENE_OR_GENE_PRODUCT", 84, 89], ["NEDD8-VME", "GENE_OR_GENE_PRODUCT", 115, 124], ["NEDD8", "GENE_OR_GENE_PRODUCT", 153, 158], ["NEDD8 A72", "PROTEIN", 20, 29], ["M48", "PROTEIN", 48, 51], ["NEDD8", "PROTEIN", 84, 89], ["NEDD8", "PROTEIN", 115, 120], ["VME", "PROTEIN", 121, 124], ["NEDD8 A72R", "PROTEIN", 153, 163], ["VME", "PROTEIN", 165, 168], ["the NEDD8 A72", "TEST", 16, 29], ["a NEDD8-based suicide inhibitor", "TREATMENT", 82, 113], ["NEDD8-VME)", "TREATMENT", 115, 125], ["its mutant derivative (NEDD8 A72R", "TREATMENT", 130, 163]]], ["In agreement with our previous data (Schlieker et al., 2005) , we observed negligible covalent adduct formation of M48 USP with NEDD8-VME.", [["NEDD8", "GENE_OR_GENE_PRODUCT", 128, 133], ["NEDD8", "PROTEIN", 128, 133], ["VME", "PROTEIN", 134, 137], ["covalent adduct", "OBSERVATION", 86, 101]]], ["In contrast, NEDD8 A72R -VME readily reacted with M48 USP to yield a covalent adduct ( Figure S2 ).", [["NEDD8", "GENE_OR_GENE_PRODUCT", 13, 18], ["NEDD8", "PROTEIN", 13, 18], ["A72R", "PROTEIN", 19, 23], ["VME", "PROTEIN", 25, 28], ["M48 USP", "PROTEIN", 50, 57], ["covalent adduct", "OBSERVATION", 69, 84]]], ["This indicates that R72 is a key determinant for M48 USP substrate specificity because the single substitution of A72 by arginine in NEDD8 renders it a M48 USP substrate.Ub Specificity and Ubl DiscriminationTaken together, we propose that M48 USP has a bipartite substrate recognition mechanism: the acidic cleft recognizes the positively charged Ub C-terminal sequence through electrostatic interactions and specific contacts with side chains of the Ub C terminus, whereas the b hairpin serves to further discriminate Ubls that feature the identical C-terminal stretch, as exemplified by ISG15.Ub Specificity and Ubl DiscriminationThe M48 USP Structure Defines a Unique Class of Deubiquitinating Enzymes All deubiquitinating enzymes known to date are either cysteine-or metalloproteases.", [["arginine", "CHEMICAL", 121, 129], ["arginine", "CHEMICAL", 121, 129], ["C", "CHEMICAL", 454, 455], ["C", "CHEMICAL", 551, 552], ["cysteine", "CHEMICAL", 759, 767], ["R72", "GENE_OR_GENE_PRODUCT", 20, 23], ["M48", "GENE_OR_GENE_PRODUCT", 49, 52], ["A72", "AMINO_ACID", 114, 117], ["arginine", "AMINO_ACID", 121, 129], ["NEDD8", "GENE_OR_GENE_PRODUCT", 133, 138], ["Ub", "GENE_OR_GENE_PRODUCT", 170, 172], ["M48 USP", "GENE_OR_GENE_PRODUCT", 239, 246], ["Ubls", "GENE_OR_GENE_PRODUCT", 519, 523], ["ISG15", "GENE_OR_GENE_PRODUCT", 589, 594], ["Ub", "GENE_OR_GENE_PRODUCT", 595, 597], ["cysteine", "AMINO_ACID", 759, 767], ["R72", "PROTEIN", 20, 23], ["NEDD8", "PROTEIN", 133, 138], ["M48 USP substrate", "PROTEIN", 152, 169], ["M48 USP", "PROTEIN", 239, 246], ["Ub C-terminal sequence", "PROTEIN", 347, 369], ["side chains", "PROTEIN", 432, 443], ["Ub C terminus", "PROTEIN", 451, 464], ["b hairpin", "PROTEIN", 478, 487], ["Ubls", "PROTEIN", 519, 523], ["ISG15", "PROTEIN", 589, 594], ["Unique Class of Deubiquitinating Enzymes", "PROTEIN", 664, 704], ["deubiquitinating enzymes", "PROTEIN", 709, 733], ["metalloproteases", "PROTEIN", 771, 787], ["the acidic cleft", "PROBLEM", 296, 312], ["electrostatic interactions", "PROBLEM", 378, 404], ["the b hairpin serves", "TREATMENT", 474, 494], ["Deubiquitinating Enzymes", "TEST", 680, 704], ["All deubiquitinating enzymes", "TEST", 705, 733], ["cysteine", "PROBLEM", 759, 767], ["metalloproteases", "PROBLEM", 771, 787], ["terminal stretch", "OBSERVATION", 553, 569]]], ["Cysteine protease DUBs can be divided into four classes: Ub C-terminal hydrolases (UCHs), Ub-specific proteases (USPs), ovarian tumor proteases (OTUs), and Machado-Joseph disease protein domain proteases (MJDs).", [["Cysteine", "CHEMICAL", 0, 8], ["ovarian tumor", "DISEASE", 120, 133], ["Cysteine", "CHEMICAL", 0, 8], ["Cysteine protease DUBs", "GENE_OR_GENE_PRODUCT", 0, 22], ["Ub C-terminal hydrolases", "GENE_OR_GENE_PRODUCT", 57, 81], ["UCHs", "GENE_OR_GENE_PRODUCT", 83, 87], ["Ub-specific proteases", "GENE_OR_GENE_PRODUCT", 90, 111], ["USPs", "GENE_OR_GENE_PRODUCT", 113, 117], ["ovarian tumor proteases", "GENE_OR_GENE_PRODUCT", 120, 143], ["DUBs", "PROTEIN", 18, 22], ["Ub C-terminal hydrolases", "PROTEIN", 57, 81], ["UCHs", "PROTEIN", 83, 87], ["Ub", "PROTEIN", 90, 92], ["specific proteases", "PROTEIN", 93, 111], ["USPs", "PROTEIN", 113, 117], ["ovarian tumor proteases", "PROTEIN", 120, 143], ["OTUs", "PROTEIN", 145, 149], ["Machado-Joseph disease protein domain proteases", "PROTEIN", 156, 203], ["MJDs", "PROTEIN", 205, 209], ["Cysteine protease DUBs", "TREATMENT", 0, 22], ["Ub C-terminal hydrolases (UCHs", "TEST", 57, 87], ["Ub", "TEST", 90, 92], ["USPs", "TEST", 113, 117], ["ovarian tumor proteases", "PROBLEM", 120, 143], ["Machado", "TEST", 156, 163], ["Joseph disease protein domain proteases", "PROBLEM", 164, 203], ["ovarian", "ANATOMY", 120, 127], ["tumor", "OBSERVATION", 128, 133]]], ["According to current estimates, the human genome encodes 4 UCHs, 58 USPs, 14 OTUs, and 5 MJDs (Nijman et al., 2005) .Ub Specificity and Ubl DiscriminationHow does the M48 USP structure compare to other protease structures and to which DUB class does M48 USP belong?", [["human", "ORGANISM", 36, 41], ["UCHs", "GENE_OR_GENE_PRODUCT", 59, 63], ["DUB", "GENE_OR_GENE_PRODUCT", 235, 238], ["M48 USP", "GENE_OR_GENE_PRODUCT", 250, 257], ["human genome", "DNA", 36, 48], ["M48 USP structure", "PROTEIN", 167, 184], ["protease structures", "PROTEIN", 202, 221], ["DUB class", "PROTEIN", 235, 244], ["M48 USP", "PROTEIN", 250, 257], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["UCHs", "TEST", 59, 63], ["USPs", "TEST", 68, 72], ["OTUs", "TEST", 77, 81], ["Specificity", "TEST", 120, 131]]], ["A structural similarity search using the DALI algorithm (Holm and Sander, 1993) showed that $140 aa in the catalytic core of M48 USP share moderate structural similarity to papain-like cysteine proteases (best Z score, 7.1) and only weak similarities to DUBs like USP6 from S. cerevisiae (1vjv; Z score, 4.2) and human UCH-L3 (1uch; Z score, 2.2) (Table S1 ).", [["cysteine", "CHEMICAL", 185, 193], ["papain", "GENE_OR_GENE_PRODUCT", 173, 179], ["DUBs", "GENE_OR_GENE_PRODUCT", 254, 258], ["USP6", "GENE_OR_GENE_PRODUCT", 264, 268], ["S. cerevisiae", "ORGANISM", 274, 287], ["human", "ORGANISM", 313, 318], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 319, 325], ["M48 USP", "PROTEIN", 125, 132], ["papain", "PROTEIN", 173, 179], ["cysteine proteases", "PROTEIN", 185, 203], ["DUBs", "PROTEIN", 254, 258], ["USP6", "PROTEIN", 264, 268], ["human UCH", "PROTEIN", 313, 322], ["S. cerevisiae", "SPECIES", 274, 287], ["human", "SPECIES", 313, 318], ["S. cerevisiae", "SPECIES", 274, 287], ["human UCH-L3", "SPECIES", 313, 325], ["moderate structural similarity to papain", "PROBLEM", 139, 179], ["cysteine proteases", "PROBLEM", 185, 203], ["best Z score", "TEST", 205, 217], ["DUBs", "TEST", 254, 258], ["S. cerevisiae", "TEST", 274, 287], ["Z score", "TEST", 295, 302], ["human UCH", "TEST", 313, 322], ["1uch", "TEST", 327, 331], ["Z score", "TEST", 333, 340], ["moderate", "OBSERVATION_MODIFIER", 139, 147], ["L3", "ANATOMY", 323, 325]]], ["For comparison, UCH-L3/ UCH-L1 and USP2/HAUSP pairwise comparisons yield Z scores of 33 and 27, respectively, whereas a pairwise comparison of two classes, e.g., UCH-L1/HAUSP as representatives from UCH and USP families, yields scores of $4.", [["UCH-L3", "GENE_OR_GENE_PRODUCT", 16, 22], ["UCH-L1", "GENE_OR_GENE_PRODUCT", 24, 30], ["USP2", "GENE_OR_GENE_PRODUCT", 35, 39], ["UCH", "DNA", 16, 19], ["L3", "DNA", 20, 22], ["UCH", "DNA", 24, 27], ["L1", "DNA", 28, 30], ["USP2", "DNA", 35, 39], ["HAUSP", "DNA", 40, 45], ["L1", "DNA", 166, 168], ["HAUSP", "DNA", 169, 174], ["UCH", "TEST", 16, 19], ["USP2", "TEST", 35, 39], ["Z scores", "TEST", 73, 81], ["L3", "ANATOMY", 20, 22], ["L1", "ANATOMY", 28, 30], ["L1", "ANATOMY", 166, 168]]], ["We conclude that M48 USP is a member of the papain protease superfamily but is only distantly related to cellular DUBs of known structure.", [["cellular", "ANATOMY", 105, 113], ["M48 USP", "GENE_OR_GENE_PRODUCT", 17, 24], ["papain", "GENE_OR_GENE_PRODUCT", 44, 50], ["cellular", "CELL", 105, 113], ["M48 USP", "PROTEIN", 17, 24], ["papain protease superfamily", "PROTEIN", 44, 71], ["cellular DUBs", "PROTEIN", 105, 118], ["the papain protease superfamily", "TREATMENT", 40, 71], ["cellular DUBs", "OBSERVATION", 105, 118]]], ["Structural database searches (DALI) or manual superimposition of active-site residues of M48 USP and members of the OTU and MJD families did not detect any structural relationships (Table S1 and data not shown). , and BPLF1 (EBV).", [["M48 USP", "GENE_OR_GENE_PRODUCT", 89, 96], ["BPLF1", "GENE_OR_GENE_PRODUCT", 218, 223], ["EBV", "ORGANISM", 225, 228], ["M48 USP", "PROTEIN", 89, 96], ["BPLF1", "PROTEIN", 218, 223], ["active", "OBSERVATION_MODIFIER", 65, 71]]], ["Conserved residues are boxed, and conserved catalytic triad residues (C23, D156, and H158) and Q10 of the oxyanion hole residues are indicated and shown in (B) as yellow sticks.", [["Q10", "CHEMICAL", 95, 98], ["Q10", "CHEMICAL", 95, 98], ["H158", "PROTEIN", 85, 89], ["Q10", "PROTEIN", 95, 98], ["Conserved residues", "PROBLEM", 0, 18], ["boxed", "PROBLEM", 23, 28], ["conserved catalytic triad residues", "PROBLEM", 34, 68], ["C23", "TEST", 70, 73], ["D156", "TEST", 75, 79], ["the oxyanion hole residues", "TREATMENT", 102, 128]]], ["Furthermore, H141, which is not conserved but might participate in catalysis, is also shown.", [["H141", "CHEMICAL", 13, 17], ["H141", "PROTEIN", 13, 17]]], ["The covalently bound UbVME is represented by green sticks.", [["UbVME", "SIMPLE_CHEMICAL", 21, 26], ["UbVME", "PROTEIN", 21, 26], ["The covalently bound UbVME", "PROBLEM", 0, 26], ["bound UbVME", "OBSERVATION", 15, 26], ["green sticks", "OBSERVATION", 45, 57]]], ["Note that the catalytic triad is misaligned because both histidines are >5 \u00c5 from C23.", [["histidines", "CHEMICAL", 57, 67], ["catalytic triad", "PROTEIN", 14, 29], ["C23", "PROTEIN", 82, 85]]], ["(C) The proposed oxyanion hole is occupied by the hydrogen atom of the b carbon atom of the former vinylmethylester moiety, thus resembling a catalytic intermediate except that the oxyanion is replaced by a hydrogen.", [["oxyanion", "CHEMICAL", 17, 25], ["vinylmethylester", "CHEMICAL", 99, 115], ["hydrogen", "CHEMICAL", 207, 215], ["hydrogen", "CHEMICAL", 50, 58], ["carbon", "CHEMICAL", 73, 79], ["vinylmethylester", "CHEMICAL", 99, 115], ["hydrogen", "CHEMICAL", 207, 215], ["b carbon atom", "SIMPLE_CHEMICAL", 71, 84], ["vinylmethylester moiety", "SIMPLE_CHEMICAL", 99, 122], ["hydrogen", "SIMPLE_CHEMICAL", 207, 215], ["The proposed oxyanion hole", "TREATMENT", 4, 30], ["the oxyanion", "TREATMENT", 177, 189], ["oxyanion hole", "OBSERVATION", 17, 30], ["hydrogen atom", "OBSERVATION", 50, 63]]], ["The Q10 side chain and NH groups of C23 and Q22 are <4 \u00c5 from this hydrogen atom and are thus likely to coordinate the oxyanion during catalysis.", [["Q10", "CHEMICAL", 4, 7], ["NH", "CHEMICAL", 23, 25], ["C23", "CHEMICAL", 36, 39], ["Q10", "CHEMICAL", 4, 7], ["NH", "CHEMICAL", 23, 25], ["C23", "CHEMICAL", 36, 39], ["Q22", "CHEMICAL", 44, 47], ["hydrogen", "CHEMICAL", 67, 75], ["C23", "SIMPLE_CHEMICAL", 36, 39], ["Q22", "SIMPLE_CHEMICAL", 44, 47], ["hydrogen atom", "SIMPLE_CHEMICAL", 67, 80], ["The Q10 side chain", "TREATMENT", 0, 18], ["NH groups of C23", "TREATMENT", 23, 39], ["the oxyanion during catalysis", "TREATMENT", 115, 144]]], ["(D) Superposition of the active sites of M48 USP (yellow) and UCH-L3 (pink).", [["M48 USP", "GENE_OR_GENE_PRODUCT", 41, 48], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 62, 68], ["M48 USP", "PROTEIN", 41, 48], ["UCH", "PROTEIN", 62, 65], ["L3", "PROTEIN", 66, 68], ["M48 USP", "TEST", 41, 48], ["active", "OBSERVATION_MODIFIER", 25, 31], ["L3", "ANATOMY", 66, 68]]], ["H141 corresponds to the location of the UCH-L3 catalytic histidine, and a conformational change of H141 may result in a similar functional catalytic triad alignment as observed for UCH-L3.", [["histidine", "CHEMICAL", 57, 66], ["histidine", "CHEMICAL", 57, 66], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 40, 46], ["histidine", "AMINO_ACID", 57, 66], ["H141", "AMINO_ACID", 99, 103], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 181, 187], ["H141", "PROTEIN", 0, 4], ["UCH", "PROTEIN", 40, 43], ["H141", "PROTEIN", 99, 103], ["UCH", "PROTEIN", 181, 184], ["the UCH-L3 catalytic histidine", "TREATMENT", 36, 66], ["a conformational change of H141", "PROBLEM", 72, 103], ["a similar functional catalytic triad alignment", "PROBLEM", 118, 164], ["L3", "ANATOMY", 44, 46], ["catalytic triad alignment", "OBSERVATION", 139, 164], ["L3", "ANATOMY", 185, 187]]], ["(E) Superposition of catalytic triad residues of M48 USP (yellow) and human Atg4B (salmon), the only known cysteine protease structure that features a catalytic triad arrangement that aligns its catalytic histidine with M48 USP H158.", [["histidine", "CHEMICAL", 205, 214], ["cysteine", "CHEMICAL", 107, 115], ["histidine", "CHEMICAL", 205, 214], ["M48 USP", "GENE_OR_GENE_PRODUCT", 49, 56], ["human", "ORGANISM", 70, 75], ["Atg4B", "GENE_OR_GENE_PRODUCT", 76, 81], ["catalytic triad residues", "PROTEIN", 21, 45], ["M48 USP", "PROTEIN", 49, 56], ["human Atg4B", "PROTEIN", 70, 81], ["cysteine protease structure", "PROTEIN", 107, 134], ["M48 USP H158", "PROTEIN", 220, 232], ["human", "SPECIES", 70, 75], ["human Atg4B (salmon", "SPECIES", 70, 89], ["human Atg4B (salmon)", "TREATMENT", 70, 90], ["known cysteine protease structure", "PROBLEM", 101, 134], ["a catalytic triad arrangement", "PROBLEM", 149, 178]]], ["A different rotamer conformation for M48 USP H158 may therefore yield an aligned catalytic triad.Ub Specificity and Ubl DiscriminationTo investigate the structural relationship of M48 USP to UCHs and USPs in detail, we compared the topology of M48 USP to the closest structural relatives in these families: UCH-L3 and HAUSP ( Figure 6 and Table S1 ).", [["Ub", "GENE_OR_GENE_PRODUCT", 97, 99], ["M48 USP", "GENE_OR_GENE_PRODUCT", 180, 187], ["UCHs", "GENE_OR_GENE_PRODUCT", 191, 195], ["M48 USP", "GENE_OR_GENE_PRODUCT", 244, 251], ["UCH-L3", "CELL", 307, 313], ["Ub", "PROTEIN", 97, 99], ["M48 USP", "PROTEIN", 180, 187], ["UCHs", "PROTEIN", 191, 195], ["USPs", "PROTEIN", 200, 204], ["M48 USP", "PROTEIN", 244, 251], ["UCH", "PROTEIN", 307, 310], ["HAUSP", "DNA", 318, 323], ["an aligned catalytic triad", "PROBLEM", 70, 96], ["HAUSP", "PROBLEM", 318, 323], ["L3", "ANATOMY", 311, 313]]], ["All three en-zymes share secondary structure elements of the papain fold.", [["papain", "GENE_OR_GENE_PRODUCT", 61, 67], ["papain fold", "PROTEIN", 61, 72], ["the papain fold", "PROBLEM", 57, 72], ["secondary structure elements", "OBSERVATION", 25, 53], ["papain fold", "OBSERVATION", 61, 72]]], ["Besides the different Ub binding mode of M48 USP compared to UCHs and USPs (see above), several topology differences between these DUB representatives The topographies (top) and ribbon diagrams (bottom) of M48 USP and representatives of the USP (HAUSP) and UCH family (UCH-L3) of DUBs, and papain, are shown.", [["Ub", "GENE_OR_GENE_PRODUCT", 22, 24], ["M48 USP", "GENE_OR_GENE_PRODUCT", 41, 48], ["DUB", "GENE_OR_GENE_PRODUCT", 131, 134], ["M48 USP", "GENE_OR_GENE_PRODUCT", 206, 213], ["USP", "GENE_OR_GENE_PRODUCT", 241, 244], ["HAUSP", "GENE_OR_GENE_PRODUCT", 246, 251], ["UCH", "GENE_OR_GENE_PRODUCT", 257, 260], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 269, 275], ["DUBs", "GENE_OR_GENE_PRODUCT", 280, 284], ["papain", "GENE_OR_GENE_PRODUCT", 290, 296], ["Ub", "PROTEIN", 22, 24], ["M48 USP", "PROTEIN", 41, 48], ["UCHs", "PROTEIN", 61, 65], ["USPs", "PROTEIN", 70, 74], ["DUB", "PROTEIN", 131, 134], ["M48 USP", "PROTEIN", 206, 213], ["USP", "PROTEIN", 241, 244], ["HAUSP", "PROTEIN", 246, 251], ["UCH family", "PROTEIN", 257, 267], ["UCH", "PROTEIN", 269, 272], ["L3", "PROTEIN", 273, 275], ["DUBs", "PROTEIN", 280, 284], ["papain", "PROTEIN", 290, 296], ["UCHs", "TEST", 61, 65], ["USPs", "TEST", 70, 74], ["The topographies (top) and ribbon diagrams", "TEST", 151, 193], ["the USP (HAUSP", "TEST", 237, 251], ["DUBs", "TEST", 280, 284], ["papain", "TREATMENT", 290, 296], ["L3", "ANATOMY", 273, 275], ["DUBs", "ANATOMY", 280, 284]]], ["Circles and triangles represent a helices and b sheets, respectively.", [["a helices and b sheets", "TREATMENT", 32, 54], ["triangles", "OBSERVATION_MODIFIER", 12, 21]]], ["In the topology diagram of M48 USP , secondary structure elements are numbered sequentially according to Figure 2A .", [["M48 USP", "GENE_OR_GENE_PRODUCT", 27, 34], ["M48 USP", "DNA", 27, 34], ["secondary structure elements", "DNA", 37, 65], ["secondary structure elements", "PROBLEM", 37, 65], ["secondary", "OBSERVATION", 37, 46], ["structure elements", "OBSERVATION", 47, 65]]], ["Secondary structure elements conserved within the cysteine protease superfamily, exemplified by papain, are shown in blue.", [["cysteine", "CHEMICAL", 50, 58], ["papain", "GENE_OR_GENE_PRODUCT", 96, 102], ["cysteine protease superfamily", "PROTEIN", 50, 79], ["papain", "PROTEIN", 96, 102], ["Secondary structure elements", "PROBLEM", 0, 28], ["the cysteine protease superfamily", "TREATMENT", 46, 79], ["structure elements", "OBSERVATION", 10, 28]]], ["The exposed b hairpin of M48 USP and the finger domain of HAUSP are orange; both interact with the Ub core.", [["M48 USP", "GENE_OR_GENE_PRODUCT", 25, 32], ["HAUSP", "GENE_OR_GENE_PRODUCT", 58, 63], ["Ub", "GENE_OR_GENE_PRODUCT", 99, 101], ["M48 USP", "PROTEIN", 25, 32], ["finger domain", "PROTEIN", 41, 54], ["HAUSP", "PROTEIN", 58, 63], ["Ub core", "PROTEIN", 99, 106], ["hairpin", "OBSERVATION_MODIFIER", 14, 21], ["finger", "ANATOMY", 41, 47]]], ["Catalytic triad residues are in yellow circles, whereas oxyanion hole residues are in white circles.", [["Catalytic triad residues", "PROBLEM", 0, 24], ["yellow circles", "PROBLEM", 32, 46], ["oxyanion hole residues", "TREATMENT", 56, 78], ["triad residues", "OBSERVATION", 10, 24], ["yellow circles", "OBSERVATION", 32, 46], ["oxyanion", "OBSERVATION", 56, 64], ["hole residues", "OBSERVATION", 65, 78], ["white circles", "OBSERVATION", 86, 99]]], ["Note that the sequential order of the more efficient M48 USP catalytic triad (C23, D156, and H158) is different compared to other cysteine proteases and that M48 USP shares more similarities to the papain topography than to the two DUB representatives.Molecular Cellvalidate their classification in three different classes.", [["cysteine", "CHEMICAL", 130, 138], ["M48 USP", "GENE_OR_GENE_PRODUCT", 158, 165], ["papain", "GENE_OR_GENE_PRODUCT", 198, 204], ["DUB", "GENE_OR_GENE_PRODUCT", 232, 235], ["M48 USP catalytic triad", "PROTEIN", 53, 76], ["H158", "PROTEIN", 93, 97], ["cysteine proteases", "PROTEIN", 130, 148], ["M48 USP", "PROTEIN", 158, 165], ["DUB representatives", "PROTEIN", 232, 251], ["C23", "TEST", 78, 81], ["other cysteine proteases", "TEST", 124, 148], ["the papain topography", "TEST", 194, 215]]], ["First, the order of secondary structure elements in UCH-L3 is different from that of other cysteine protease DUBs (Figure 6) .", [["cysteine", "CHEMICAL", 91, 99], ["UCH-L3", "GENE_OR_GENE_PRODUCT", 52, 58], ["cysteine protease DUBs", "GENE_OR_GENE_PRODUCT", 91, 113], ["UCH", "PROTEIN", 52, 55], ["cysteine protease DUBs", "PROTEIN", 91, 113], ["secondary structure elements in UCH-L3", "PROBLEM", 20, 58], ["secondary", "OBSERVATION", 20, 29], ["structure elements", "OBSERVATION", 30, 48], ["L3", "ANATOMY", 56, 58], ["different", "OBSERVATION_MODIFIER", 62, 71]]], ["Second, UCH-L3 features a crossover loop that is disordered in the substrate-free structure and ordered above the active-site cleft when Ub is bound (Johnston et al., 1997; Misaghi et al., 2005) .", [["Ub", "GENE_OR_GENE_PRODUCT", 137, 139], ["UCH", "PROTEIN", 8, 11], ["L3", "PROTEIN", 12, 14], ["substrate-free structure", "PROTEIN", 67, 91], ["Ub", "PROTEIN", 137, 139], ["a crossover loop", "PROBLEM", 24, 40], ["L3", "ANATOMY", 12, 14], ["crossover loop", "OBSERVATION", 26, 40], ["active", "OBSERVATION_MODIFIER", 114, 120], ["cleft", "OBSERVATION", 126, 131]]], ["Third, HAUSP lacks an a helix corresponding to a helix C in M48 USP and features an extensive ''N-terminal'' insertion dubbed the finger domain that forms mainly water-mediated contacts with the Ub (Ubl) core domain during catalysis (Hu et al., 2002) .", [["N", "CHEMICAL", 96, 97], ["M48 USP", "GENE_OR_GENE_PRODUCT", 60, 67], ["Ub", "GENE_OR_GENE_PRODUCT", 195, 197], ["HAUSP", "PROTEIN", 7, 12], ["helix C", "PROTEIN", 49, 56], ["M48 USP", "PROTEIN", 60, 67], ["N-terminal'' insertion", "DNA", 96, 118], ["finger domain", "PROTEIN", 130, 143], ["Ub (Ubl) core domain", "PROTEIN", 195, 215], ["terminal'' insertion", "TREATMENT", 98, 118], ["extensive", "OBSERVATION_MODIFIER", 84, 93], ["finger", "ANATOMY", 130, 136]]], ["Fourth, M48 USP is more closely related to the classic papain-like proteases than to other DUBs and features a unique b hairpin to recognize Ub and discriminate other Ubls (see above and Table S1 ).", [["M48 USP", "GENE_OR_GENE_PRODUCT", 8, 15], ["papain", "GENE_OR_GENE_PRODUCT", 55, 61], ["DUBs", "GENE_OR_GENE_PRODUCT", 91, 95], ["Ub", "GENE_OR_GENE_PRODUCT", 141, 143], ["Ubls", "GENE_OR_GENE_PRODUCT", 167, 171], ["M48 USP", "PROTEIN", 8, 15], ["papain-like proteases", "PROTEIN", 55, 76], ["DUBs", "PROTEIN", 91, 95], ["Ub", "PROTEIN", 141, 143], ["Ubls", "PROTEIN", 167, 171], ["S1", "PROTEIN", 193, 195], ["the classic papain-like proteases", "PROBLEM", 43, 76], ["a unique b hairpin", "TREATMENT", 109, 127]]], ["Fifth, sequence alignments ( Figure 4A ) and our mutational data suggest that H158 is the principal participant of the catalytic triad, yielding the primary sequence order cysteine / aspartic acid / histidine.", [["H158", "CHEMICAL", 78, 82], ["aspartic acid", "CHEMICAL", 183, 196], ["histidine", "CHEMICAL", 199, 208], ["cysteine", "CHEMICAL", 172, 180], ["aspartic acid", "CHEMICAL", 183, 196], ["histidine", "CHEMICAL", 199, 208], ["H158", "GENE_OR_GENE_PRODUCT", 78, 82], ["cysteine", "AMINO_ACID", 172, 180], ["aspartic acid", "AMINO_ACID", 183, 196], ["histidine", "AMINO_ACID", 199, 208], ["H158", "PROTEIN", 78, 82], ["catalytic triad", "PROTEIN", 119, 134], ["our mutational data", "TEST", 45, 64], ["cysteine", "TREATMENT", 172, 180], ["aspartic acid / histidine", "TREATMENT", 183, 208]]], ["This order has so far been observed only in Atg4B (Kumanomidou et al., 2006) , whereas all other cysteine proteases of known structure, including DUBs, feature a cysteine / histidine / aspartic acid/ asparagine catalytic triad in their primary sequence.", [["cysteine", "CHEMICAL", 162, 170], ["histidine", "CHEMICAL", 173, 182], ["aspartic acid", "CHEMICAL", 185, 198], ["asparagine", "CHEMICAL", 200, 210], ["cysteine", "CHEMICAL", 97, 105], ["cysteine", "CHEMICAL", 162, 170], ["histidine", "CHEMICAL", 173, 182], ["aspartic acid", "CHEMICAL", 185, 198], ["asparagine", "CHEMICAL", 200, 210], ["DUBs", "GENE_OR_GENE_PRODUCT", 146, 150], ["cysteine", "AMINO_ACID", 162, 170], ["histidine", "AMINO_ACID", 173, 182], ["aspartic acid", "AMINO_ACID", 185, 198], ["asparagine", "AMINO_ACID", 200, 210], ["cysteine proteases", "PROTEIN", 97, 115], ["DUBs", "PROTEIN", 146, 150], ["cysteine / histidine / aspartic acid/ asparagine catalytic triad", "PROTEIN", 162, 226], ["DUBs", "TEST", 146, 150], ["a cysteine", "TEST", 160, 170], ["histidine / aspartic acid/ asparagine catalytic triad", "TREATMENT", 173, 226]]], ["In conclusion, M48 USP shows distinct features in its tertiary fold and catalytic triad and a unique Ub binding b hairpin.", [["M48 USP", "GENE_OR_GENE_PRODUCT", 15, 22], ["Ub", "GENE_OR_GENE_PRODUCT", 101, 103], ["M48 USP", "PROTEIN", 15, 22], ["catalytic triad", "PROTEIN", 72, 87], ["Ub binding b hairpin", "PROTEIN", 101, 121], ["M48 USP", "TEST", 15, 22], ["distinct features in its tertiary fold", "PROBLEM", 29, 67], ["catalytic triad", "PROBLEM", 72, 87], ["a unique Ub binding b hairpin", "TREATMENT", 92, 121], ["distinct", "OBSERVATION_MODIFIER", 29, 37], ["tertiary fold", "OBSERVATION", 54, 67], ["catalytic triad", "OBSERVATION", 72, 87], ["binding b hairpin", "OBSERVATION", 104, 121]]], ["In agreement with the listing of HSV UL36 as the founding member of a new cysteine protease family in the MEROPS database (Gao and Luo, 2006; Rawlings et al., 2004) , we conclude that the M48 USP structure defines a previously unknown class of cysteine protease DUBs and confirms the existence of a new cysteine protease family (C76), which we term herpesvirus tegument USPs (htUSPs).Concluding RemarksA number of viruses modulate the Ub system of the host, both by ubiquitination and deubiquitination.", [["cysteine", "CHEMICAL", 74, 82], ["cysteine", "CHEMICAL", 244, 252], ["cysteine", "CHEMICAL", 303, 311], ["HSV", "ORGANISM", 33, 36], ["UL36", "GENE_OR_GENE_PRODUCT", 37, 41], ["M48", "GENE_OR_GENE_PRODUCT", 188, 191], ["cysteine protease DUBs", "GENE_OR_GENE_PRODUCT", 244, 266], ["herpesvirus", "ORGANISM", 349, 360], ["USPs", "GENE_OR_GENE_PRODUCT", 370, 374], ["htUSPs", "GENE_OR_GENE_PRODUCT", 376, 382], ["Ub", "GENE_OR_GENE_PRODUCT", 435, 437], ["HSV UL36", "PROTEIN", 33, 41], ["cysteine protease family", "PROTEIN", 74, 98], ["M48 USP structure", "PROTEIN", 188, 205], ["cysteine protease DUBs", "PROTEIN", 244, 266], ["cysteine protease family", "PROTEIN", 303, 327], ["C76", "PROTEIN", 329, 332], ["herpesvirus tegument USPs", "PROTEIN", 349, 374], ["htUSPs", "PROTEIN", 376, 382], ["Ub", "PROTEIN", 435, 437], ["HSV", "SPECIES", 33, 36], ["a new cysteine protease", "TREATMENT", 68, 91], ["cysteine protease DUBs", "TREATMENT", 244, 266], ["a new cysteine protease family", "TREATMENT", 297, 327], ["viruses", "OBSERVATION", 414, 421], ["ubiquitination", "OBSERVATION", 466, 480], ["deubiquitination", "OBSERVATION_MODIFIER", 485, 501]]], ["Recent examples include the paramyxovirus V protein, which hijacks the DSB1-Cul4A Ub ligase (Li et al., 2006) , a deubiquitinating module of the USP family embedded in a nonstructural protein encoded by severe acute respiratory syndrome (SARS) coronavirus (Ratia et al., 2006) , and an adenovirus protease endowed with deubiquitinating activity (Balakirev et al., 2002) .", [["acute respiratory syndrome (SARS) coronavirus", "DISEASE", 210, 255], ["paramyxovirus V", "GENE_OR_GENE_PRODUCT", 28, 43], ["DSB1", "GENE_OR_GENE_PRODUCT", 71, 75], ["Cul4A Ub", "GENE_OR_GENE_PRODUCT", 76, 84], ["USP", "GENE_OR_GENE_PRODUCT", 145, 148], ["adenovirus", "ORGANISM", 286, 296], ["paramyxovirus V protein", "PROTEIN", 28, 51], ["DSB1", "PROTEIN", 71, 75], ["Cul4A Ub ligase", "PROTEIN", 76, 91], ["deubiquitinating module", "PROTEIN", 114, 137], ["USP family", "PROTEIN", 145, 155], ["nonstructural protein", "PROTEIN", 170, 191], ["adenovirus protease", "PROTEIN", 286, 305], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 203, 255], ["adenovirus", "SPECIES", 286, 296], ["the paramyxovirus V protein", "TEST", 24, 51], ["the DSB1", "TEST", 67, 75], ["severe acute respiratory syndrome", "PROBLEM", 203, 236], ["SARS) coronavirus", "PROBLEM", 238, 255], ["an adenovirus protease", "TREATMENT", 283, 305], ["paramyxovirus V", "OBSERVATION", 28, 43], ["ligase", "OBSERVATION_MODIFIER", 85, 91], ["severe", "OBSERVATION_MODIFIER", 203, 209], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["respiratory syndrome", "OBSERVATION", 216, 236]]], ["Deubiquitinating activities were also found to be encoded by pathogenic intracellular bacteria, such as Yersinia spp.", [["intracellular", "ANATOMY", 72, 85], ["Yersinia spp", "DISEASE", 104, 116], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["Yersinia spp", "ORGANISM", 104, 116], ["Yersinia spp", "SPECIES", 104, 116], ["pathogenic intracellular bacteria", "PROBLEM", 61, 94], ["Yersinia spp", "PROBLEM", 104, 116], ["bacteria", "OBSERVATION", 86, 94], ["Yersinia spp", "OBSERVATION", 104, 116]]], ["(Zhou et al., 2005) and Chlamydia trachomatis (Misaghi et al., 2006) .", [["Chlamydia trachomatis", "DISEASE", 24, 45], ["Chlamydia trachomatis", "ORGANISM", 24, 45], ["Chlamydia trachomatis", "SPECIES", 24, 45], ["Chlamydia trachomatis", "SPECIES", 24, 45], ["Chlamydia trachomatis", "PROBLEM", 24, 45], ["Chlamydia", "OBSERVATION_MODIFIER", 24, 33], ["trachomatis", "OBSERVATION", 34, 45]]], ["For most of these examples, the precise biological role has yet to be defined.Concluding RemarksWe have meanwhile generated an MCMV mutant in which M48 is deprived of its USP activity via an in-frame deletion.", [["MCMV", "ORGANISM", 127, 131], ["USP", "GENE_OR_GENE_PRODUCT", 171, 174], ["M48", "PROTEIN", 148, 151], ["USP", "PROTEIN", 171, 174], ["MCMV", "SPECIES", 127, 131]]], ["This mutant is impaired in sustaining a productive infection in mice in vivo (L.M.K, C.S., H.L.P., unpublished data).", [["infection", "DISEASE", 51, 60], ["mice", "ORGANISM", 64, 68], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["a productive infection", "PROBLEM", 38, 60], ["C.S.", "TEST", 85, 89], ["impaired", "OBSERVATION_MODIFIER", 15, 23], ["productive", "OBSERVATION_MODIFIER", 40, 50], ["infection", "OBSERVATION", 51, 60]]], ["With additional data in support of an essential role of the USP activity in vivo, htUSPs, and possibly other pathogen-encoded DUBs, deserve scrutiny from the perspective of drug design for treating pathogen infections.", [["pathogen infections", "DISEASE", 198, 217], ["USP", "GENE_OR_GENE_PRODUCT", 60, 63], ["htUSPs", "GENE_OR_GENE_PRODUCT", 82, 88], ["DUBs", "GENE_OR_GENE_PRODUCT", 126, 130], ["USP", "PROTEIN", 60, 63], ["htUSPs", "PROTEIN", 82, 88], ["DUBs", "PROTEIN", 126, 130], ["other pathogen", "PROBLEM", 103, 117], ["treating pathogen infections", "PROBLEM", 189, 217]]], ["The respective structures will be important scaffolds to facilitate the design of specific inhibitors, all the more so if the pathogen-encoded DUBs are sufficiently different from cellular proteases, as exemplified by htUSPs.Kinetic AssaysThe M48 USP domain specifying aa 1-236 of the MCMV-encoded M48 tegument protein was expressed and purified as described previously (Schlieker et al., 2005) .", [["cellular", "ANATOMY", 180, 188], ["DUBs", "GENE_OR_GENE_PRODUCT", 143, 147], ["cellular", "CELL", 180, 188], ["htUSPs", "GENE_OR_GENE_PRODUCT", 218, 224], ["MCMV", "ORGANISM", 285, 289], ["M48", "GENE_OR_GENE_PRODUCT", 298, 301], ["DUBs", "PROTEIN", 143, 147], ["cellular proteases", "PROTEIN", 180, 198], ["htUSPs", "PROTEIN", 218, 224], ["M48 USP domain", "PROTEIN", 243, 257], ["MCMV-encoded M48 tegument protein", "PROTEIN", 285, 318], ["MCMV", "SPECIES", 285, 289], ["important scaffolds", "TREATMENT", 34, 53], ["specific inhibitors", "TREATMENT", 82, 101], ["the pathogen", "PROBLEM", 122, 134], ["cellular proteases", "PROBLEM", 180, 198], ["Kinetic Assays", "TEST", 225, 239], ["aa", "TEST", 269, 271], ["the MCMV", "TREATMENT", 281, 289], ["cellular proteases", "OBSERVATION", 180, 198]]], ["The corresponding domain of EBV, BPLF USP , specifying aa 1-276, was purified accordingly.", [["aa 1-276", "CHEMICAL", 55, 63], ["EBV", "ORGANISM", 28, 31], ["BPLF USP", "GENE_OR_GENE_PRODUCT", 33, 41], ["BPLF USP", "PROTEIN", 33, 41], ["BPLF USP", "TEST", 33, 41], ["domain", "OBSERVATION_MODIFIER", 18, 24], ["EBV", "OBSERVATION", 28, 31]]], ["Ub C-terminal 7amido-4-methylcoumarin (UbAMC) and diubiquitin (K63-and K48-linked) were purchased from Boston Biochem.", [["Ub C-terminal 7amido-4-methylcoumarin", "CHEMICAL", 0, 37], ["UbAMC", "CHEMICAL", 39, 44], ["diubiquitin", "CHEMICAL", 50, 61], ["C-terminal 7amido-4-methylcoumarin", "CHEMICAL", 3, 37], ["UbAMC", "CHEMICAL", 39, 44], ["diubiquitin", "CHEMICAL", 50, 61], ["K63-and K48", "CHEMICAL", 63, 74], ["Ub C-terminal 7amido-4-methylcoumarin", "SIMPLE_CHEMICAL", 0, 37], ["UbAMC", "SIMPLE_CHEMICAL", 39, 44], ["diubiquitin", "SIMPLE_CHEMICAL", 50, 61], ["K63", "SIMPLE_CHEMICAL", 63, 66], ["K48", "SIMPLE_CHEMICAL", 71, 74], ["UbAMC", "PROTEIN", 39, 44], ["diubiquitin", "PROTEIN", 50, 61], ["K63", "PROTEIN", 63, 66], ["K48", "PROTEIN", 71, 74], ["Ub C-terminal 7amido", "TEST", 0, 20], ["methylcoumarin (UbAMC)", "TREATMENT", 23, 45], ["diubiquitin (K63", "TREATMENT", 50, 66]]], ["Densiometric quantifications for diUb conversions were obtained with ImageJ and subsequently fitted to a single exponential decay in Kaleidagraph.", [["diUb", "DNA", 33, 37], ["diUb conversions", "TEST", 33, 49], ["ImageJ", "TEST", 69, 75]]], ["UbAMC hydrolysis assays were performed in assay buffer (50 mM Tris/HCl, 150 mM NaCl, 2 mM EDTA, 2 mM DTT [pH 7.5]), supplemented with 1 mg/ml bovine serum albumin (Roche) at 25 C. Enzyme concentrations were determined with the Bradford reagent (Biorad) and BSA (Pierce) as standard.", [["serum", "ANATOMY", 149, 154], ["NaCl", "CHEMICAL", 79, 83], ["Tris", "CHEMICAL", 62, 66], ["HCl", "CHEMICAL", 67, 70], ["NaCl", "CHEMICAL", 79, 83], ["EDTA", "CHEMICAL", 90, 94], ["DTT", "CHEMICAL", 101, 104], ["UbAMC", "SIMPLE_CHEMICAL", 0, 5], ["EDTA", "SIMPLE_CHEMICAL", 90, 94], ["bovine", "ORGANISM", 142, 148], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["albumin", "SIMPLE_CHEMICAL", 155, 162], ["Roche", "ORGANISM_SUBSTANCE", 164, 169], ["BSA", "SIMPLE_CHEMICAL", 257, 260], ["bovine", "SPECIES", 142, 148], ["bovine", "SPECIES", 142, 148], ["UbAMC hydrolysis assays", "TEST", 0, 23], ["NaCl", "TEST", 79, 83], ["2 mM EDTA", "TREATMENT", 85, 94], ["2 mM DTT", "TREATMENT", 96, 104], ["pH", "TEST", 106, 108], ["bovine serum albumin", "TEST", 142, 162], ["Enzyme concentrations", "TEST", 180, 201], ["the Bradford reagent", "TREATMENT", 223, 243]]], ["Measurements were performed in triplicate with 20 pM (unless stated otherwise) of the respective enzyme in a total volume of 30 ml/well in a 384-well plate (NUNC) using a Spectramax M2 plate reader (Molecular Devices), with a 368 nm/467 nm filter pair and a 455 nm cutoff.", [["enzyme", "PROTEIN", 97, 103], ["the respective enzyme", "TEST", 82, 103], ["a Spectramax M2 plate reader (Molecular Devices", "TREATMENT", 169, 216], ["a 368 nm/467 nm filter pair", "TREATMENT", 224, 251]]], ["7-amido-4-methylcoumarin (Anaspec Inc.) was used for calibration.", [["7-amido-4-methylcoumarin", "CHEMICAL", 0, 24], ["7-amido-4-methylcoumarin", "CHEMICAL", 0, 24], ["7-amido-4-methylcoumarin", "SIMPLE_CHEMICAL", 0, 24], ["amido", "TREATMENT", 2, 7], ["methylcoumarin (Anaspec Inc.)", "TREATMENT", 10, 39]]], ["Kinetic parameters (V max , K M ) were calculated by fitting initial velocities via a nonlinear regression to the Michaelis-Menten equation in Kaleidagraph, using substrate concentrations ranging from 0 to 5 mM. k cat was determined from the equation k cat = V max / [E]; with [E] = total enzyme concentration.Deubiquitination of Cellular Ub Conjugates293T cells at 70%-80% confluence were transfected with 5 mg of pcDNA3.1+ (Invitrogen) encoding HA-tagged Ub (or empty pcDNA3.1+ as control) per 10 cm dish, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.", [["293T cells", "ANATOMY", 352, 362], ["Kaleidagraph", "SIMPLE_CHEMICAL", 143, 155], ["Cellular Ub", "GENE_OR_GENE_PRODUCT", 330, 341], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 415, 421], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 426, 436], ["HA", "GENE_OR_GENE_PRODUCT", 447, 449], ["Ub", "GENE_OR_GENE_PRODUCT", 457, 459], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 470, 476], ["293T cells", "CELL_LINE", 352, 362], ["pcDNA3", "DNA", 415, 421], ["HA", "PROTEIN", 447, 449], ["Ub", "PROTEIN", 457, 459], ["pcDNA3", "PROTEIN", 470, 476], ["Kinetic parameters", "TEST", 0, 18], ["V max , K M )", "TEST", 20, 33], ["the Michaelis", "TEST", 110, 123], ["substrate concentrations", "TEST", 163, 187], ["k cat", "TEST", 212, 217], ["the equation k cat", "TEST", 238, 256], ["total enzyme concentration", "TEST", 283, 309], ["Cellular Ub Conjugates", "TEST", 330, 352], ["cells", "TEST", 357, 362], ["pcDNA3", "TREATMENT", 415, 421], ["encoding HA", "PROBLEM", 438, 449], ["tagged Ub", "PROBLEM", 450, 459], ["empty pcDNA3", "TREATMENT", 464, 476], ["Lipofectamine", "TREATMENT", 514, 527], ["Invitrogen", "TREATMENT", 534, 544], ["Ub", "ANATOMY_MODIFIER", 339, 341], ["Conjugates293T cells", "OBSERVATION", 342, 362], ["10 cm", "OBSERVATION_MODIFIER", 496, 501]]], ["To enrich for polyubiquitinated species, cells were exposed to 50 mM proteasome inhibitor ZL 3 VS 1 hr prior to cell lysis.", [["cells", "ANATOMY", 41, 46], ["cell", "ANATOMY", 112, 116], ["cells", "CELL", 41, 46], ["cell", "CELL", 112, 116], ["proteasome", "PROTEIN", 69, 79], ["polyubiquitinated species", "PROBLEM", 14, 39], ["50 mM proteasome inhibitor ZL", "TREATMENT", 63, 92], ["cell lysis", "TREATMENT", 112, 122], ["cell lysis", "OBSERVATION", 112, 122]]], ["Soluble cell extracts were prepared 24 hr posttransfection by resuspension in 1 ml assay buffer supplemented with 0.5% (v/v) NP-40.", [["cell extracts", "ANATOMY", 8, 21], ["cell extracts", "ORGANISM_SUBSTANCE", 8, 21], ["NP-40", "SIMPLE_CHEMICAL", 125, 130], ["Soluble cell extracts", "TREATMENT", 0, 21]]], ["Cellular debris was removed by centrifugation (1200 3 g), and the supernatants were adjusted to 1 mg/ml protein with assay buffer supplemented with 0.1% (v/v) NP-40.", [["Cellular debris", "ANATOMY", 0, 15], ["supernatants", "ANATOMY", 66, 78], ["NP-40", "SIMPLE_CHEMICAL", 159, 164], ["Cellular debris", "PROBLEM", 0, 15], ["the supernatants", "TREATMENT", 62, 78], ["assay buffer supplemented", "TREATMENT", 117, 142], ["debris", "OBSERVATION", 9, 15]]], ["The soluble extracts were then incubated in the absence or presence of enzyme (50 nM final concentration) in a total volume of 50 ml for 1 hr at 37 C. Reactions were stopped by addition of SDS-PAGE sample buffer and subjected to SDS-PAGE and immunoblotting according to standard procedures.Deubiquitination of Cellular Ub ConjugatesPreparation of M48 USP -UbVME and Crystallization M48 USP bearing an N-terminal histidine tag was purified as described previously (Schlieker et al., 2005) .", [["extracts", "ANATOMY", 12, 20], ["N-terminal histidine", "CHEMICAL", 401, 421], ["SDS", "CHEMICAL", 189, 192], ["N", "CHEMICAL", 401, 402], ["histidine", "CHEMICAL", 412, 421], ["extracts", "ORGANISM_SUBSTANCE", 12, 20], ["Crystallization M48 USP", "GENE_OR_GENE_PRODUCT", 366, 389], ["enzyme", "PROTEIN", 71, 77], ["M48 USP", "PROTEIN", 347, 354], ["UbVME", "PROTEIN", 356, 361], ["Crystallization M48 USP", "PROTEIN", 366, 389], ["N-terminal histidine tag", "PROTEIN", 401, 425], ["The soluble extracts", "TREATMENT", 0, 20], ["enzyme", "TEST", 71, 77], ["a total volume", "TREATMENT", 109, 123], ["SDS", "TREATMENT", 189, 192], ["immunoblotting", "TREATMENT", 242, 256], ["standard procedures", "TREATMENT", 270, 289], ["USP", "TEST", 351, 354], ["Crystallization", "TREATMENT", 366, 381], ["an N-terminal histidine tag", "TREATMENT", 398, 425], ["Cellular Ub Conjugates", "OBSERVATION", 310, 332]]], ["The histidine tag was removed by PreScission protease (GE Healthcare) treatment according to the manufacturer's instructions, followed by size exclusion chromatography (S75 HiLoad, GE Healthcare) in 50 mM Tris/HCl, 150 mM NaCl, and 2 mM DTT (pH 7.5).", [["histidine", "CHEMICAL", 4, 13], ["Tris/HCl", "CHEMICAL", 205, 213], ["NaCl", "CHEMICAL", 222, 226], ["histidine", "CHEMICAL", 4, 13], ["Tris", "CHEMICAL", 205, 209], ["HCl", "CHEMICAL", 210, 213], ["NaCl", "CHEMICAL", 222, 226], ["DTT", "CHEMICAL", 237, 240], ["histidine", "AMINO_ACID", 4, 13], ["DTT", "SIMPLE_CHEMICAL", 237, 240], ["The histidine tag", "TREATMENT", 0, 17], ["PreScission protease (GE Healthcare) treatment", "TREATMENT", 33, 79], ["150 mM NaCl", "TREATMENT", 215, 226], ["2 mM DTT", "TREATMENT", 232, 240], ["pH", "TEST", 242, 244]]], ["M48 USP was reacted with a $1.5-fold molar excess of Ub-vinylmethylester (UbVME) (Borodovsky et al., 2002) at room temperature for 2 hr to achieve quantitative covalent modification.", [["Ub-vinylmethylester", "CHEMICAL", 53, 72], ["UbVME", "CHEMICAL", 74, 79], ["Ub-vinylmethylester", "CHEMICAL", 53, 72], ["UbVME", "CHEMICAL", 74, 79], ["Ub-vinylmethylester", "SIMPLE_CHEMICAL", 53, 72], ["UbVME", "SIMPLE_CHEMICAL", 74, 79], ["M48 USP", "PROTEIN", 0, 7], ["quantitative covalent modification", "TREATMENT", 147, 181], ["covalent modification", "OBSERVATION", 160, 181]]], ["The covalent M48 USP -UbVME adduct was subjected to size exclusion chromatography (S75 HiLoad) in 10 mM HEPES, 50 mM NaCl, and 2 mM DTT (pH 7.5) to remove excess UbVME.", [["M48 USP -UbVME", "CHEMICAL", 13, 27], ["NaCl", "CHEMICAL", 117, 121], ["M48 USP -UbVME", "CHEMICAL", 13, 27], ["HEPES", "CHEMICAL", 104, 109], ["NaCl", "CHEMICAL", 117, 121], ["DTT", "CHEMICAL", 132, 135], ["UbVME", "CHEMICAL", 162, 167], ["DTT", "SIMPLE_CHEMICAL", 132, 135], ["UbVME", "SIMPLE_CHEMICAL", 162, 167], ["The covalent M48 USP", "TEST", 0, 20], ["UbVME adduct", "PROBLEM", 22, 34], ["chromatography", "TEST", 67, 81], ["10 mM HEPES", "TREATMENT", 98, 109], ["50 mM NaCl", "TREATMENT", 111, 121], ["2 mM DTT", "TEST", 127, 135], ["pH", "TEST", 137, 139], ["excess UbVME", "PROBLEM", 155, 167], ["size", "OBSERVATION_MODIFIER", 52, 56]]], ["The sample was concentrated to 10 mg/ml by ultrafiltration (Centriprep YM10, Millipore) and used in sparse matrix crystallization screens (Hampton Research, Qiagen).", [["sample", "ANATOMY", 4, 10], ["The sample", "TREATMENT", 0, 10], ["ultrafiltration (Centriprep YM10, Millipore", "TREATMENT", 43, 86]]], ["Initial crystals grew from a condition containing 200 mM magnesium formate and 14% PEG 3350 to maximum dimensions of 0.2 3 0.2 3 0.1 mm and were used in microseeding of SeMet-modified M48 USP -UbVME mixed with equal volumes of 100 mM imidazole (pH 6.0), 20 mM MnCl 2 , 200 mM magnesium formate, and 12%-14% PEG3350.", [["magnesium formate", "CHEMICAL", 57, 74], ["PEG 3350", "CHEMICAL", 83, 91], ["SeMet", "CHEMICAL", 169, 174], ["M48 USP -UbVME", "CHEMICAL", 184, 198], ["imidazole", "CHEMICAL", 234, 243], ["MnCl 2", "CHEMICAL", 260, 266], ["magnesium formate", "CHEMICAL", 276, 293], ["PEG3350", "CHEMICAL", 307, 314], ["magnesium formate", "CHEMICAL", 57, 74], ["PEG", "CHEMICAL", 83, 86], ["SeMet", "CHEMICAL", 169, 174], ["imidazole", "CHEMICAL", 234, 243], ["MnCl 2", "CHEMICAL", 260, 266], ["magnesium formate", "CHEMICAL", 276, 293], ["PEG3350", "CHEMICAL", 307, 314], ["magnesium formate", "SIMPLE_CHEMICAL", 57, 74], ["SeMet", "SIMPLE_CHEMICAL", 169, 174], ["M48 USP -UbVME", "SIMPLE_CHEMICAL", 184, 198], ["imidazole", "SIMPLE_CHEMICAL", 234, 243], ["MnCl 2", "SIMPLE_CHEMICAL", 260, 266], ["magnesium formate", "SIMPLE_CHEMICAL", 276, 293], ["PEG3350", "SIMPLE_CHEMICAL", 307, 314], ["Initial crystals", "TEST", 0, 16], ["magnesium formate", "TEST", 57, 74], ["maximum dimensions", "TEST", 95, 113], ["SeMet", "TEST", 169, 174], ["imidazole", "TEST", 234, 243], ["pH", "TEST", 245, 247], ["MnCl", "TEST", 260, 264], ["mM magnesium formate", "TEST", 273, 293]]], ["Crystals were harvested with a nylon loop and quickly dipped in crystallization solution supplemented with 25% PEG400 prior to flash-freezing in liquid N 2 .Deubiquitination of Cellular Ub ConjugatesX-Ray Data Collection, Structure Determination, and Refinement X-ray diffraction data were collected on crystals of SeMet-labeled M48 USP -UbVME at 100 K at NE-CAT beamline ID24 at the Advanced Photon Source, Argonne, IL and processed with HKL2000 (Otwinowski and Minor, 1997) .", [["Crystals", "ANATOMY", 0, 8], ["PEG400", "CHEMICAL", 111, 117], ["SeMet", "CHEMICAL", 315, 320], ["NE", "CHEMICAL", 356, 358], ["PEG400", "CHEMICAL", 111, 117], ["SeMet", "CHEMICAL", 315, 320], ["Crystals", "ORGANISM_SUBSTANCE", 0, 8], ["PEG400", "SIMPLE_CHEMICAL", 111, 117], ["SeMet", "SIMPLE_CHEMICAL", 315, 320], ["M48 USP -UbVME", "SIMPLE_CHEMICAL", 329, 343], ["Cellular Ub ConjugatesX", "PROTEIN", 177, 200], ["NE", "PROTEIN", 356, 358], ["CAT", "PROTEIN", 359, 362], ["Crystals", "TEST", 0, 8], ["a nylon loop", "TREATMENT", 29, 41], ["crystallization solution", "TREATMENT", 64, 88], ["flash-freezing in liquid N", "TREATMENT", 127, 153], ["Cellular Ub ConjugatesX", "TEST", 177, 200], ["Structure Determination", "TEST", 222, 245], ["Refinement X-ray diffraction data", "TEST", 251, 284], ["SeMet", "TEST", 315, 320], ["harvested", "OBSERVATION", 14, 23], ["nylon loop", "OBSERVATION", 31, 41]]], ["The M48 USP -UbVME crystal structure was determined by using a single-wavelength anomalous dispersion experiment at the Se K edge (Table 1 ).", [["Se K", "CHEMICAL", 120, 124], ["Se", "CHEMICAL", 120, 122], ["M48 USP -UbVME crystal structure", "DNA", 4, 36], ["The M48 USP", "TEST", 0, 11], ["a single-wavelength anomalous dispersion experiment", "TREATMENT", 61, 112]]], ["All 12 expected Se sites for two M48 USP chains in the asymmetric unit were determined by using the program SHELXD (Schneider and Sheldrick, 2002) and used for phasing with the program SHARP (de La Fortelle and Bricogne, 1997) .", [["Se", "CHEMICAL", 16, 18], ["Se", "CHEMICAL", 16, 18], ["Se sites", "DNA", 16, 24], ["M48 USP chains", "PROTEIN", 33, 47], ["asymmetric", "OBSERVATION_MODIFIER", 55, 65]]], ["Density modification and subsequent automated model building in RESOLVE (Terwilliger, 2003) provided an 80% complete model.", [["Density modification", "PROBLEM", 0, 20]]], ["This model was further improved to 97% completeness with ARP/wARP run in alternating mode with restrained and TLS refinement in REFMAC5 (Murshudov et al., 1997) .", [["ARP", "PROTEIN", 57, 60], ["ARP", "TEST", 57, 60], ["alternating mode", "TREATMENT", 73, 89], ["restrained", "TREATMENT", 95, 105], ["TLS refinement", "TREATMENT", 110, 124], ["improved", "OBSERVATION_MODIFIER", 23, 31]]], ["Remaining residues and the VME moieties were built manually in O (Jones et al., 1991) .Deubiquitination of Cellular Ub ConjugatesData collection and refinement statistics are summarized in Table 1 .", [["VME moieties", "PROTEIN", 27, 39], ["Remaining residues", "PROBLEM", 0, 18], ["the VME moieties", "PROBLEM", 23, 39], ["residues", "OBSERVATION", 10, 18], ["Cellular Ub Conjugates", "OBSERVATION", 107, 129]]], ["Figures 2, 3 , and 4 were created with PyMOL.Supplemental DataSupplemental Data include two figures and one table and can be found with this article online at http://www.molecule.org/cgi/content/full/ 25/5/677/DC1/.", [["Figures", "TEST", 0, 7]]], ["This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines of the Advanced Photon Source, supported by award RR-15301 from the National Center for Research Resources at the National Institutes of Health.", [["RR-15301", "CHEMICAL", 149, 157]]], ["W-31-109-ENG-38.", [["W-31-109-ENG-38", "CHEMICAL", 0, 15], ["ENG-38", "CHEMICAL", 9, 15], ["ENG-38", "GENE_OR_GENE_PRODUCT", 9, 15], ["W-31-109-ENG-38", "DNA", 0, 15]]], ["We thank Thomas U. Schwartz and Howard C. Hang for critically reading the manuscript and Kanagalaghatta Rajashankar for beamline assistance.", [["Kanagalaghatta Rajashankar", "TREATMENT", 89, 115], ["beamline assistance", "TREATMENT", 120, 139]]]], "PMC7453848": [["The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has spread quickly throughout the world with the World Health Organization (WHO) declaring a global pandemic on March 11, 2020 [1].", [["acute respiratory syndrome coronavirus", "DISEASE", 11, 49], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 4, 51], ["SARS-CoV-2", "ORGANISM", 53, 63], ["severe acute respiratory syndrome coronavirus", "SPECIES", 4, 49], ["SARS-CoV-2", "SPECIES", 53, 63], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 49], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome coronavirus", "OBSERVATION", 17, 49]]], ["As community transmission has increased, health officials and governments are recommending or requiring people to stay home for all but essential needs.", [["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["While the healthcare system strives to treat the rising number of people with coronavirus disease-2019 (COVID-19), the need to provide medical care remains for persons with chronic health conditions.", [["coronavirus disease", "DISEASE", 78, 97], ["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["persons", "SPECIES", 160, 167], ["coronavirus disease", "PROBLEM", 78, 97], ["COVID", "TEST", 104, 109], ["medical care", "TREATMENT", 135, 147], ["chronic health conditions", "PROBLEM", 173, 198]]], ["During this period of rapid viral spread, the benefit of each medical intervention requires careful evaluation and must clearly outweigh the risk of increased rate of infection.", [["infection", "DISEASE", 167, 176], ["rapid viral spread", "PROBLEM", 22, 40], ["each medical intervention", "TREATMENT", 57, 82], ["careful evaluation", "TEST", 92, 110], ["increased rate of infection", "PROBLEM", 149, 176], ["rapid", "OBSERVATION_MODIFIER", 22, 27], ["viral spread", "OBSERVATION", 28, 40], ["increased", "OBSERVATION_MODIFIER", 149, 158], ["infection", "OBSERVATION", 167, 176]]]], "PMC7268949": []}